<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2014//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_140101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25140037</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1523-5866</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neuro-oncology</Title>
                <ISOAbbreviation>Neuro-oncology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Efficacy of cabazitaxel in mouse models of pediatric brain tumors.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">nou163</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is an unmet need in the treatment of pediatric brain tumors for chemotherapy that is efficacious, avoids damage to the developing brain, and crosses the blood-brain barrier. These experiments evaluated the efficacy of cabazitaxel in mouse models of pediatric brain tumors.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The antitumor activity of cabazitaxel and docetaxel were compared in flank and orthotopic xenograft models of patient-derived atypical teratoid rhabdoid tumor (ATRT), medulloblastoma, and central nervous system primitive neuroectodermal tumor (CNS-PNET). Efficacy of cabazitaxel and docetaxel were also assessed in the Smo/Smo spontaneous mouse medulloblastoma tumor model.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">This study observed significant tumor growth inhibition in pediatric patient-derived flank xenograft tumor models of ATRT, medulloblastoma, and CNS-PNET after treatment with either cabazitaxel or docetaxel. Cabazitaxel, but not docetaxel, treatment resulted in sustained tumor growth inhibition in the ATRT and medulloblastoma flank xenograft models. Patient-derived orthotopic xenograft models of ATRT, medulloblastoma, and CNS-PNET showed significantly improved survival with treatment of cabazitaxel.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These data support further testing of cabazitaxel as a therapy for treating human pediatric brain tumors.</AbstractText>
                <CopyrightInformation>?? The Author(s) 2014. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Girard</LastName>
                    <ForeName>Emily</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington (E.G., S.D., A.R., J.O.); Department of Radiology, University of Washington, Seattle, Washington (D.L., K.Y., J.P., H.E.); Sanofi Oncology, Global Oncology Division, Cambridge, Massachusetts 02142 (D.B.); Oncology/Translational and Experimental Medicine, Sanofi Inc, Vitry sur Seine, France (P.V.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Ditzler</LastName>
                    <ForeName>Sally</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington (E.G., S.D., A.R., J.O.); Department of Radiology, University of Washington, Seattle, Washington (D.L., K.Y., J.P., H.E.); Sanofi Oncology, Global Oncology Division, Cambridge, Massachusetts 02142 (D.B.); Oncology/Translational and Experimental Medicine, Sanofi Inc, Vitry sur Seine, France (P.V.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Donghoon</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington (E.G., S.D., A.R., J.O.); Department of Radiology, University of Washington, Seattle, Washington (D.L., K.Y., J.P., H.E.); Sanofi Oncology, Global Oncology Division, Cambridge, Massachusetts 02142 (D.B.); Oncology/Translational and Experimental Medicine, Sanofi Inc, Vitry sur Seine, France (P.V.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Richards</LastName>
                    <ForeName>Andrew</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington (E.G., S.D., A.R., J.O.); Department of Radiology, University of Washington, Seattle, Washington (D.L., K.Y., J.P., H.E.); Sanofi Oncology, Global Oncology Division, Cambridge, Massachusetts 02142 (D.B.); Oncology/Translational and Experimental Medicine, Sanofi Inc, Vitry sur Seine, France (P.V.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Yagle</LastName>
                    <ForeName>Kevin</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington (E.G., S.D., A.R., J.O.); Department of Radiology, University of Washington, Seattle, Washington (D.L., K.Y., J.P., H.E.); Sanofi Oncology, Global Oncology Division, Cambridge, Massachusetts 02142 (D.B.); Oncology/Translational and Experimental Medicine, Sanofi Inc, Vitry sur Seine, France (P.V.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Park</LastName>
                    <ForeName>Joshua</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington (E.G., S.D., A.R., J.O.); Department of Radiology, University of Washington, Seattle, Washington (D.L., K.Y., J.P., H.E.); Sanofi Oncology, Global Oncology Division, Cambridge, Massachusetts 02142 (D.B.); Oncology/Translational and Experimental Medicine, Sanofi Inc, Vitry sur Seine, France (P.V.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Eslamy</LastName>
                    <ForeName>Hedieh</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington (E.G., S.D., A.R., J.O.); Department of Radiology, University of Washington, Seattle, Washington (D.L., K.Y., J.P., H.E.); Sanofi Oncology, Global Oncology Division, Cambridge, Massachusetts 02142 (D.B.); Oncology/Translational and Experimental Medicine, Sanofi Inc, Vitry sur Seine, France (P.V.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Bobilev</LastName>
                    <ForeName>Dmitri</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington (E.G., S.D., A.R., J.O.); Department of Radiology, University of Washington, Seattle, Washington (D.L., K.Y., J.P., H.E.); Sanofi Oncology, Global Oncology Division, Cambridge, Massachusetts 02142 (D.B.); Oncology/Translational and Experimental Medicine, Sanofi Inc, Vitry sur Seine, France (P.V.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Vrignaud</LastName>
                    <ForeName>Patricia</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington (E.G., S.D., A.R., J.O.); Department of Radiology, University of Washington, Seattle, Washington (D.L., K.Y., J.P., H.E.); Sanofi Oncology, Global Oncology Division, Cambridge, Massachusetts 02142 (D.B.); Oncology/Translational and Experimental Medicine, Sanofi Inc, Vitry sur Seine, France (P.V.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Olson</LastName>
                    <ForeName>James</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington (E.G., S.D., A.R., J.O.); Department of Radiology, University of Washington, Seattle, Washington (D.L., K.Y., J.P., H.E.); Sanofi Oncology, Global Oncology Division, Cambridge, Massachusetts 02142 (D.B.); Oncology/Translational and Experimental Medicine, Sanofi Inc, Vitry sur Seine, France (P.V.).</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Neuro Oncol</MedlineTA>
            <NlmUniqueID>100887420</NlmUniqueID>
            <ISSNLinking>1522-8517</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">animals/in vivo models for carcinogenesis</Keyword>
            <Keyword MajorTopicYN="N">brain/central nervous system cancers</Keyword>
            <Keyword MajorTopicYN="N">pediatric cancers</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">nou163</ArticleId>
            <ArticleId IdType="doi">10.1093/neuonc/nou163</ArticleId>
            <ArticleId IdType="pubmed">25140037</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139998</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1557-3125</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular cancer research : MCR</Title>
                <ISOAbbreviation>Mol. Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Annexin 2-CXCL12 Interactions Regulate Metastatic Cell Targeting and Growth in the Bone Marrow.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">molcanres.0118.2014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Annexin 2 (ANXA2) plays a critical role in hematopoietic stem cell (HSC) localization to the marrow niche. In part, ANXA2 supports HSCs by serving as an anchor for stromal-derived factor-1 (CXCL12/SDF-1). Recently it was demonstrated that prostate cancer (PCa) cells, like HSCs, use ANXA2 to establish metastases in marrow. The present study determined the capacity of ANXA2 expression by bone marrow stromal cells (BMSC) to facilitate tumor recruitment and growth through ANXA2-CXCL12 interactions. Significantly more CXCL12 was expressed by BMSCAnxa2+/+ compared to BMSCAnxa2-/- resulting in more PCa cells migrating and binding to BMSCAnxa2+/+ than BMSCAnxa2-/-, and these activities were reduced when CXCL12 interactions were blocked. To further confirm that BMSC signaling through ANXA2-CXCL12 plays a critical role in tumor growth, immunocompromised SCID mice were subcutaneously implanted with human PCa cells mixed with BMSCAnxa2+/+ or BMSCAnxa2-/-. Significantly larger tumors grew in the mice when the tumors were established with BMSCAnxa2+/+ compared to the tumors established with BMSCAnxa2-/-. In addition, fewer PCa cells underwent apoptosis when co-cultured with BMSCAnxa2+/+ compared to BMSCAnxa2-/-, and similar results were obtained in tumors grown in vivo. Finally, significantly more vascular structures were observed in the tumors established with the BMSCAnxa2+/+ compared to the tumors established with BMSCAnxa2-/-. Thus, ANXA2-CXCL12 interactions play a crucial role in the recruitment, growth, and survival of PCa cells in the marrow. Implications: The tumor microenvironment interaction between ANXA2-CXCL12 is critical for metastatic phenotypes and may impact chemotherapeutic potential.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Jung</LastName>
                    <ForeName>Younghun</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Periodontics and Oral Medicine, University of Michigan School of Dentistry.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Jingcheng</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Periodontics and Oral Medicine, University of Michigan School of Dentistry.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Eunsohl</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Periodontics and Oral Medicine, University of Michigan School of Dentistry.</Affiliation>
                </Author>
                <Author>
                    <LastName>McGee</LastName>
                    <ForeName>Samantha</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Periodontics and Oral Medicine, University of Michigan School of Dentistry.</Affiliation>
                </Author>
                <Author>
                    <LastName>Berry</LastName>
                    <ForeName>Janice E</ForeName>
                    <Initials>JE</Initials>
                    <Affiliation>Periodontics and Oral Medicine, University of Michigan School of Dentistry.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yumoto</LastName>
                    <ForeName>Kenji</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Periodontics and Oral Medicine, University of Michigan School of Dentistry.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dai</LastName>
                    <ForeName>Jinlu</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Urology and Pathology, University of Michigan School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Keller</LastName>
                    <ForeName>Evan T</ForeName>
                    <Initials>ET</Initials>
                    <Affiliation>Urology and Pathology, University of Michigan School of Medicine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shiozawa</LastName>
                    <ForeName>Yusuke</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Periodontics and Oral Medicine, University of Michigan School of Dentistry.</Affiliation>
                </Author>
                <Author>
                    <LastName>Taichman</LastName>
                    <ForeName>Russell S</ForeName>
                    <Initials>RS</Initials>
                    <Affiliation>Periodontics and Oral Medicine, University of Michigan School of Dentistry rtaich@umich.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <GrantList>
                <Grant>
                    <GrantID>P01 CA093900</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 AR046024</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R43 AR056893</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R44 DE022493</GrantID>
                    <Acronym>DE</Acronym>
                    <Agency>NIDCR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U54 CA163124</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Mol Cancer Res</MedlineTA>
            <NlmUniqueID>101150042</NlmUniqueID>
            <ISSNLinking>1541-7786</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1541-7786.MCR-14-0118</ArticleId>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-14-0118</ArticleId>
            <ArticleId IdType="pubmed">25139998</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139996</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1091-6490</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
                <ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Nedd9 restrains renal cystogenesis in Pkd1-/- mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">201405362</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Mutations inactivating the cilia-localized Pkd1 protein result in autosomal dominant polycystic kidney disease (ADPKD), a serious inherited syndrome affecting ???1 in 500 people, in which accumulation of renal cysts eventually destroys kidney function. Severity of ADPKD varies throughout the population, for reasons thought to involve differences both in intragenic Pkd1 mutations and in modifier alleles. The scaffolding protein NEDD9, commonly dysregulated during cancer progression, interacts with Aurora-A (AURKA) kinase to control ciliary resorption, and with Src and other partners to influence proliferative signaling pathways often activated in ADPKD. We here demonstrate Nedd9 expression is deregulated in human ADPKD and a mouse ADPKD model. Although genetic ablation of Nedd9 does not independently influence cystogenesis, constitutive absence of Nedd9 strongly promotes cyst formation in the tamoxifen-inducible Pkd1fl/fl;Cre/Esr1(+) mouse model of ADPKD. This cystogenic effect is associated with striking morphological defects in the cilia of Pkd1(-/-);Nedd9(-/-) mice, associated with specific loss of ciliary localization of adenylase cyclase III in the doubly mutant genotype. Ciliary phenotypes imply a failure of Aurora-A activation: Compatible with this idea, Pkd1(-/-);Nedd9(-/-) mice had ciliary resorption defects, and treatment of Pkd1(-/-) mice with a clinical Aurora-A kinase inhibitor exacerbated cystogenesis. In addition, activation of the ADPKD-associated signaling effectors Src, Erk, and the mTOR effector S6 was enhanced, and Ca(2+) response to external stimuli was reduced, in Pkd1(-/-);Nedd9(-/-) versus Pkd1(-/-) mice. Together, these results indicated an important modifier action of Nedd9 on ADPKD pathogenesis involving failure to activate Aurora-A.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Nikonova</LastName>
                    <ForeName>Anna S</ForeName>
                    <Initials>AS</Initials>
                    <Affiliation>Programs in Developmental Therapeutics and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Plotnikova</LastName>
                    <ForeName>Olga V</ForeName>
                    <Initials>OV</Initials>
                    <Affiliation>Programs in Developmental Therapeutics and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Serzhanova</LastName>
                    <ForeName>Victoria</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Programs in Developmental Therapeutics and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Efimov</LastName>
                    <ForeName>Andrey</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Cancer Biology, Fox Chase Cancer Center, Philadelphia, PA 19111.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bogush</LastName>
                    <ForeName>Igor</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Programs in Developmental Therapeutics and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cai</LastName>
                    <ForeName>Kathy Q</ForeName>
                    <Initials>KQ</Initials>
                    <Affiliation>Cancer Biology, Fox Chase Cancer Center, Philadelphia, PA 19111.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hensley</LastName>
                    <ForeName>Harvey H</ForeName>
                    <Initials>HH</Initials>
                    <Affiliation>Programs in Developmental Therapeutics and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Egleston</LastName>
                    <ForeName>Brian L</ForeName>
                    <Initials>BL</Initials>
                    <Affiliation>Programs in Developmental Therapeutics and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Klein-Szanto</LastName>
                    <ForeName>Andres</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Cancer Biology, Fox Chase Cancer Center, Philadelphia, PA 19111.</Affiliation>
                </Author>
                <Author>
                    <LastName>Seeger-Nukpezah</LastName>
                    <ForeName>Tamina</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Programs in Developmental Therapeutics and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Golemis</LastName>
                    <ForeName>Erica A</ForeName>
                    <Initials>EA</Initials>
                    <Affiliation>Programs in Developmental Therapeutics and erica.golemis@fccc.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
            <NlmUniqueID>7505876</NlmUniqueID>
            <ISSNLinking>0027-8424</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">HEF1</Keyword>
            <Keyword MajorTopicYN="N">STA-2842</Keyword>
            <Keyword MajorTopicYN="N">ganetespib</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1405362111</ArticleId>
            <ArticleId IdType="doi">10.1073/pnas.1405362111</ArticleId>
            <ArticleId IdType="pubmed">25139996</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139994</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1091-6490</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
                <ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">201414364</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Conflicting results have been reported for the roles of cGMP and cGMP-dependent protein kinase I (cGKI) in various pathological conditions leading to cardiac hypertrophy and fibrosis. A cardioprotective effect of cGMP/cGKI has been reported in whole animals and isolated cardiomyocytes, but recent evidence from a mouse model expressing cGKI?? only in smooth muscle (??RM) but not in cardiomyocytes, endothelial cells, or fibroblasts has forced a reevaluation of the requirement for cGKI activity in the cardiomyocyte antihypertrophic effects of cGMP. In particular, ??RM mice developed the same hypertrophy as WT controls when subjected to thoracic aortic constriction or isoproterenol infusion. Here, we challenged ??RM and WT (Ctr) littermate control mice with angiotensin II (AII) infusion (7 d; 2 mg???kg(-1)???d(-1)) to induce hypertrophy. Both genotypes developed cardiac hypertrophy, which was more pronounced in Ctr animals. Cardiomyocyte size and interstitial fibrosis were increased equally in both genotypes. Addition of sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, in the drinking water had a small effect in reducing myocyte hypertrophy in WT mice and no effect in ??RM mice. However, sildenafil substantially blocked the increase in collagen I, fibronectin 1, TGF??, and CTGF mRNA in Ctr but not in ??RM hearts. These data indicate that, for the initial phase of AII-induced cardiac hypertrophy, lack of cardiomyocyte cGKI activity does not worsen hypertrophic growth. However, expression of cGKI in one or more cell types other than smooth muscle is necessary to allow the antifibrotic effect of sildenafil.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Patrucco</LastName>
                    <ForeName>Enrico</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Forschergruppe 923, Institut f??r Pharmakologie und Toxikologie, Technische Universit??t M??nchen, 80802 Munich, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Domes</LastName>
                    <ForeName>Katrin</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Forschergruppe 923, Institut f??r Pharmakologie und Toxikologie, Technische Universit??t M??nchen, 80802 Munich, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Sbroggi??</LastName>
                    <ForeName>Mauro</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Centro Nacional de Investigaciones Cardiovasculares, E-28029 Madrid, Spain;</Affiliation>
                </Author>
                <Author>
                    <LastName>Blaich</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Forschergruppe 923, Institut f??r Pharmakologie und Toxikologie, Technische Universit??t M??nchen, 80802 Munich, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Schlossmann</LastName>
                    <ForeName>Jens</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Lehrstuhl f??r Pharmakologie und Toxikologie, Institut f??r Pharmazie, Universit??t Regensburg, 93055 Regensburg, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Desch</LastName>
                    <ForeName>Matthias</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Lehrstuhl f??r Pharmakologie und Toxikologie, Institut f??r Pharmazie, Universit??t Regensburg, 93055 Regensburg, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Rybalkin</LastName>
                    <ForeName>Sergei D</ForeName>
                    <Initials>SD</Initials>
                    <Affiliation>Department of Pharmacology, University of Washington, Seattle, WA 98195-7280; and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Beavo</LastName>
                    <ForeName>Joseph A</ForeName>
                    <Initials>JA</Initials>
                    <Affiliation>Department of Pharmacology, University of Washington, Seattle, WA 98195-7280; and franz.hofmann@mytum.de beavo@u.washington.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lukowski</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Institute of Pharmacy, Department of Pharmacology, Toxicology and Clinical Pharmacy, University of T??bingen, D-72076 T??bingen, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hofmann</LastName>
                    <ForeName>Franz</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Forschergruppe 923, Institut f??r Pharmakologie und Toxikologie, Technische Universit??t M??nchen, 80802 Munich, Germany; franz.hofmann@mytum.de beavo@u.washington.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
            <NlmUniqueID>7505876</NlmUniqueID>
            <ISSNLinking>0027-8424</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">NO/cyclic GMP system</Keyword>
            <Keyword MajorTopicYN="N">PDE</Keyword>
            <Keyword MajorTopicYN="N">PKGI</Keyword>
            <Keyword MajorTopicYN="N">cardiac failure</Keyword>
            <Keyword MajorTopicYN="N">hypertension</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1414364111</ArticleId>
            <ArticleId IdType="doi">10.1073/pnas.1414364111</ArticleId>
            <ArticleId IdType="pubmed">25139994</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139991</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1091-6490</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
                <ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">201324235</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Endothelial cells (ECs) express fibroblast growth factor receptors (FGFRs) and are exquisitely sensitive to FGF signals. However, whether the EC or another vascular cell type requires FGF signaling during development, homeostasis, and response to injury is not known. Here, we show that Flk1-Cre or Tie2-Cre mediated deletion of FGFR1 and FGFR2 (Fgfr1/2(Flk1-Cre) or Fgfr1/2(Tie2-Cre) mice), which results in deletion in endothelial and hematopoietic cells, is compatible with normal embryonic development. As adults, Fgfr1/2(Flk1-Cre) mice maintain normal blood pressure and vascular reactivity and integrity under homeostatic conditions. However, neovascularization after skin or eye injury was significantly impaired in both Fgfr1/2(Flk1-Cre) and Fgfr1/2(Tie2-Cre) mice, independent of either hematopoietic cell loss of FGFR1/2 or vascular endothelial growth factor receptor 2 (Vegfr2) haploinsufficiency. Also, impaired neovascularization was associated with delayed cutaneous wound healing. These findings reveal a key requirement for cell-autonomous EC FGFR signaling in injury-induced angiogenesis, but not for vascular homeostasis, identifying the EC FGFR signaling pathway as a target for diseases associated with aberrant vascular proliferation, such as age-related macular degeneration, and for modulating wound healing without the potential toxicity associated with direct manipulation of systemic FGF or VEGF activity.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Oladipupo</LastName>
                    <ForeName>Sunday S</ForeName>
                    <Initials>SS</Initials>
                    <Affiliation>Departments of Developmental Biology.</Affiliation>
                </Author>
                <Author>
                    <LastName>Smith</LastName>
                    <ForeName>Craig</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Departments of Developmental Biology.</Affiliation>
                </Author>
                <Author>
                    <LastName>Santeford</LastName>
                    <ForeName>Andrea</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Ophthalmology and Visual Sciences.</Affiliation>
                </Author>
                <Author>
                    <LastName>Park</LastName>
                    <ForeName>Changwon</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Pathology and Immunology.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sene</LastName>
                    <ForeName>Abdoulaye</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Ophthalmology and Visual Sciences.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wiley</LastName>
                    <ForeName>Luke A</ForeName>
                    <Initials>LA</Initials>
                    <Affiliation>Ophthalmology and Visual Sciences.</Affiliation>
                </Author>
                <Author>
                    <LastName>Osei-Owusu</LastName>
                    <ForeName>Patrick</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Cell Biology and Physiology, and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hsu</LastName>
                    <ForeName>Joann</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Departments of Developmental Biology.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zapata</LastName>
                    <ForeName>Nicole</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Ophthalmology and Visual Sciences.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Fang</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Pathology and Immunology.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nakamura</LastName>
                    <ForeName>Rei</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Ophthalmology and Visual Sciences.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lavine</LastName>
                    <ForeName>Kory J</ForeName>
                    <Initials>KJ</Initials>
                    <Affiliation>Departments of Developmental Biology,Medicine, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation>
                </Author>
                <Author>
                    <LastName>Blumer</LastName>
                    <ForeName>Kendall J</ForeName>
                    <Initials>KJ</Initials>
                    <Affiliation>Cell Biology and Physiology, and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Choi</LastName>
                    <ForeName>Kyunghee</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Pathology and Immunology.</Affiliation>
                </Author>
                <Author>
                    <LastName>Apte</LastName>
                    <ForeName>Rajendra S</ForeName>
                    <Initials>RS</Initials>
                    <Affiliation>Departments of Developmental Biology,Ophthalmology and Visual Sciences, apte@vision.wustl.edu dornitz@wustl.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ornitz</LastName>
                    <ForeName>David M</ForeName>
                    <Initials>DM</Initials>
                    <Affiliation>Departments of Developmental Biology, apte@vision.wustl.edu dornitz@wustl.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
            <NlmUniqueID>7505876</NlmUniqueID>
            <ISSNLinking>0027-8424</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">choroidal neovascularization</Keyword>
            <Keyword MajorTopicYN="N">neoangiogenesis</Keyword>
            <Keyword MajorTopicYN="N">oxygen-induced retinopathy</Keyword>
            <Keyword MajorTopicYN="N">retinopathy of prematurity</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1324235111</ArticleId>
            <ArticleId IdType="doi">10.1073/pnas.1324235111</ArticleId>
            <ArticleId IdType="pubmed">25139991</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25139902</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2150-7511</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>5</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>mBio</Title>
                <ISOAbbreviation>MBio</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genome-Wide Mutant Fitness Profiling Identifies Nutritional Requirements for Optimal Growth of Yersinia pestis in Deep Tissue.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1128/mBio.01385-14</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">e01385-14</ELocationID>
            <Abstract>
                <AbstractText Label="UNLABELLED">Rapid growth in deep tissue is essential to the high virulence of Yersinia pestis, causative agent of plague. To better understand the mechanisms underlying this unusual ability, we used transposon mutagenesis and high-throughput sequencing (Tn-seq) to systematically probe the Y.??pestis genome for elements contributing to fitness during infection. More than a million independent insertion mutants representing nearly 200,000 unique genotypes were generated in fully virulent Y.??pestis. Each mutant in the library was assayed for its ability to proliferate in vitro on rich medium and in mice following intravenous injection. Virtually all genes previously established to contribute to virulence following intravenous infection showed significant fitness defects, with the exception of genes for yersiniabactin biosynthesis, which were masked by strong intercellular complementation effects. We also identified more than 30 genes with roles in nutrient acquisition and metabolism as experiencing strong selection during infection. Many of these genes had not previously been implicated in Y.??pestis virulence. We further examined the fitness defects of strains carrying mutations in two such genes-encoding a branched-chain amino acid importer (brnQ) and a glucose importer (ptsG)-both in vivo and in a novel defined synthetic growth medium with nutrient concentrations matching those in serum. Our findings suggest that diverse nutrient limitations in deep tissue play a more important role in controlling bacterial infection than has heretofore been appreciated. Because much is known about Y.??pestis pathogenesis, this study also serves as a test case that assesses the ability of Tn-seq to detect virulence genes.</AbstractText>
                <AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Our understanding of the functions required by bacteria to grow in deep tissues is limited, in part because most growth studies of pathogenic bacteria are conducted on laboratory media that do not reflect conditions prevailing in infected animal tissues. Improving our knowledge of this aspect of bacterial biology is important as a potential pathway to the development of novel therapeutics. Yersinia pestis, the plague bacterium, is highly virulent due to its rapid dissemination and growth in deep tissues, making it a good model for discovering bacterial adaptations that promote rapid growth during infection. Using Tn-seq, a genome-wide fitness profiling technique, we identified several functions required for fitness of Y.??pestis in vivo that were not previously known to be important. Most of these functions are needed to acquire or synthesize nutrients. Interference with these critical nutrient acquisition pathways may be an effective strategy for designing novel antibiotics and vaccines.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Palace et al.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Palace</LastName>
                    <ForeName>Samantha G</ForeName>
                    <Initials>SG</Initials>
                    <Affiliation>Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Proulx</LastName>
                    <ForeName>Megan K</ForeName>
                    <Initials>MK</Initials>
                    <Affiliation>Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Shan</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baker</LastName>
                    <ForeName>Richard E</ForeName>
                    <Initials>RE</Initials>
                    <Affiliation>Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goguen</LastName>
                    <ForeName>Jon D</ForeName>
                    <Initials>JD</Initials>
                    <Affiliation>Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts, USA jon.goguen@umassmed.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>MBio</MedlineTA>
            <NlmUniqueID>101519231</NlmUniqueID>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">mBio.01385-14</ArticleId>
            <ArticleId IdType="doi">10.1128/mBio.01385-14</ArticleId>
            <ArticleId IdType="pubmed">25139902</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139875</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1524-4628</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Stroke; a journal of cerebral circulation</Title>
                <ISOAbbreviation>Stroke</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Intervention of Death-Associated Protein Kinase 1-p53 Interaction Exerts the Therapeutic Effects Against Stroke.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">STROKEAHA.114.006348</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND AND PURPOSE" NlmCategory="OBJECTIVE">Death-associated protein kinase 1 (DAPK1) interacts with the tumor suppressor gene p53 via a direct binding of a death domain of DAPK1 to a DNA-binding motif (DM) of p53 (p53DM) and converges multiple cell death pathways in stroke. The goals of this study are to determine whether disruption of DAPK1-p53 interaction is therapeutically effective against stroke.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We synthesized a membrane-permeable p53DM peptide (Tat-p53DM) and tested the therapeutic effects of Tat-p53DM in a mouse model with stroke.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We showed that Tat-p53DM blocked DAPK1-p53 interaction in brain cells in vivo. When administered 6 hours after stroke onset in adult male mice, Tat-p53DM was still therapeutically effective against brain damages and improved neurological functions.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">DAPK1-p53 interaction is a preferred target for therapeutic intervention of stroke.</AbstractText>
                <CopyrightInformation>?? 2014 American Heart Association, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Xiaoxi</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>From the Department of Physiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (X.W., L.P., H.Y., N.W., S.W., X.Y., Q.T., Y.L.); Department of Physiology and Pathophysiology, Jiujiang University, Jiujiang, China (Z.W.); and Institute for Brain Research, Huazhong University of Science and Technology, Wuhan, China (X.W., L.P., H.Y., Z.W., N.W., S.W., X.Y., Y.L.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Pei</LastName>
                    <ForeName>Lei</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>From the Department of Physiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (X.W., L.P., H.Y., N.W., S.W., X.Y., Q.T., Y.L.); Department of Physiology and Pathophysiology, Jiujiang University, Jiujiang, China (Z.W.); and Institute for Brain Research, Huazhong University of Science and Technology, Wuhan, China (X.W., L.P., H.Y., Z.W., N.W., S.W., X.Y., Y.L.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Yan</LastName>
                    <ForeName>Honglin</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>From the Department of Physiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (X.W., L.P., H.Y., N.W., S.W., X.Y., Q.T., Y.L.); Department of Physiology and Pathophysiology, Jiujiang University, Jiujiang, China (Z.W.); and Institute for Brain Research, Huazhong University of Science and Technology, Wuhan, China (X.W., L.P., H.Y., Z.W., N.W., S.W., X.Y., Y.L.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Zhongping</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>From the Department of Physiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (X.W., L.P., H.Y., N.W., S.W., X.Y., Q.T., Y.L.); Department of Physiology and Pathophysiology, Jiujiang University, Jiujiang, China (Z.W.); and Institute for Brain Research, Huazhong University of Science and Technology, Wuhan, China (X.W., L.P., H.Y., Z.W., N.W., S.W., X.Y., Y.L.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Wei</LastName>
                    <ForeName>Na</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>From the Department of Physiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (X.W., L.P., H.Y., N.W., S.W., X.Y., Q.T., Y.L.); Department of Physiology and Pathophysiology, Jiujiang University, Jiujiang, China (Z.W.); and Institute for Brain Research, Huazhong University of Science and Technology, Wuhan, China (X.W., L.P., H.Y., Z.W., N.W., S.W., X.Y., Y.L.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Shan</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>From the Department of Physiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (X.W., L.P., H.Y., N.W., S.W., X.Y., Q.T., Y.L.); Department of Physiology and Pathophysiology, Jiujiang University, Jiujiang, China (Z.W.); and Institute for Brain Research, Huazhong University of Science and Technology, Wuhan, China (X.W., L.P., H.Y., Z.W., N.W., S.W., X.Y., Y.L.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Xin</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>From the Department of Physiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (X.W., L.P., H.Y., N.W., S.W., X.Y., Q.T., Y.L.); Department of Physiology and Pathophysiology, Jiujiang University, Jiujiang, China (Z.W.); and Institute for Brain Research, Huazhong University of Science and Technology, Wuhan, China (X.W., L.P., H.Y., Z.W., N.W., S.W., X.Y., Y.L.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Tian</LastName>
                    <ForeName>Qing</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>From the Department of Physiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (X.W., L.P., H.Y., N.W., S.W., X.Y., Q.T., Y.L.); Department of Physiology and Pathophysiology, Jiujiang University, Jiujiang, China (Z.W.); and Institute for Brain Research, Huazhong University of Science and Technology, Wuhan, China (X.W., L.P., H.Y., Z.W., N.W., S.W., X.Y., Y.L.). tianq@hust.edu.cn lym@hust.edu.cn.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lu</LastName>
                    <ForeName>Youming</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>From the Department of Physiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (X.W., L.P., H.Y., N.W., S.W., X.Y., Q.T., Y.L.); Department of Physiology and Pathophysiology, Jiujiang University, Jiujiang, China (Z.W.); and Institute for Brain Research, Huazhong University of Science and Technology, Wuhan, China (X.W., L.P., H.Y., Z.W., N.W., S.W., X.Y., Y.L.). tianq@hust.edu.cn lym@hust.edu.cn.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Stroke</MedlineTA>
            <NlmUniqueID>0235266</NlmUniqueID>
            <ISSNLinking>0039-2499</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">death-associated protein kinases</Keyword>
            <Keyword MajorTopicYN="N">stroke</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">STROKEAHA.114.006348</ArticleId>
            <ArticleId IdType="doi">10.1161/STROKEAHA.114.006348</ArticleId>
            <ArticleId IdType="pubmed">25139875</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25139858</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1477-9129</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>141</Volume>
                    <Issue>17</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Development (Cambridge, England)</Title>
                <ISOAbbreviation>Development</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Nephric duct insertion requires EphA4/EphA7 signaling from the pericloacal mesenchyme.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3420-30</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.113928</ELocationID>
            <Abstract>
                <AbstractText>The vesico-ureteric junction (VUJ) forms through a complex developmental program that connects the primordium of the upper urinary tract [the nephric duct (ND)] with that of the lower urinary tract (the cloaca). The signals that orchestrate the various tissue interactions in this program are poorly understood. Here, we show that two members of the EphA subfamily of receptor tyrosine kinases, EphA4 and EphA7, are specifically expressed in the mesenchyme surrounding the caudal ND and the cloaca, and that Epha4(-/-);Epha7(+/-) and Epha4(-/-);Epha7(-/-) (DKO) mice display distal ureter malformations including ureterocele, blind and ectopically ending ureters with associated hydroureter, megaureter and hydronephrosis. We trace these defects to a late or absent fusion of the ND with the cloaca. In DKO embryos, the ND extends normally and approaches the cloaca but the tip subsequently looses its integrity. Expression of Gata3 and Lhx1 and their downstream target Ret is severely reduced in the caudal ND. Conditional deletion of ephrin B2 from the ND largely phenocopies these changes, suggesting that EphA4/EphA7 from the pericloacal mesenchyme signal via ephrin B2 to mediate ND insertion. Disturbed activity of this signaling module may entail defects of the VUJ, which are frequent in the spectrum of congenital anomalies of the kidney and the urinary tract (CAKUT) in human newborns.</AbstractText>
                <CopyrightInformation>?? 2014. Published by The Company of Biologists Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Weiss</LastName>
                    <ForeName>Anna-Carina</ForeName>
                    <Initials>AC</Initials>
                    <Affiliation>Institut f??r Molekularbiologie, Medizinische Hochschule Hannover, D-30625 Hannover, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Airik</LastName>
                    <ForeName>Rannar</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Institut f??r Molekularbiologie, Medizinische Hochschule Hannover, D-30625 Hannover, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bohnenpoll</LastName>
                    <ForeName>Tobias</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Institut f??r Molekularbiologie, Medizinische Hochschule Hannover, D-30625 Hannover, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Greulich</LastName>
                    <ForeName>Franziska</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Institut f??r Molekularbiologie, Medizinische Hochschule Hannover, D-30625 Hannover, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Foik</LastName>
                    <ForeName>Anna</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Institut f??r Molekularbiologie, Medizinische Hochschule Hannover, D-30625 Hannover, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trowe</LastName>
                    <ForeName>Mark-Oliver</ForeName>
                    <Initials>MO</Initials>
                    <Affiliation>Institut f??r Molekularbiologie, Medizinische Hochschule Hannover, D-30625 Hannover, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rudat</LastName>
                    <ForeName>Carsten</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Institut f??r Molekularbiologie, Medizinische Hochschule Hannover, D-30625 Hannover, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Costantini</LastName>
                    <ForeName>Frank</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Genetics and Development, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adams</LastName>
                    <ForeName>Ralf H</ForeName>
                    <Initials>RH</Initials>
                    <Affiliation>Max-Planck-Institute for Molecular Biomedicine, Department of Tissue Morphogenesis, and University of M??nster, Faculty of Medicine, D-48149 M??nster, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kispert</LastName>
                    <ForeName>Andreas</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Institut f??r Molekularbiologie, Medizinische Hochschule Hannover, D-30625 Hannover, Germany kispert.andreas@mh-hannover.de.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Development</MedlineTA>
            <NlmUniqueID>8701744</NlmUniqueID>
            <ISSNLinking>0950-1991</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CAKUT</Keyword>
            <Keyword MajorTopicYN="N">Eph</Keyword>
            <Keyword MajorTopicYN="N">Ephrin</Keyword>
            <Keyword MajorTopicYN="N">Mouse</Keyword>
            <Keyword MajorTopicYN="N">Nephric duct</Keyword>
            <Keyword MajorTopicYN="N">Vesicoureteric junction obstruction</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">141/17/3420</ArticleId>
            <ArticleId IdType="doi">10.1242/dev.113928</ArticleId>
            <ArticleId IdType="pubmed">25139858</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25139855</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1477-9129</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>141</Volume>
                    <Issue>17</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Development (Cambridge, England)</Title>
                <ISOAbbreviation>Development</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Nuclear removal during terminal lens fiber cell differentiation requires CDK1 activity: appropriating mitosis-related nuclear disassembly.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3388-98</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.106005</ELocationID>
            <Abstract>
                <AbstractText>Lens epithelial cells and early lens fiber cells contain the typical complement of intracellular organelles. However, as lens fiber cells mature they must destroy their organelles, including nuclei, in a process that has remained enigmatic for over a century, but which is crucial for the formation of the organelle-free zone in the center of the lens that assures clarity and function to transmit light. Nuclear degradation in lens fiber cells requires the nuclease DNase II?? (DLAD) but the mechanism by which DLAD gains access to nuclear DNA remains unknown. In eukaryotic cells, cyclin-dependent kinase 1 (CDK1), in combination with either activator cyclins A or B, stimulates mitotic entry, in part, by phosphorylating the nuclear lamin proteins leading to the disassembly of the nuclear lamina and subsequent nuclear envelope breakdown. Although most post-mitotic cells lack CDK1 and cyclins, lens fiber cells maintain these proteins. Here, we show that loss of CDK1 from the lens inhibited the phosphorylation of nuclear lamins A and C, prevented the entry of DLAD into the nucleus, and resulted in abnormal retention of nuclei. In the presence of CDK1, a single focus of the phosphonuclear mitotic apparatus is observed, but it is not focused in CDK1-deficient lenses. CDK1 deficiency inhibited mitosis, but did not prevent DNA replication, resulting in an overall reduction of lens epithelial cells, with the remaining cells possessing an abnormally large nucleus. These observations suggest that CDK1-dependent phosphorylations required for the initiation of nuclear membrane disassembly during mitosis are adapted for removal of nuclei during fiber cell differentiation.</AbstractText>
                <CopyrightInformation>?? 2014. Published by The Company of Biologists Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chaffee</LastName>
                    <ForeName>Blake R</ForeName>
                    <Initials>BR</Initials>
                    <Affiliation>Department of Biology, Miami University, Oxford, OH 45056, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shang</LastName>
                    <ForeName>Fu</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Laboratory for Nutrition and Vision Research, Human Nutrition Research Center on Aging, Nutrition &amp;Vision Res-USDA-HNRCA, Tufts University, Boston 02111, MA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Min-Lee</ForeName>
                    <Initials>ML</Initials>
                    <Affiliation>Laboratory for Nutrition and Vision Research, Human Nutrition Research Center on Aging, Nutrition &amp;Vision Res-USDA-HNRCA, Tufts University, Boston 02111, MA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Clement</LastName>
                    <ForeName>Tracy M</ForeName>
                    <Initials>TM</Initials>
                    <Affiliation>National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC 27709, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eddy</LastName>
                    <ForeName>Edward M</ForeName>
                    <Initials>EM</Initials>
                    <Affiliation>National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC 27709, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wagner</LastName>
                    <ForeName>Brad D</ForeName>
                    <Initials>BD</Initials>
                    <Affiliation>Department of Biology, Miami University, Oxford, OH 45056, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakahara</LastName>
                    <ForeName>Masaki</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Molecular and Cellular Physiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nagata</LastName>
                    <ForeName>Shigekazu</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Medical Chemistry, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robinson</LastName>
                    <ForeName>Michael L</ForeName>
                    <Initials>ML</Initials>
                    <Affiliation>Department of Biology, Miami University, Oxford, OH 45056, USA robinsm5@miamioh.edu allen.taylor@tufts.edu.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Taylor</LastName>
                    <ForeName>Allen</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Laboratory for Nutrition and Vision Research, Human Nutrition Research Center on Aging, Nutrition &amp;Vision Res-USDA-HNRCA, Tufts University, Boston 02111, MA, USA Department of Biological Chemistry, Weizmann Institute of Science, Rehovot, Israel robinsm5@miamioh.edu allen.taylor@tufts.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Development</MedlineTA>
            <NlmUniqueID>8701744</NlmUniqueID>
            <ISSNLinking>0950-1991</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CDK1</Keyword>
            <Keyword MajorTopicYN="N">Lens fiber differentiation</Keyword>
            <Keyword MajorTopicYN="N">Mouse</Keyword>
            <Keyword MajorTopicYN="N">Organelle-free zone</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">141/17/3388</ArticleId>
            <ArticleId IdType="doi">10.1242/dev.106005</ArticleId>
            <ArticleId IdType="pubmed">25139855</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25139854</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1477-9129</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>141</Volume>
                    <Issue>17</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Development (Cambridge, England)</Title>
                <ISOAbbreviation>Development</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Runx1 is required for progression of CD41+ embryonic precursors into HSCs but not prior to this.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3319-23</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.110841</ELocationID>
            <Abstract>
                <AbstractText>Haematopoiesis in adult animals is maintained by haematopoietic stem cells (HSCs), which self-renew and can give rise to all blood cell lineages. The AGM region is an important intra-embryonic site of HSC development and a wealth of evidence indicates that HSCs emerge from the endothelium of the embryonic dorsal aorta and extra-embryonic large arteries. This, however, is a stepwise process that occurs through sequential upregulation of CD41 and CD45 followed by emergence of fully functional definitive HSCs. Although largely dispensable at later stages, the Runx1 transcription factor is crucially important during developmental maturation of HSCs; however, exact points of crucial involvement of Runx1 in this multi-step developmental maturation process remain unclear. Here, we have investigated requirements for Runx1 using a conditional reversible knockout strategy. We report that Runx1 deficiency does not preclude formation of VE-cad+CD45-CD41+ cells, which are phenotypically equivalent to precursors of definitive HSCs (pre-HSC Type I) but blocks transition to the subsequent CD45+ stage (pre-HSC Type II). These data emphasise that developmental progression of HSCs during a very short period of time is regulated by precise stage-specific molecular mechanisms.</AbstractText>
                <CopyrightInformation>?? 2014. Published by The Company of Biologists Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Liakhovitskaia</LastName>
                    <ForeName>Anna</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rybtsov</LastName>
                    <ForeName>Stanislav</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smith</LastName>
                    <ForeName>Tom</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Batsivari</LastName>
                    <ForeName>Antoniana</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rybtsova</LastName>
                    <ForeName>Natalia</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rode</LastName>
                    <ForeName>Christina</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Bruijn</LastName>
                    <ForeName>Marella</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buchholz</LastName>
                    <ForeName>Frank</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gordon-Keylock</LastName>
                    <ForeName>Sabrina</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Suling</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Medvinsky</LastName>
                    <ForeName>Alexander</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK a.medvinsky@ed.ac.uk.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Development</MedlineTA>
            <NlmUniqueID>8701744</NlmUniqueID>
            <ISSNLinking>0950-1991</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">AGM region</Keyword>
            <Keyword MajorTopicYN="N">CD41</Keyword>
            <Keyword MajorTopicYN="N">HSC</Keyword>
            <Keyword MajorTopicYN="N">Mouse</Keyword>
            <Keyword MajorTopicYN="N">Runx1</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">141/17/3319</ArticleId>
            <ArticleId IdType="doi">10.1242/dev.110841</ArticleId>
            <ArticleId IdType="pubmed">25139854</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139839</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1460-2091</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of antimicrobial chemotherapy</Title>
                <ISOAbbreviation>J. Antimicrob. Chemother.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">dku318</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Over-the-counter access to an inexpensive, effective topical microbicide could reduce the transmission of HIV and would increase women's control over their health and eliminate the need to obtain their partners' consent for prophylaxis. Chronic infection with herpes simplex virus 2 (HSV-2), also known as human herpes virus 2, has been shown to facilitate HIV infection and speed the progression to immunodeficiency disease. Our objective is to develop a drug formulation that protects against both HSV-2 and HIV infection and adheres to the vaginal surface with extended residence time.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We developed a formulation using two approved antiviral active pharmaceutical ingredients, aciclovir and tenofovir, in a novel bioadhesive vaginal delivery platform (designated SR-2P) composed of two polymers, poloxamer 407 NF (Pluronic(??) F-127) and polycarbophil USP (Noveon(??) AA-1). The efficacy of the formulation to protect from HSV-2 infection was tested in vitro and in vivo. In addition to its efficacy, it is essential for a successful microbicide to be non-irritating to the vaginal mucosa. We therefore tested our SR-2P platform gel in the FDA gold-standard microbicide safety model in rabbits and also in a rat vaginal irritation model.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Our studies indicated that SR-2P containing 1% aciclovir and 5% tenofovir protects (i) Vero cells from HSV-2 infection in vitro and (ii) mice from HSV-2 infection in vivo. Our results further demonstrated that SR-2P was not irritating in either vaginal irritation model.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We conclude that SR-2P containing aciclovir and tenofovir may be a suitable candidate microbicide to protect humans from vaginal HSV-2 infection.</AbstractText>
                <CopyrightInformation>?? The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Shankar</LastName>
                    <ForeName>Gita N</ForeName>
                    <Initials>GN</Initials>
                    <Affiliation>Pharmaceutical Development, Biosciences Division, SRI International, Menlo Park, CA, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Alt</LastName>
                    <ForeName>Carsten</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Palo Alto Veterans Institute for Research (PAVIR), VA Palo Alto Health Care System, Palo Alto, CA, USA carstalt@gmail.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Antimicrob Chemother</MedlineTA>
            <NlmUniqueID>7513617</NlmUniqueID>
            <ISSNLinking>0305-7453</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">HSV-2</Keyword>
            <Keyword MajorTopicYN="N">acyclovir</Keyword>
            <Keyword MajorTopicYN="N">antiviral</Keyword>
            <Keyword MajorTopicYN="N">microbicide</Keyword>
            <Keyword MajorTopicYN="N">vaginal</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">dku318</ArticleId>
            <ArticleId IdType="doi">10.1093/jac/dku318</ArticleId>
            <ArticleId IdType="pubmed">25139839</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139833</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0631</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Life sciences</Title>
                <ISOAbbreviation>Life Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prostaglandin E2 produced by inducible COX-2 and mPGES-1 promoting cancer cell proliferation in vitro and in vivo.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0024-3205(14)00680-8</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.lfs.2014.07.042</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">Many cancers originate and flourish in a prolonged inflammatory environment. Our aim is to understand the mechanisms of how the pathway of prostaglandin E2 (PGE2) biosynthesis and signaling can promote cancer growth in inflammatory environment at cellular and animal model levels.</AbstractText>
                <AbstractText Label="MAIN METHODS" NlmCategory="METHODS">In this study, a chronic inflammation pathway was mimicked with a stable cell line that over-expressed a novel human enzyme consisting of cyclooxygenase isoform-2 (COX-2) linked to microsomal (PGE2 synthase-1 (mPGES-1) for the overproduction of pathogenic PGE2. This PGE2-producing cell line was co-cultured and co-implanted with three human cancer cell lines including prostate, lung, and colon cancers in vitro and in vivo, respectively.</AbstractText>
                <AbstractText Label="KEY FINDINGS" NlmCategory="RESULTS">Increases in cell doubling rates for the three cancer cell types in the presence of the PGE2-producing cell line were clearly observed. In addition, one of the four human PGE2 subtype receptors, EP1, was used as a model to identify PGE2-signaling involved in promoting the cancer cell growth. This finding was further proven in vivo by co-implanting the PGE2-producing cells line and the EP1-positive cancer cells into the immune deficient mice, after that, it was observed that the PGE2-producing cells promoted all three types of cancer formation in the mice.</AbstractText>
                <AbstractText Label="SIGNIFICANCE" NlmCategory="CONCLUSIONS">This study clearly demonstrated that the human COX-2 linked to mPGES-1 is a pathway that, when mediated by the EP, is linked to promoting cancer growth in a chronic inflammatory environment. The identified pathway could be used as a novel target for developing and advancing anti-inflammation and anti-cancer interventions.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ruan</LastName>
                    <ForeName>Diana</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>I.I. Rabi Scholar Research Program, Columbia College, Columbia University, New York, New York 10027.</Affiliation>
                </Author>
                <Author>
                    <LastName>So</LastName>
                    <ForeName>Shui-Ping</ForeName>
                    <Initials>SP</Initials>
                    <Affiliation>Center for Experimental Therapeutics and Pharmacoinformatics, Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, TX 77204, USA. Electronic address: dtr2111@columbia.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Life Sci</MedlineTA>
            <NlmUniqueID>0375521</NlmUniqueID>
            <ISSNLinking>0024-3205</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cancers</Keyword>
            <Keyword MajorTopicYN="N">Cyclooxygenase</Keyword>
            <Keyword MajorTopicYN="N">Inflammation</Keyword>
            <Keyword MajorTopicYN="N">Microsomal PGE(2) synthase</Keyword>
            <Keyword MajorTopicYN="N">PGE(2) receptor</Keyword>
            <Keyword MajorTopicYN="N">Prostaglandin E(2) (PGE(2))</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0024-3205(14)00680-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.lfs.2014.07.042</ArticleId>
            <ArticleId IdType="pubmed">25139833</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139813</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1521-4184</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Archiv der Pharmazie</Title>
                <ISOAbbreviation>Arch. Pharm. (Weinheim)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Synthesis, Physicochemical, and Anticonvulsant Properties of New N-Mannich Bases Derived from Pyrrolidine-2,5-dione and Its 3-Methyl Analog.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/ardp.201400152</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">A series of 22 new N-[(4-phenylpiperazin-1-yl)-methyl]-3-methyl-pyrrolidine-2,5-dione and pyrrolidine-2,5-dione derivatives were synthesized and evaluated for their anticonvulsant activities in the maximum electroshock (MES) and subcutaneous pentylenetetrazole (scPTZ) seizure tests after intraperitoneal injection into mice. The neurotoxicity was determined applying the rotarod test. The in vivo results in mice showed that seven compounds were effective in the MES or/and scPTZ seizure tests. The quantitative evaluation in both tests after i.p. administration into mice revealed that the most active compounds were N-[{4-(3,4-dichlorophenyl)-piperazin-1-yl}-methyl]-3-methylpyrrolidine-2,5-dione (12) with ED50 ???=???16.13???mg/kg (MES), ED50 ???=???133.99???mg/kg (scPTZ) and N-[{4-(3,4-dichlorophenyl)-piperazin-1-yl}-methyl]-pyrrolidine-2,5-dione (23) with ED50 ???=???37.79???mg/kg (MES), ED50 ???=???128.82???mg/kg (scPTZ), whereas N-[{4-(3-trifluoromethylphenyl)-piperazin-1-yl}-methyl]-pyrrolidine-2,5-dione (24) was effective only in the MES test with ED50 ???=???16.37???mg/kg. These molecules showed higher potency and also lower neurotoxicity than the reference antiepileptic drugs such as ethosuximide and valproic acid.</AbstractText>
                <CopyrightInformation>?? 2014 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Rybka</LastName>
                    <ForeName>Sabina</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Faculty of Pharmacy, Department of Medicinal Chemistry, Jagiellonian University, Medical College, Krak??w, Poland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Obniska</LastName>
                    <ForeName>Jolanta</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Rapacz</LastName>
                    <ForeName>Anna</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Filipek</LastName>
                    <ForeName>Barbara</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author>
                    <LastName>Kami??ski</LastName>
                    <ForeName>Krzysztof</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Arch Pharm (Weinheim)</MedlineTA>
            <NlmUniqueID>0330167</NlmUniqueID>
            <ISSNLinking>0365-6233</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Anticonvulsant activity</Keyword>
            <Keyword MajorTopicYN="N">In vivo studies</Keyword>
            <Keyword MajorTopicYN="N">Mannich bases</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ardp.201400152</ArticleId>
            <ArticleId IdType="pubmed">25139813</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139798</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-2396</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Synapse (New York, N.Y.)</Title>
                <ISOAbbreviation>Synapse</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Reduced gene expression levels of Munc13-1 and additional components of the presynaptic exocytosis machinery upon conditional targeting of Vglut2 in the adolescent mouse.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/syn.21776</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Presynaptic proteins orchestrate an intricate interplay of dynamic interactions in order to regulate quantal exocytosis of transmitter-filled vesicles, and their dysregulation might cause neurological and neuropsychiatric dysfunction. Mice carrying a spatio-temporal restriction in the expression of the Vesicular glutamate transporter 2 (Vglut2; aka Slc17a6) in the cortex, amygdala and hippocampal subiculum from the third postnatal week show a strong anxiolytic phenotype and certain behavioural correlates of schizophrenia. To further understand the molecular consequences of this targeted deletion of Vglut2, we performed an unbiased microarray analysis comparing gene expression levels in the subiculum of these conditional Vglut2 knockout mice (Vglut2(f/f) (;CamKII) cKO) to those in control littermates. Expression of Unc13C (Munc13-3), a member of the Unc/Munc family, previously shown to be important for glutamatergic transmission, was identified to be significantly down-regulated. Subsequent analysis by quantitative RT-PCR revealed a 50% down-regulation of Munc 13-1, the gene encoding the Unc/Munc subtype described as an essential component in the majority of glutamtergic synapses in the hippocampus. Genes encoding additional components of the presynaptic machinery were also found regulated, including Rab3A, RIM1??, as well as Syntaxin1 and Synaptobrevin. Altered expression levels of these genes were further found in the amygdala and in the retrosplenial group of the cortex, additional regions in which Vglut2 was conditionally targeted. These findings suggest that expression levels of Vglut2 might be important for the maintenance of gene expression in the presynaptic machinery in the adult mouse brain. Synapse, 2014. ?? 2014 Wiley Periodicals, Inc.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Wiley Periodicals, Inc., a Wiley company.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Rajagopalan</LastName>
                    <ForeName>Aparna</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Neuroscience, Uppsala University, Box 593, S-752 37, Uppsala, Sweden.</Affiliation>
                </Author>
                <Author>
                    <LastName>Schweizer</LastName>
                    <ForeName>Nadine</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author>
                    <LastName>Nordenankar</LastName>
                    <ForeName>Karin</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Nilufar Jahan</LastName>
                    <ForeName>Sultana</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Emilsson</LastName>
                    <ForeName>Lina</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author>
                    <LastName>Wall??n-Mackenzie</LastName>
                    <ForeName>Asa</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Synapse</MedlineTA>
            <NlmUniqueID>8806914</NlmUniqueID>
            <ISSNLinking>0887-4476</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Amygdala</Keyword>
            <Keyword MajorTopicYN="N">Cortex</Keyword>
            <Keyword MajorTopicYN="N">Hippocampus</Keyword>
            <Keyword MajorTopicYN="N">Microarray, Schizophrenia</Keyword>
            <Keyword MajorTopicYN="N">Slc17a6</Keyword>
            <Keyword MajorTopicYN="N">Subiculum</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/syn.21776</ArticleId>
            <ArticleId IdType="pubmed">25139798</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139754</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-3231</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Theriogenology</Title>
                <ISOAbbreviation>Theriogenology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Relationship between macrophages in mouse uteri and angiogenesis in endometrium during the peri-implantation period.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0093-691X(14)00384-7</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.theriogenology.2014.07.025</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The objective of this study is to examine the change in macrophage numbers, inducible form of NO synthase (iNOS), and vascular endothelial growth factor (VEGF) expression both before and after embryo implantation in the uterine tissue of mice. In order to explore the mechanism of macrophages in endometrial angiogenesis, 8-week-old female mice were divided into three groups: pregnant group, pseudopregnant group (mated to male mice that had been vasectomized), and estrous group (unmated). Individuals from these three groups were sacrificed at time intervals D1.5 to D6.5. Formalin-fixed paraffin-embedded tissue was used for immunocytochemical localization of M??, iNOS, and VEGF utilizing standard methodology. The proportion of macrophages in the peripheral blood was determined by flow cytometry, and the relationship between macrophage, iNOS, and VEGF expression was analyzed. The proportion of peripheral blood macrophages in the pregnancy group was significantly higher than that in the other groups. The results of immunohistochemistry determined that the macrophages exhibited changes in both numbers and distribution. The number of macrophages in the endometrium of the pregnancy and pseudopregnancy groups was significantly higher than that in the control (estrous) group. In the pregnancy group, macrophage numbers dramatically decreased and gradually transferred to the perimetrium on D4.5. Immunostaining revealed strong staining in the pregnancy group and weaker staining in the pseudopregnant and control groups for both iNOS and VEGF. There was strong, dense immunostaining at the implantation site for both iNOS and VEGF, whereas light immunostaining was seen in interimplantation tissues on D5.5 to D6.5. In the pregnant group, peripheral blood and uterine macrophage proportions were negatively correlated, whereas the amount of macrophages, iNOS, and VEGF expression in the endometrium were positively correlated. The expression of iNOS and VEGF in the endometrium also displayed a strong positive correlation. In conclusion, during embryo implantation, macrophages levels decreased in the uterus, whereas the number of peripheral macrophages increased, suggesting that macrophages may migrate into the peripheral blood and uterus to adapt for pregnancy. Additionally, an increase in the expression of iNOS and VEGF was observed during the implantation window, implying that iNOS and VEGF may play an important role in promoting embryo implantation. The positive correlation between macrophages, iNOS, and VEGF in the implanting uterus implied that macrophages might regulate iNOS and VEGF during the implantation process.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Tan</LastName>
                    <ForeName>Wenya</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Leining</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Guo</LastName>
                    <ForeName>Lei</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ou</LastName>
                    <ForeName>Xianghong</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Xie</LastName>
                    <ForeName>Duo</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Quan</LastName>
                    <ForeName>Song</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, China. Electronic address: quansong2008@aliyun.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Theriogenology</MedlineTA>
            <NlmUniqueID>0421510</NlmUniqueID>
            <ISSNLinking>0093-691X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Angiogenesis</Keyword>
            <Keyword MajorTopicYN="N">Endometrium</Keyword>
            <Keyword MajorTopicYN="N">Induced nitric oxide synthase</Keyword>
            <Keyword MajorTopicYN="N">Macrophage</Keyword>
            <Keyword MajorTopicYN="N">Vascular endothelial growth factor</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0093-691X(14)00384-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.theriogenology.2014.07.025</ArticleId>
            <ArticleId IdType="pubmed">25139754</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139745</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1755-3245</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cardiovascular research</Title>
                <ISOAbbreviation>Cardiovasc. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Scrib:Rac1 interactions are required for the morphogenesis of the ventricular myocardium.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">cvu193</ELocationID>
            <Abstract>
                <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The organization and maturation of ventricular cardiomyocytes from the embryonic to the adult form is crucial for normal cardiac function. We have shown that a polarity protein, Scrib, may be involved in regulating the early stages of this process. Our goal was to establish whether Scrib plays a cell autonomous role in the ventricular myocardium and whether this involves well-known polarity pathways.</AbstractText>
                <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Deletion of Scrib in cardiac precursors utilising Scrib(flox) mice together with the Nkx2.5-Cre driver resulted in disruption of the cytoarchitecture of the forming trabeculae and ventricular septal defects. Although the majority of mice lacking Scrib in the myocardium survived to adulthood, they developed marked cardiac fibrosis. Scrib did not physically interact with the planar cell polarity protein (PCP) Vangl2 in early cardiomyocytes, as it does in other tissues, suggesting that the anomalies did not result from disruption of PCP signaling. However, Scrib interacted with Rac1 physically in embryonic cardiomyocytes and genetically to result in ventricular abnormalities, suggesting that this interaction is crucial for the development of the early myocardium.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The Scrib-Rac1 interaction plays a crucial role in the organization of developing cardiomyocytes and formation of the ventricular myocardium. Thus, we have identified a novel signaling pathway in the early, functioning, heart muscle. These data also show that the fetus can recover from relatively severe abnormalities in prenatal ventricular development, although cardiac fibrosis can be a long-term consequence.</AbstractText>
                <CopyrightInformation>?? The Author 2014. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Boczonadi</LastName>
                    <ForeName>Veronika</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Institute of Genetic Medicine, Newcastle University, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gillespie</LastName>
                    <ForeName>Rachel</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Institute of Genetic Medicine, Newcastle University, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Keenan</LastName>
                    <ForeName>Iain</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Institute of Genetic Medicine, Newcastle University, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ramsbottom</LastName>
                    <ForeName>Simon A</ForeName>
                    <Initials>SA</Initials>
                    <Affiliation>Institute of Genetic Medicine, Newcastle University, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Donald-Wilson</LastName>
                    <ForeName>Charlotte</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Institute of Genetic Medicine, Newcastle University, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Al Nazer</LastName>
                    <ForeName>Mariana</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Institute of Genetic Medicine, Newcastle University, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Humbert</LastName>
                    <ForeName>Patrick</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Cell Cycle and Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Australia Sir Peter MacCallum Department of Oncology Department of Biochemistry and Molecular Biology Department of Pathology, University of Melbourne, Parkville, Melbourne, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Schwarz</LastName>
                    <ForeName>Robert J</ForeName>
                    <Initials>RJ</Initials>
                    <Affiliation>University of Houston, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chaudhry</LastName>
                    <ForeName>Bill</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Institute of Genetic Medicine, Newcastle University, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Henderson</LastName>
                    <ForeName>Deborah J</ForeName>
                    <Initials>DJ</Initials>
                    <Affiliation>Institute of Genetic Medicine, Newcastle University, UK deborah.henderson@ncl.ac.uk.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Cardiovasc Res</MedlineTA>
            <NlmUniqueID>0077427</NlmUniqueID>
            <ISSNLinking>0008-6363</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">cvu193</ArticleId>
            <ArticleId IdType="doi">10.1093/cvr/cvu193</ArticleId>
            <ArticleId IdType="pubmed">25139745</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139744</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1755-3245</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cardiovascular research</Title>
                <ISOAbbreviation>Cardiovasc. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>THE CELLULAR PRION PROTEIN COUNTERACTS CARDIAC OXIDATIVE STRESS.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">cvu194</ELocationID>
            <Abstract>
                <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The cellular prion protein, PrP(C), whose aberrant isoforms are related to prion diseases of humans and animals, has a still obscure physiologic function. Having observed an increased expression of PrP(C) in two in vivo paradigms of heart remodelling, we focused on isolated mouse hearts to ascertain the capacity of PrP(C) to antagonize oxidative damage induced by ischemic and non-ischemic protocols.</AbstractText>
                <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Hearts isolated from mice expressing PrP(C) in variable amounts were subjected to different and complementary oxidative perfusion protocols. Accumulation of reactive oxygen species, oxidation of myofibrillar proteins and cell death were evaluated. We found that overexpressed PrP(C) reduced oxidative stress and cell death caused by post-ischemic reperfusion. Conversely, deletion of PrP(C) increased oxidative stress during both ischemic preconditioning and perfusion (15 min) with H2O2. Supporting its relation with intracellular systems involved in oxidative stress, PrP(C) was found to influence the activity of catalase and, for the first time, the expression of p66(Shc), a protein implicated in oxidative stress-mediated cell death.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our data demonstrate that PrP(C) contributes to the cardiac mechanisms antagonizing oxidative insults.</AbstractText>
                <CopyrightInformation>Published on behalf of the European Society of Cardiology. All rights reserved. ?? The Author 2014. For permissions please email: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Zanetti</LastName>
                    <ForeName>Filippo</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Biomedical Science.</Affiliation>
                </Author>
                <Author>
                    <LastName>Carpi</LastName>
                    <ForeName>Andrea</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Experimental Oncology, European Institute of Oncology, Milano, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Menab??</LastName>
                    <ForeName>Roberta</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>CNR Institute of Neuroscience, University of Padova, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Giorgio</LastName>
                    <ForeName>Marco</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Experimental Oncology, European Institute of Oncology, Milano, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Schulz</LastName>
                    <ForeName>Rainer</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Institut f??r Physiologie, Justus-Liebig Universit??t, Gie??en, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Valen</LastName>
                    <ForeName>Guro</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Physiology, University of Oslo, Norway.</Affiliation>
                </Author>
                <Author>
                    <LastName>Baysa</LastName>
                    <ForeName>Anton</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Physiology, University of Oslo, Norway.</Affiliation>
                </Author>
                <Author>
                    <LastName>Massimino</LastName>
                    <ForeName>Maria Lina</ForeName>
                    <Initials>ML</Initials>
                    <Affiliation>CNR Institute of Neuroscience, University of Padova, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sorgato</LastName>
                    <ForeName>M Catia</ForeName>
                    <Initials>MC</Initials>
                    <Affiliation>Department of Biomedical Science CNR Institute of Neuroscience, University of Padova, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bertoli</LastName>
                    <ForeName>Alessandro</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Biomedical Science dilisa@bio.unipd.it alessandro.bertoli@unipd.it.</Affiliation>
                </Author>
                <Author>
                    <LastName>Di Lisa</LastName>
                    <ForeName>Fabio</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Biomedical Science dilisa@bio.unipd.it alessandro.bertoli@unipd.it.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Cardiovasc Res</MedlineTA>
            <NlmUniqueID>0077427</NlmUniqueID>
            <ISSNLinking>0008-6363</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">PrP</Keyword>
            <Keyword MajorTopicYN="N">ROS</Keyword>
            <Keyword MajorTopicYN="N">cellular prion protein</Keyword>
            <Keyword MajorTopicYN="N">heart</Keyword>
            <Keyword MajorTopicYN="N">oxidative stress</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">cvu194</ArticleId>
            <ArticleId IdType="doi">10.1093/cvr/cvu194</ArticleId>
            <ArticleId IdType="pubmed">25139744</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139743</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1755-3245</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cardiovascular research</Title>
                <ISOAbbreviation>Cardiovasc. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Glyoxalase 1 overexpression does not affect atherosclerotic lesion size and severity in ApoE-/- mice with or without diabetes.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">cvu189</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Advanced glycation endproducts (AGEs) and their precursors have been associated with the development of atherosclerosis. We recently discovered that glyoxalase 1 (GLO1), the major detoxifying enzyme for AGE-precursors, is decreased in ruptured human plaques and that levels of AGEs are higher in rupture-prone plaques. We here investigated whether overexpression of human GLO1 in ApoE(-/-) mice could reduce development of atherosclerosis METHODS AND RESULTS: We crossed C57Bl6 ApoE(-/-) mice with C57Bl6 GLO1 overexpressing mice (huGLO1(+/-)) to generate ApoE(-/-) (n=16) and ApoE(-/-) huGLO1(+/-) (n=20) mice. To induce diabetes, we injected a subset with streptozotocin to generate diabetic ApoE(-/-) (n=8) and ApoE(-/-) huGLO1(+/-) (n=13) mice. All mice were fed chow and sacrificed at 25 weeks of age. The GLO1 activity was threefold increased in huGLO1(+/-) aorta, but aortic root lesion size and phenotype did not differ between mice with- and without huGLO1(+/-) overexpression. We detected no differences in gene expression in aortic arches, in AGE levels and cytokines, in circulating cells and endothelial function between ApoE(-/-) mice with- and without huGLO1(+/-) overexpression. Although diabetic mice showed decreased GLO1 expression (p&lt;0.05) and increased lesion size (p&lt;0.05) in comparison to non-diabetic mice, GLO1 overexpression also did not affect the aortic root lesion size or inflammation in diabetic mice.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In ApoE(-/-) mice with or without diabetes, GLO1 overexpression did not lead to decreased atherosclerotic lesion size or systemic inflammation. Increasing GLO1 levels does not seem to be an effective strategy to reduce glycation in atherosclerotic lesions, likely due to increased AGE formation through GLO1 independent mechanisms.</AbstractText>
                <CopyrightInformation>Published on behalf of the European Society of Cardiology. All rights reserved. ?? The Author 2014. For permissions please email: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hanssen</LastName>
                    <ForeName>Nordin M J</ForeName>
                    <Initials>NM</Initials>
                    <Affiliation>Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Dept. of Internal Medicine, MUMC, Maastricht, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Brouwers</LastName>
                    <ForeName>Olaf</ForeName>
                    <Initials>O</Initials>
                    <Affiliation>Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Dept. of Internal Medicine, MUMC, Maastricht, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gijbels</LastName>
                    <ForeName>Marion J</ForeName>
                    <Initials>MJ</Initials>
                    <Affiliation>Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Dept. of Pathology, MUMC, Maastricht, The Netherlands Dept. of Molecular genetics, MUMC, Maastricht, The Netherlands Dept. of Medical biochemistry, Amsterdam Medical Centre, Amsterdam, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wouters</LastName>
                    <ForeName>Kristiaan</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Dept. of Internal Medicine, MUMC, Maastricht, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wijnands</LastName>
                    <ForeName>Erwin</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Dept. of Pathology, MUMC, Maastricht, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cleutjens</LastName>
                    <ForeName>Jack P M</ForeName>
                    <Initials>JP</Initials>
                    <Affiliation>Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Dept. of Pathology, MUMC, Maastricht, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>De Mey</LastName>
                    <ForeName>Jo G</ForeName>
                    <Initials>JG</Initials>
                    <Affiliation>Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark.</Affiliation>
                </Author>
                <Author>
                    <LastName>Miyata</LastName>
                    <ForeName>Toshio</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>United Centers for Advanced Research and Translational Medicine (ART), Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Biessen</LastName>
                    <ForeName>Erik A</ForeName>
                    <Initials>EA</Initials>
                    <Affiliation>Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Dept. of Pathology, MUMC, Maastricht, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Stehouwer</LastName>
                    <ForeName>Coen D A</ForeName>
                    <Initials>CD</Initials>
                    <Affiliation>Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Dept. of Internal Medicine, MUMC, Maastricht, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Schalkwijk</LastName>
                    <ForeName>Casper G</ForeName>
                    <Initials>CG</Initials>
                    <Affiliation>Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Dept. of Internal Medicine, MUMC, Maastricht, The Netherlands.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Cardiovasc Res</MedlineTA>
            <NlmUniqueID>0077427</NlmUniqueID>
            <ISSNLinking>0008-6363</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Advanced glycation endproducts</Keyword>
            <Keyword MajorTopicYN="N">Atherosclerosis</Keyword>
            <Keyword MajorTopicYN="N">Diabetes</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">cvu189</ArticleId>
            <ArticleId IdType="doi">10.1093/cvr/cvu189</ArticleId>
            <ArticleId IdType="pubmed">25139743</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139738</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1552-5783</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Investigative ophthalmology &amp; visual science</Title>
                <ISOAbbreviation>Invest. Ophthalmol. Vis. Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>HE3286 Reduces Axonal Loss and Preserves Retinal Ganglion Cell Function in Experimental Optic Neuritis.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">IOVS-14-14672</ELocationID>
            <ELocationID EIdType="doi">10.1167/iovs.14-14672</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Purpose: Optic nerve inflammation, demyelination and axonal loss are all prominent features of optic neuritis. While corticosteroids hasten visual recovery in optic neuritis, no treatment improves final visual outcomes. HE3286 (17??-ethynyl-5-androstene-3??,7??,17??-triol), a synthetic derivative of a natural steroid, ??-AET (5-androstene-3??,7??,17??-triol), exerts anti-inflammatory effects in several disease models, and has purported neuroprotective effects as well. HE3286's ability to suppress optic neuritis was examined in experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis. Methods: EAE was induced in C57/BL6 mice. Mice were treated daily with intraperitoneal vehicle or 40 mg/kg HE3286. Visual function was assessed by optokinetic responses (OKR) at baseline and every 10 days until sacrifice 40 days post-immunization. Retinas and optic nerves were isolated. Inflammation (H&amp;E &amp; Iba1 staining), demyelination (luxol fast blue staining) and axonal loss (neurofilament staining) were assessed in optic nerve sections. Retinal ganglion cells (RGCs) were immunolabeled with Brn3a antibodies to quantify RGC survival. Results: Progressive decreases in OKR occurred in vehicle-treated EAE mice, and HE3286 treatment reduced the level of this vision loss. HE3286 also attenuated the degree of inflammation, demyelination and axonal loss in EAE optic nerves as compared to nerves from vehicle-treated EAE mice. RGC loss that occurred in both vehicle- and HE3286-treated EAE mice was reduced in the temporal retinal quadrant of HE3286-treated mice. Conclusions: HE3286 suppresses inflammation, reduces demyelination and axonal loss, and promotes RGC survival during experimental optic neuritis. Importantly, HE3286 treatment also preserves some RGC function. Results suggest HE3286 is a potential novel treatment for optic neuritis.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 by Association for Research in Vision and Ophthalmology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Khan</LastName>
                    <ForeName>Reas S</ForeName>
                    <Initials>RS</Initials>
                    <Affiliation>University of Pennsylvania, Philadelphia, 19104, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dine</LastName>
                    <ForeName>Kimberly</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>University of Pennsylvania, Philadelphia, 19104, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Luna</LastName>
                    <ForeName>Esteban</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>University of Pennsylvania, Philadelphia, 19104, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ahlem</LastName>
                    <ForeName>Clarence</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Harbor Therapeutics, Inc., 9191 Towne Centre Drive, suite 409, San Diego, California, 92122, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shindler</LastName>
                    <ForeName>Kenneth S</ForeName>
                    <Initials>KS</Initials>
                    <Affiliation>Ophthalmology, University of Pennsylvania, 51 N. 39th Street, Philadelphia, Pennsylvania, 19104, United States kenneth.shindler@uphs.upenn.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Invest Ophthalmol Vis Sci</MedlineTA>
            <NlmUniqueID>7703701</NlmUniqueID>
            <ISSNLinking>0146-0404</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">iovs.14-14672</ArticleId>
            <ArticleId IdType="doi">10.1167/iovs.14-14672</ArticleId>
            <ArticleId IdType="pubmed">25139738</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139737</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1552-5783</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Investigative ophthalmology &amp; visual science</Title>
                <ISOAbbreviation>Invest. Ophthalmol. Vis. Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>CCR7 is critical for the induction and maintenance of Th17 immunity in dry eye disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">IOVS-14-14481</ELocationID>
            <ELocationID EIdType="doi">10.1167/iovs.14-14481</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Purpose: To characterize antigen presenting cell (APC)-relevant chemokine receptor expression in dry eye disease (DED), and to investigate the effect of topical CC chemokine receptor (CCR)7 blockade specifically on Th17 cell immunity and on dry eye disease severity. Methods: DED was induced in female C57BL/6 mice. Chemokine receptor expression by corneal APCs was characterized using immunohistochemistry. To determine the functional role of CCR7 in DED, mice were treated topically with either anti-CCR7, a control isotype antibody, or left untreated, and clinical disease severity, Th17 responses, and molecular markers of DED were quantified. Results: Frequencies of CD11b+ cells and their chemokine expression were increased in the cornea of DED mice. Mice treated topically with anti-CCR7 antibody displayed a significant reduction in clinical disease severity and Th17 response compared to the isotype and untreated groups. Topical CCR7 blockade was effective in ameliorating DED in both its acute and chronic stages. Conclusions: Our findings suggest that CCR7-mediated trafficking of APCs drives the induction and maintenance of Th17 immunity in DED and that CCR7 blockade is effective in suppressing the immunopathogenic mechanisms in DED.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 by Association for Research in Vision and Ophthalmology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kodati</LastName>
                    <ForeName>Shilpa</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary, Harvard Medical School, 20 Staniford street, Boston, MA, 02114, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chauhan</LastName>
                    <ForeName>Sunil</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute, Massachusetts Eye &amp; Ear Infirmary, 20 Staniford Street, Boston, MA, 02114, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Yihe</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Schepens Eye Research Institute, 20 Staniford St, Boston, MA, 02114, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dohlman</LastName>
                    <ForeName>Thomas H</ForeName>
                    <Initials>TH</Initials>
                    <Affiliation>Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary, Harvard Medical School, 20 Staniford Street, Boston, MA, 02114, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Karimian</LastName>
                    <ForeName>Parisa</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary, Harvard Medical School, 20 Staniford street, Boston, MA, 02114, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Saban</LastName>
                    <ForeName>Daniel R</ForeName>
                    <Initials>DR</Initials>
                    <Affiliation>Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston, MA, 02114, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dana</LastName>
                    <ForeName>Reza</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary, Harvard Medical School, 20 Staniford Street, Boston, MA, 02114, United States Reza_dana@meei.harvard.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Invest Ophthalmol Vis Sci</MedlineTA>
            <NlmUniqueID>7703701</NlmUniqueID>
            <ISSNLinking>0146-0404</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">iovs.14-14481</ArticleId>
            <ArticleId IdType="doi">10.1167/iovs.14-14481</ArticleId>
            <ArticleId IdType="pubmed">25139737</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139734</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1552-5783</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Investigative ophthalmology &amp; visual science</Title>
                <ISOAbbreviation>Invest. Ophthalmol. Vis. Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mesothelial cells: A cellular surrogate for tissue engineering of corneal endothelium.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">IOVS-14-14706</ELocationID>
            <ELocationID EIdType="doi">10.1167/iovs.14-14706</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">PURPOSE. To evaluate whether mouse adipose tissue mesothelial cells (ATMCs) share morphological and biochemical characteristics with mouse corneal endothelial cells (CECs) and to evaluate their capacity to adhere onto the decellularized basal membrane of human anterior lens capsules (HALCs) as a potential tissue engineered surrogate for corneal endothelium replacement. METHODS. ATMCs were isolated from the visceral adipose tissue of adult mice and their expression of several corneal endothelium markers was determined with qRT-PCR, immunofluorescence and Western blotting. ATMCs were shortly cultured in a Mesothelial Retaining Phenotype Media (MRPM) and further seeded and cultured on top of the decellularized basal membrane of HALCs. ATMCs-HALCs composites were evaluated by optical microscopy, immunofluorescence and transmission electron microscopy. RESULTS. MRPM cultured ATMCs express the corneal endothelium markers COL4A2, C0L8A2, SLC4A4, CAR2, Na+/K+-ATPase, ??-catenin, Zona Occludens-1 and N-cadherin in a pattern similar to mouse CECs. Furthermore, ATMCs displayed strong adhesion capacity onto the basal membrane of HALCs and formed a confluent monolayer within 72 hours of culture in MRPM. Ultrastructural morphological and marker characteristics displayed by ATMCs monolayer onto HALCs clearly indicate that ATMCs retained their original phenotype of squamous epithelial-like cells. CONCLUSIONS. CECs and ATMCs share morphological (structural) and markers (functional) similarities. ATMCs adhered and formed structures mimicking focal adhesion complexes with the HALCs basal membrane. Monolayer structure and achieved density of ATMCs support the proposal of using adult human MCs as a possible surrogate of damaged corneal endothelium.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 by Association for Research in Vision and Ophthalmology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Lachaud</LastName>
                    <ForeName>Christian Claude</ForeName>
                    <Initials>CC</Initials>
                    <Affiliation>CABIMER-FPS, Sevilla, 41092, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Soria</LastName>
                    <ForeName>Felipe A</ForeName>
                    <Initials>FA</Initials>
                    <Affiliation>R&amp;D Department, VISSUM Corporacion, Caba??al, 1, Alicante, Alicante, 03016, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Escacena</LastName>
                    <ForeName>Natalia</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>CABIMER-FPS, Sevilla, 41092, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Quesada-Hern??ndez</LastName>
                    <ForeName>Elena</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>NBT, Bollullos de la Mitaci??n, Sevilla, 41110, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hmadcha</LastName>
                    <ForeName>Abdelkrim</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Stem Cells, CABIMER-FPS, Avda. Americo Vespucio s/n Isla de la Cartuja, Sevilla, 41092, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Alio</LastName>
                    <ForeName>Jorge L</ForeName>
                    <Initials>JL</Initials>
                    <Affiliation>Vissum-Instituto Oftalmologico de Alicante, Universidad Miguel Hernandez, Caba??al,1, Alicante, 03016, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Soria</LastName>
                    <ForeName>Bernat</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Stem Cells, CABIMER, Avda Americo Vespucio s/n, Sevilla, 41092, Spain bernat.soria@cabimer.es.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Invest Ophthalmol Vis Sci</MedlineTA>
            <NlmUniqueID>7703701</NlmUniqueID>
            <ISSNLinking>0146-0404</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">iovs.14-14706</ArticleId>
            <ArticleId IdType="doi">10.1167/iovs.14-14706</ArticleId>
            <ArticleId IdType="pubmed">25139734</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139677</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1860-7314</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biotechnology journal</Title>
                <ISOAbbreviation>Biotechnol J</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) provides quantitative and high-throughput analysis of mammalian cell culture for monitoring metabolites.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/biot.201400292</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Current methods for monitoring multiple intracellular metabolite levels in parallel are limited in sample throughput capabilities and analyte selectivity. This article presents a novel high-throughput method based on matrix-assisted laser desorption/ionization (MALDI) time-of-flight mass spectrometry (TOF-MS) for monitoring intracellular metabolite levels in fed-batch processes. The MALDI-TOF-MS method presented here is based on a new microarray sample target and allows the detection of nucleoside phosphates and various other metabolites using stable isotope labeled internal standards. With short sample preparation steps and thus high sample throughput capabilities, the method is suitable for monitoring mammalian cell cultures, such as antibody producing hybridoma cell lines in industrial environments. The method is capable of reducing the runtime of standard LC-UV methods to approximately 1 minute per sample (including 10 technical replicates). Its performance is exemplarily demonstrated in an 8-day monitoring experiment of independently controlled fed-batches, containing an antibody producing mouse hybridoma cell culture. The monitoring profiles clearly confirmed differences between cultivation conditions. Hypothermia and hyperosmolarity were studied in four bioreactors, where hypothermia was found to have a positive effect on the longevity of the cell culture, whereas hyperosmolarity lead to an arrest of cell proliferation. The results are in good agreement with HPLC-UV cross validation experiments. Subsequent principal component analysis (PCA) clearly separates the different bioreactor conditions based on the measured mass spectral profiles. This method is not limited to any cell line and can be applied as a process analytical tool in biotechnological processes.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Steinhoff</LastName>
                    <ForeName>Robert F</ForeName>
                    <Initials>RF</Initials>
                    <Affiliation>Laboratory of Organic Chemistry ETH Zurich, CH-8093 Zurich, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ivarsson</LastName>
                    <ForeName>Marija</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Habicher</LastName>
                    <ForeName>Tobias</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Villiger</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Boertz</LastName>
                    <ForeName>Jens</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Krismer</LastName>
                    <ForeName>Jasmin</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Fagerer</LastName>
                    <ForeName>Stephan</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Soos</LastName>
                    <ForeName>Miroslav</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Morbidelli</LastName>
                    <ForeName>Massimo</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Pabst</LastName>
                    <ForeName>Martin</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Zenobi</LastName>
                    <ForeName>Renato</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biotechnol J</MedlineTA>
            <NlmUniqueID>101265833</NlmUniqueID>
            <ISSNLinking>1860-6768</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ATP</Keyword>
            <Keyword MajorTopicYN="N">MALDI-MS</Keyword>
            <Keyword MajorTopicYN="N">automated sample aliquoting</Keyword>
            <Keyword MajorTopicYN="N">microarrays for mass spectrometry (MAMS)</Keyword>
            <Keyword MajorTopicYN="N">monoclonal antibody production</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/biot.201400292</ArticleId>
            <ArticleId IdType="pubmed">25139677</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139675</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1097-4547</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of neuroscience research</Title>
                <ISOAbbreviation>J. Neurosci. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Beneficial effect of cilostazol-mediated neuronal repair following trimethyltin-induced neuronal loss in the dentate gyrus.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/jnr.23472</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Cilostazol acts as an antiplatelet agent and has other pleiotropic effects based on phosphodiesterase-3-dependent mechanisms. We evaluated whether cilostazol would have a beneficial effect on neuronal repair following hippocampal neuronal damage by using a mouse model of trimethyltin (TMT)-induced neuronal loss/self-repair in the hippocampal dentate gyrus [Ogita et al. (2005) J Neurosci Res 82:609-621]; these mice will hereafter be referred to as impaired animals. A single treatment with cilostazol (10 mg/kg, i.p.) produced no significant change in the number of 5-bromo-2'-deoxyuridine (BrdU)-incorporating cells in the dentate granule cell layer (GCL) or subgranular zone on day 3 after TMT treatment. However, chronic treatment with cilostazol on days 3-15 posttreatment resulted in an increase in the number of BrdU-incorporating cells in the dentate GCL of the impaired animals, and these cells were positive for neuronal nuclear antigen or doublecortin. Cilostazol was effective in elevating the level of phosphorylated cyclic adrenosine monophosphate response element-binding protein (pCREB) in the dentate gyrus of impaired animals. The results of a forced swimming test revealed that the chronic treatment with cilostazol improved the depression-like behavior seen in the impaired animals. In the cultures of hippocampal neural stem/progenitor cells, exposure to cilostazol produced not only enhancement of proliferation activity but also elevation of pCREB levels. Taken together, our data suggest that cilostazol has a beneficial effect on neuronal repair following neuronal loss in the dentate gyrus through promotion of proliferation and/or neuronal differentiation of neural progenitor cells in the subgranular zone. ?? 2014 Wiley Periodicals, Inc.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Wiley Periodicals, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Yoneyama</LastName>
                    <ForeName>Masanori</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Laboratory of Pharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Osaka, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tanaka</LastName>
                    <ForeName>Masayuki</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Hasebe</LastName>
                    <ForeName>Shigeru</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Yamaguchi</LastName>
                    <ForeName>Taro</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Shiba</LastName>
                    <ForeName>Tatsuo</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Ogita</LastName>
                    <ForeName>Kiyokazu</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Neurosci Res</MedlineTA>
            <NlmUniqueID>7600111</NlmUniqueID>
            <ISSNLinking>0360-4012</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">cilostazol</Keyword>
            <Keyword MajorTopicYN="N">dentate gyrus</Keyword>
            <Keyword MajorTopicYN="N">depression</Keyword>
            <Keyword MajorTopicYN="N">neural progenitor cell</Keyword>
            <Keyword MajorTopicYN="N">neuronal loss</Keyword>
            <Keyword MajorTopicYN="N">neuronal regeneration</Keyword>
            <Keyword MajorTopicYN="N">trimethyltin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jnr.23472</ArticleId>
            <ArticleId IdType="pubmed">25139675</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139670</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-9368</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Transgenic research</Title>
                <ISOAbbreviation>Transgenic Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Skeletal defects in Osterix-Cre transgenic mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Cre/loxP recombination is a powerful strategy widely used for in vivo conditional gene targeting. This technique has made possible many important discoveries of gene function in normal and disease biology. However, due to the transgenic nature of most Cre mouse strains undesired phenotypes occasionally occur in Cre mice. Here we report skeletal defects in Osterix-Cre (Osx-Cre) transgenic mice including delayed calvarial ossification and fracture calluses at multiple skeletal sites. These data suggest that Osx-Cre containing controls should be used for both in vivo and in vitro skeletal analyses of conditional knockout mice generated with this Osx-Cre mouse strain.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Department of Developmental Biology, Harvard School of Dental Medicine, 188 Longwood Avenue, Boston, MA, 02115, USA, wei_huang@hms.harvard.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Olsen</LastName>
                    <ForeName>Bjorn R</ForeName>
                    <Initials>BR</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Transgenic Res</MedlineTA>
            <NlmUniqueID>9209120</NlmUniqueID>
            <ISSNLinking>0962-8819</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11248-014-9828-6</ArticleId>
            <ArticleId IdType="pubmed">25139670</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139623</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1863-2661</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Brain structure &amp; function</Title>
                <ISOAbbreviation>Brain Struct Funct</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cerebellar control of gait and interlimb coordination.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Synaptic and intrinsic processing in Purkinje cells, interneurons and granule cells of the cerebellar cortex have been shown to underlie various relatively simple, single-joint, reflex types of motor learning, including eyeblink conditioning and adaptation of the vestibulo-ocular reflex. However, to what extent these processes contribute to more complex, multi-joint motor behaviors, such as locomotion performance and adaptation during obstacle crossing, is not well understood. Here, we investigated these functions using the Erasmus Ladder in cell-specific mouse mutant lines that suffer from impaired Purkinje cell output (Pcd), Purkinje cell potentiation (L7-Pp2b), molecular layer interneuron output (L7-????2), and granule cell output (??6-Cacna1a). We found that locomotion performance was severely impaired with small steps and long step times in Pcd and L7-Pp2b mice, whereas it was mildly altered in L7-????2 and not significantly affected in ??6-Cacna1a mice. Locomotion adaptation triggered by pairing obstacle appearances with preceding tones at fixed time intervals was impaired in all four mouse lines, in that they all showed inaccurate and inconsistent adaptive walking patterns. Furthermore, all mutants exhibited altered front-hind and left-right interlimb coordination during both performance and adaptation, and inconsistent walking stepping patterns while crossing obstacles. Instead, motivation and avoidance behavior were not compromised in any of the mutants during the Erasmus Ladder task. Our findings indicate that cell type-specific abnormalities in cerebellar microcircuitry can translate into pronounced impairments in locomotion performance and adaptation as well as interlimb coordination, highlighting the general role of the cerebellar cortex in spatiotemporal control of complex multi-joint movements.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Vinueza Veloz</LastName>
                    <ForeName>Mar??a Fernanda</ForeName>
                    <Initials>MF</Initials>
                    <Affiliation>Department of Neuroscience, Erasmus MC, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Kuikui</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Bosman</LastName>
                    <ForeName>Laurens W J</ForeName>
                    <Initials>LW</Initials>
                </Author>
                <Author>
                    <LastName>Potters</LastName>
                    <ForeName>Jan-Willem</ForeName>
                    <Initials>JW</Initials>
                </Author>
                <Author>
                    <LastName>Negrello</LastName>
                    <ForeName>Mario</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Seepers</LastName>
                    <ForeName>Robert M</ForeName>
                    <Initials>RM</Initials>
                </Author>
                <Author>
                    <LastName>Strydis</LastName>
                    <ForeName>Christos</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Koekkoek</LastName>
                    <ForeName>Sebastiaan K E</ForeName>
                    <Initials>SK</Initials>
                </Author>
                <Author>
                    <LastName>De Zeeuw</LastName>
                    <ForeName>Chris I</ForeName>
                    <Initials>CI</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Brain Struct Funct</MedlineTA>
            <NlmUniqueID>101282001</NlmUniqueID>
            <ISSNLinking>1863-2653</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00429-014-0870-1</ArticleId>
            <ArticleId IdType="pubmed">25139623</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139621</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1090-2422</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>17</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Experimental cell research</Title>
                <ISOAbbreviation>Exp. Cell Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Erg cooperates with TGF-?? to control mesenchymal differentiation.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0014-4827(14)00343-7</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.yexcr.2014.08.015</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Transforming growth factor ?? (TGF-??) signaling plays an integral role in skeletal development. Conditional deletion of the TGF-?? type II receptor (Tgfbr2) from type II Collagen (Col2a) expressing cells results in defects in development of the annulus fibrosus (AF) of the intervertebral disc (IVD). We previously used microarray analysis to search for marker genes of AF as well as transcription factors regulated by TGF-?? during AF development. The transcription factor avian erythroblastosis virus E-26 (v-ets) oncogene related (Erg) was identified in the microarray screen as a candidate regulator of AF development. To study the effects of TGF-?? on AF differentiation and the role of Erg in this process, we used mouse sclerotome grown in micromass cultures. At 0.5ng TGF-??/ml, sclerotome cells started to express markers of AF. Regulation of Erg by TGF-?? was confirmed in these cells. In addition, TGF-?? soaked Affi-gel beads implanted into the axial skeleton of stage HH 25 chick embryos showed that TGF-?? could induce expression of Erg mRNA in vivo. Next, an adenovirus to over-express Erg in primary sclerotome micromass cultures was generated. Over-expression of Erg led to a change in cell morphology and inhibition of differentiation into hyaline cartilage as seen by reduced Alcian blue staining and decreased Sox9 and c-Maf expression. Erg was not sufficient to induce expression of AF markers and expression of Sca1, a marker of pluripotent progenitor cells, was up-regulated in Erg expressing cells. When cells that ectopically expressed Erg were treated with TGF-??, enhanced expression of specific differentiation markers was observed suggesting Erg can cooperate with TGF-?? to regulate differentiation of the sclerotome. Furthermore, we showed using co-immunopreciptiation that Erg and Smad3 bind to each other suggesting a mechanism for their functional interaction.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Cox</LastName>
                    <ForeName>Megan K</ForeName>
                    <Initials>MK</Initials>
                    <Affiliation>Department of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, 1918 University Blvd, MCLM 660, Birmingham, AL 35294-0005, United States. Electronic address: Megan.Cox@genzyme.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Appelboom</LastName>
                    <ForeName>Brittany L</ForeName>
                    <Initials>BL</Initials>
                    <Affiliation>Department of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, 1918 University Blvd, MCLM 660, Birmingham, AL 35294-0005, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ban</LastName>
                    <ForeName>Ga I</ForeName>
                    <Initials>GI</Initials>
                    <Affiliation>Department of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, 1918 University Blvd, MCLM 660, Birmingham, AL 35294-0005, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Serra</LastName>
                    <ForeName>Rosa</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, 1918 University Blvd, MCLM 660, Birmingham, AL 35294-0005, United States. Electronic address: rserra@uab.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Exp Cell Res</MedlineTA>
            <NlmUniqueID>0373226</NlmUniqueID>
            <ISSNLinking>0014-4827</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Adamtsl2</Keyword>
            <Keyword MajorTopicYN="N">Annulus fibrosus</Keyword>
            <Keyword MajorTopicYN="N">Intervertebral disc</Keyword>
            <Keyword MajorTopicYN="N">Scleraxis</Keyword>
            <Keyword MajorTopicYN="N">Sclerotome</Keyword>
            <Keyword MajorTopicYN="N">Smad3</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25139621</ArticleId>
            <ArticleId IdType="pii">S0014-4827(14)00343-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.yexcr.2014.08.015</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139620</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1090-2422</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>17</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Experimental cell research</Title>
                <ISOAbbreviation>Exp. Cell Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Downregulation of endogenous STAT3 augments tumoricidal activity of interleukin 15 activated dendritic cell against lymphoma and leukemia via TRAIL.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0014-4827(14)00340-1</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.yexcr.2014.08.012</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Effector functions in tumor resistance by dendritic cells (DCs) are less well characterized. In this study, we describe that the murine DCs upon stimulation with recombinant IL-15 in vitro or in vivo, expresses TNF superfamily member TRAIL which mediates cytotoxicity and growth inhibition against a murine lymphoma called Dalton lymphoma (DL) via apoptosis. Presence of tumor lysate or intact tumor cells significantly reduces the DC mediated tumoricidal effect, possibly via masking and down-regulating TRAIL in DCs. The antitumor effect of DC derived TRAIL was further augmented by deactivation of STAT3 in tumor cells by cucurbitacin I, which makes it more susceptible to DC derived TRAIL Treatment of tumor cells with cucurbitacin I upregulates TRAIL receptor expression in addition to activation of caspases. Compared to na??ve DCs, DCs from tumor bearing mice are significantly impaired in TRAIL expression and consequent antitumor functions against DL which was partially restored by activation with IL-15 or LPS. Priming with recombinant IL-15 prolongs the survival of tumor bearing mice treated with cucurbitacin I. Na??ve peripheral blood DCs derived from chronic myeloid leukemia (CML) patients have significant impairment in expression of TRAIL and consequent tumoricidal properties against TRAIL sensitive lymphoma cell lines and primary tumor cells compared to normal control.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kumar Hira</LastName>
                    <ForeName>Sumit</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Immunobiology Laboratory, Banaras Hindu University, Varanasi 221005, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mondal</LastName>
                    <ForeName>Indrani</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Department of Pathology, Burdwan Medical College, West Bengal 713104, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bhattacharya</LastName>
                    <ForeName>Debasis</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Pathology, Burdwan Medical College, West Bengal 713104, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Manna</LastName>
                    <ForeName>Partha Pratim</ForeName>
                    <Initials>PP</Initials>
                    <Affiliation>Immunobiology Laboratory, Banaras Hindu University, Varanasi 221005, India. Electronic address: pp_manna@yahoo.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Exp Cell Res</MedlineTA>
            <NlmUniqueID>0373226</NlmUniqueID>
            <ISSNLinking>0014-4827</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Dendritic cell</Keyword>
            <Keyword MajorTopicYN="N">IL-15</Keyword>
            <Keyword MajorTopicYN="N">Lymphoma</Keyword>
            <Keyword MajorTopicYN="N">STAT3</Keyword>
            <Keyword MajorTopicYN="N">TRAIL</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25139620</ArticleId>
            <ArticleId IdType="pii">S0014-4827(14)00340-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.yexcr.2014.08.012</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139616</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1365-2184</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cell proliferation</Title>
                <ISOAbbreviation>Cell Prolif.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>JLK1486, a N,N-[(8-hydroxyquinoline)methyl]-substituted benzylamine analogue, inhibits melanoma proliferation and induces autophagy.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1111/cpr.12127</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To investigate anti-proliferatory activity of a selected N,N-[(8-hydroxyquinoline)methyl]-substituted benzylamine (JLK1486) on melanoma cells and to characterize its mechanism of cell population growth inhibition.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">In vitro cultures of B16F10 (mouse melanoma) cells were used as a model to characterize anti-proliferatory activity of JLK1486 using MTT growth assay, trypan blue viability assessment, cell cycle analysis, melanin production, ??-galactosidase and acridine orange staining.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Proliferating B16F10 and also MeWo (human melanoma) cells were strongly growth inhibited by JLK1486, displaying IC50 values of 196??nm and 110??nm respectively. Anti-proliferatory effects were independent of cell death and were characterized by a distinct accumulation of cells in G0 /G1 phase. Tyrosinase activity and relative melanin content remained unchanged indicating that the anti-proliferatory activity was not due to phenotype differentiation. Although treated B16F10 cells stained strongly positive for senescence marker ??-galactosidase, cells regained near normal proliferatory activity after removal of JLK1486. Increased acridine orange staining and presence of perinuclear vacuoles suggested induction of autophagy in B16F10 cells. Furthermore, JLK1486 pre-treatment completely abolished melphalan and antimycin A-induced apoptosis.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">JLK1486 provides a promising chemical scaffold to develop new anti-melanoma drugs or combination therapies, due to its potent inhibition of cell proliferation and induction of autophagy, at pharmacologically relevant concentrations.</AbstractText>
                <CopyrightInformation>?? 2014 John Wiley &amp; Sons Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Koekemoer</LastName>
                    <ForeName>T C</ForeName>
                    <Initials>TC</Initials>
                    <Affiliation>Department of Biochemistry and Microbiology, Nelson Mandela Metropolitan University, Port Elizabeth, 6031, South Africa.</Affiliation>
                </Author>
                <Author>
                    <LastName>van de Venter</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Kraus</LastName>
                    <ForeName>J-L</ForeName>
                    <Initials>JL</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Cell Prolif</MedlineTA>
            <NlmUniqueID>9105195</NlmUniqueID>
            <ISSNLinking>0960-7722</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cpr.12127</ArticleId>
            <ArticleId IdType="pubmed">25139616</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139591</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-6623</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Pain</Title>
                <ISOAbbreviation>Pain</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Supraspinal TRPV1 modulates the emotional expression of abdominal pain.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0304-3959(14)00371-6</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.pain.2014.08.012</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The transient receptor potential vanilloid receptor type-1 (TRPV1) is critically involved in peripheral nociceptive processes of somatic and visceral pain. However, the role of the capsaicin receptor in the brain regarding visceral pain remains elusive. Here, we studied the contribution of TRPV1 to abdominal pain transmission at different nociceptive pathway levels using TRPV1 knock-out mice, resiniferatoxin-mediated deletion of TRPV1-positive primary sensory neurons and intracerebral TRPV1 antagonism. We found that constitutive genetic TRPV1 deletion or peripheral TRPV1 deletion reduced acetic acid - evoked abdominal constrictions, without affecting referred abdominal hyperalgesia or allodynia in an acute pancreatitis-model of visceral pain. Notably, intracerebral TRPV1 antagonism by SB 366791 significantly reduced chemical and inflammatory spontaneous abdominal nocifensive responses as observed by reduced expressions of nociceptive facial grimacing, illustrating the affective component of pain. In addition to the established role of cerebral TRPV1 in anxiety, fear or emotional stress, we demonstrate here for the first time that TRPV1 in the brain modulates visceral nociception by interfering with the affective component of abdominal pain.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Jurik</LastName>
                    <ForeName>Angela</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>II. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technical University of Munich, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ressle</LastName>
                    <ForeName>Andrea</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Max Planck Institute of Psychiatry, Munich, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Schmid</LastName>
                    <ForeName>Roland M</ForeName>
                    <Initials>RM</Initials>
                    <Affiliation>II. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technical University of Munich, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wotjak</LastName>
                    <ForeName>Carsten T</ForeName>
                    <Initials>CT</Initials>
                    <Affiliation>Max Planck Institute of Psychiatry, Munich, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Thoeringer</LastName>
                    <ForeName>Christoph K</ForeName>
                    <Initials>CK</Initials>
                    <Affiliation>II. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technical University of Munich, Germany. Electronic address: christoph.thoeringer@lrz.tum.de.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Pain</MedlineTA>
            <NlmUniqueID>7508686</NlmUniqueID>
            <ISSNLinking>0304-3959</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Pancreatitis</Keyword>
            <Keyword MajorTopicYN="N">Resiniferatoxin</Keyword>
            <Keyword MajorTopicYN="N">SB366791</Keyword>
            <Keyword MajorTopicYN="N">TRPV1</Keyword>
            <Keyword MajorTopicYN="N">Visceral pain</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0304-3959(14)00371-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.pain.2014.08.012</ArticleId>
            <ArticleId IdType="pubmed">25139591</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139590</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-6623</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Pain</Title>
                <ISOAbbreviation>Pain</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Nox2-dependent signaling between macrophages and sensory neurons contributes to neuropathic pain hypersensitivity.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0304-3959(14)00372-8</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.pain.2014.08.013</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Emerging lines of evidence indicate that production of reactive oxygen species (ROS) at distinct sites of the nociceptive system contributes to the processing of neuropathic pain. However, the mechanisms underlying ROS production during neuropathic pain processing are not fully understood. We here detected the ROS-generating NADPH oxidase isoform Nox2 in macrophages of dorsal root ganglia (DRGs) in mice. In response to peripheral nerve injury, Nox2-positive macrophages were recruited to DRGs, and ROS production was increased in a Nox2-dependent manner. Nox2-deficient mice displayed reduced neuropathic pain behavior after peripheral nerve injury, whereas their immediate responses to noxious stimuli were normal. Moreover, injury-induced upregulation of tumor necrosis factor ?? was absent and ATF3-induction was reduced in DRGs of Nox2-deficient mice suggesting an attenuated macrophage-neuron signaling. These data suggest that Nox2-dependent ROS production in macrophages recruited to DRGs contributes to neuropathic pain hypersensitivity, underlining the observation that Nox-derived ROS exert specific functions during the processing of pain.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kallenborn-Gerhardt</LastName>
                    <ForeName>Wiebke</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Goethe University Medical School, Frankfurt am Main, Germany. Electronic address: Achim.Schmidtko@uni-wh.de.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hohmann</LastName>
                    <ForeName>Stephan W</ForeName>
                    <Initials>SW</Initials>
                    <Affiliation>Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Goethe University Medical School, Frankfurt am Main, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Syhr</LastName>
                    <ForeName>Katharina M J</ForeName>
                    <Initials>KM</Initials>
                    <Affiliation>Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Goethe University Medical School, Frankfurt am Main, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Schr??der</LastName>
                    <ForeName>Katrin</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Institute of Cardiovascular Physiology, Goethe University Medical School, Frankfurt am Main, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sisignano</LastName>
                    <ForeName>Marco</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Goethe University Medical School, Frankfurt am Main, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Weigert</LastName>
                    <ForeName>Andreas</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Institute of Biochemistry I/ZAFES, Goethe University Frankfurt, Frankfurt am Main, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lorenz</LastName>
                    <ForeName>Jana E</ForeName>
                    <Initials>JE</Initials>
                    <Affiliation>Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Goethe University Medical School, Frankfurt am Main, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lu</LastName>
                    <ForeName>Ruirui</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Goethe University Medical School, Frankfurt am Main, Germany; Institute of Pharmacology and Toxicology, ZBAF, Witten/Herdecke University, Witten, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Br??ne</LastName>
                    <ForeName>Bernhard</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Institute of Biochemistry I/ZAFES, Goethe University Frankfurt, Frankfurt am Main, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Brandes</LastName>
                    <ForeName>Ralf P</ForeName>
                    <Initials>RP</Initials>
                    <Affiliation>Institute of Pharmacology and Toxicology, ZBAF, Witten/Herdecke University, Witten, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Geisslinger</LastName>
                    <ForeName>Gerd</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Goethe University Medical School, Frankfurt am Main, Germany; Fraunhofer Institute for Molecular Biology and Applied Ecology - Project Group Translational Medicine and Pharmacology (IME-TMP), 60590 Frankfurt am Main, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Schmidtko</LastName>
                    <ForeName>Achim</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Goethe University Medical School, Frankfurt am Main, Germany; Institute of Pharmacology and Toxicology, ZBAF, Witten/Herdecke University, Witten, Germany.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Pain</MedlineTA>
            <NlmUniqueID>7508686</NlmUniqueID>
            <ISSNLinking>0304-3959</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Dorsal root ganglion</Keyword>
            <Keyword MajorTopicYN="N">Knockout mice</Keyword>
            <Keyword MajorTopicYN="N">Neuropathic pain</Keyword>
            <Keyword MajorTopicYN="N">Peripheral nerve injury</Keyword>
            <Keyword MajorTopicYN="N">Reactive oxygen species</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0304-3959(14)00372-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.pain.2014.08.013</ArticleId>
            <ArticleId IdType="pubmed">25139590</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139577</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1618-0372</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Acta histochemica</Title>
                <ISOAbbreviation>Acta Histochem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Nestin expression and glial response in the hippocampus of mice after trimethyltin treatment.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0065-1281(14)00209-8</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.acthis.2014.07.009</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Nestin is a protein of embryonic intermediate filaments expressed by multipotent neural stem cells. In the present study, the nestin expression pattern in the mouse hippocampus 1, 2, 3, 4, and 8 days after treatment with trimethyltin (TMT) was examined to explore the possible role played by nestin in chemically induced hippocampal injury. TMT treatment (2.5mg/kg, intraperitoneally) selectively injured the dentate gyrus (DG) of the mouse hippocampus. The level of hippocampal mRNA encoding nestin increased significantly 2 and 3 days post-treatment and thereafter decreased (at 4 and 8 days post-treatment). The level of nestin protein significantly increased 2 - 4 days post-treatment, particularly in the injured region of the DG, and predominantly in glial fibrillary acidic protein-positive astrocytes in the hippocampal DG. Ki67-positive proliferating cells were increased following TMT treatment and co-localized with nestin-positive reactive astrocytes. Thus, we suggest that nestin contributes to remodeling of the chemically injured DG via glial scar formation and the alteration of neurogenesis.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier GmbH. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Sueun</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>College of Veterinary Medicine and Animal Medical Institute, Chonnam National University, Gwangju 500-757, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Miyoung</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>College of Veterinary Medicine and Animal Medical Institute, Chonnam National University, Gwangju 500-757, Republic of Korea; Department of Physiology and Neuroscience Program, Michigan State University, MI 48824, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Jinwook</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>College of Veterinary Medicine and Animal Medical Institute, Chonnam National University, Gwangju 500-757, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Juhwan</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>College of Veterinary Medicine and Animal Medical Institute, Chonnam National University, Gwangju 500-757, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Son</LastName>
                    <ForeName>Yeonghoon</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>College of Veterinary Medicine and Animal Medical Institute, Chonnam National University, Gwangju 500-757, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kwon</LastName>
                    <ForeName>Seungjoo</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>College of Veterinary Medicine and Animal Medical Institute, Chonnam National University, Gwangju 500-757, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Sung-Ho</ForeName>
                    <Initials>SH</Initials>
                    <Affiliation>College of Veterinary Medicine and Animal Medical Institute, Chonnam National University, Gwangju 500-757, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Jong-Choon</ForeName>
                    <Initials>JC</Initials>
                    <Affiliation>College of Veterinary Medicine and Animal Medical Institute, Chonnam National University, Gwangju 500-757, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kang</LastName>
                    <ForeName>Seong Soo</ForeName>
                    <Initials>SS</Initials>
                    <Affiliation>College of Veterinary Medicine and Animal Medical Institute, Chonnam National University, Gwangju 500-757, Republic of Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Hongbing</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Physiology and Neuroscience Program, Michigan State University, MI 48824, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shin</LastName>
                    <ForeName>Taekyun</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>College of Veterinary Medicine, Jeju National University, Jeju 690-756, Republic of Korea. Electronic address: shint@jejunu.ac.kr.</Affiliation>
                </Author>
                <Author>
                    <LastName>Moon</LastName>
                    <ForeName>Changjong</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>College of Veterinary Medicine and Animal Medical Institute, Chonnam National University, Gwangju 500-757, Republic of Korea. Electronic address: moonc@chonnam.ac.kr.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Acta Histochem</MedlineTA>
            <NlmUniqueID>0370320</NlmUniqueID>
            <ISSNLinking>0065-1281</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Astrocytes</Keyword>
            <Keyword MajorTopicYN="N">Dentate gyrus</Keyword>
            <Keyword MajorTopicYN="N">Hippocampus</Keyword>
            <Keyword MajorTopicYN="N">Mice</Keyword>
            <Keyword MajorTopicYN="N">Nestin</Keyword>
            <Keyword MajorTopicYN="N">Trimethyltin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0065-1281(14)00209-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.acthis.2014.07.009</ArticleId>
            <ArticleId IdType="pubmed">25139577</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139562</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0006-3002</ISSN>
                <JournalIssue CitedMedium="Print">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochimica et biophysica acta</Title>
                <ISOAbbreviation>Biochim. Biophys. Acta</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Protectins and Maresins: New Pro-Resolving Families of Mediators in Acute Inflammation and Resolution Bioactive Metabolome.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S1388-1981(14)00161-9</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.bbalip.2014.08.006</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Acute inflammatory responses are protective, yet without timely resolution can lead to chronic inflammation and organ fibrosis. A systems approach to investigate self-limited (self-resolving) inflammatory exudates in mice and structural elucidation uncovered novel resolution phase mediators in vivo that stimulate endogenous resolution mechanisms in inflammation. Resolving inflammatory exudates and human leukocytes utilize DHA and other n-3 EFA to produce three structurally distinct families of potent di- and trihydroxy-containing products, with several stereospecific potent mediators in each family. Given their potent and stereoselective picogram actions, specific members of these new families of mediators from the DHA metabolome were named D-series resolvins (Resolvin D1 to Resolvin D6), protectins (including protectin D1- neuroprotectin D1), and maresins (MaR1 and MaR2). In this review, we focus on a) biosynthesis of protectins and maresins as anti-inflammatory - pro-resolving mediators; b) their complete stereochemical assignments and actions in vivo in disease models. Each pathway involves the biosynthesis of epoxide-containing intermediates produced from hydroperoxy-containing precursors from human leukocytes and within exudates. Also, aspirin triggers an endogenous DHA metabolome that biosynthesizes potent products in inflammatory exudates and human leukocytes, namely aspirin-triggered Neuroprotectin D1/Protectin D1 [AT-(NPD1/PD1)]. Identification and structural elucidation of these new families of bioactive mediators in resolution has opened the possibility of diverse patho-physiologic actions in several processes including infection, inflammatory pain, tissue regeneration, neuroprotection-neurodegenerative disorders, wound healing, and others. This article is part of a Special Issue entitled &quot;Oxygenated metabolism of PUFA: analysis and biological relevance.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Serhan</LastName>
                    <ForeName>Charles N</ForeName>
                    <Initials>CN</Initials>
                    <Affiliation>Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, 02115. Electronic address: cnserhan@zeus.bwh.harvard.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dalli</LastName>
                    <ForeName>Jesmond</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, 02115.</Affiliation>
                </Author>
                <Author>
                    <LastName>Colas</LastName>
                    <ForeName>Romain A</ForeName>
                    <Initials>RA</Initials>
                    <Affiliation>Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, 02115.</Affiliation>
                </Author>
                <Author>
                    <LastName>Winkler</LastName>
                    <ForeName>Jeremy W</ForeName>
                    <Initials>JW</Initials>
                    <Affiliation>Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, 02115.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chiang</LastName>
                    <ForeName>Nan</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, 02115.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>REVIEW</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biochim Biophys Acta</MedlineTA>
            <NlmUniqueID>0217513</NlmUniqueID>
            <ISSNLinking>0006-3002</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">LC-MS-MS-based targeted lipid mediator metabolomics</Keyword>
            <Keyword MajorTopicYN="N">Resolvins</Keyword>
            <Keyword MajorTopicYN="N">eicosanoids</Keyword>
            <Keyword MajorTopicYN="N">leukocytes</Keyword>
            <Keyword MajorTopicYN="N">lipid mediators</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1388-1981(14)00161-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbalip.2014.08.006</ArticleId>
            <ArticleId IdType="pubmed">25139562</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139561</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0006-3002</ISSN>
                <JournalIssue CitedMedium="Print">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>17</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochimica et biophysica acta</Title>
                <ISOAbbreviation>Biochim. Biophys. Acta</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Tissue-specific actions of FXR in metabolism and cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S1388-1981(14)00160-7</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.bbalip.2014.08.005</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The nuclear Farnesoid X Receptor (FXR) is a transcription factor critically involved in metabolic homeostasis in the gut-liver axis. FXR activity is mediated by hormonal and dietary signals and driven by bile acids (BAs), which are the natural FXR ligands. Given the great physiological importance in BA homeostasis, as well as in the regulation of glucose and lipid metabolism, FXR plays a pivotal role in the pathogenesis of a wide range of disease of the liver, biliary tract and intestine, including hepatic and colorectal cancer. In the last years several studies have shown the relative FXR tissue-specific importance, highlighting synergism and additive effects in the liver and intestine. Gain- and loss-of-FXR-function mouse models have been generated in order to identify the biological processes and the molecular FXR targets. Taking advantage of the knowledge on the structure-activity relationship of BAs for FXR, semi-synthetic and synthetic molecules have been generated to obtain more selective and powerful FXR activators than BAs. This article is part of a Special Issue entitled: Linking transcription to physiology in lipodomics.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Gadaleta</LastName>
                    <ForeName>Raffaella Maria</ForeName>
                    <Initials>RM</Initials>
                    <Affiliation>Division of Cancer, Imperial Centre for Translational and Experimental Medicine, Imperial College London, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cariello</LastName>
                    <ForeName>Marica</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>National Cancer Research Center, IRCCS Istituto Oncologico &quot;Giovanni Paolo II&quot;, Bari, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sabb??</LastName>
                    <ForeName>Carlo</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Clinica Medica Frugoni, Department of Interdisciplinary Medicine, University of Bari, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Moschetta</LastName>
                    <ForeName>Antonio</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>National Cancer Research Center, IRCCS Istituto Oncologico &quot;Giovanni Paolo II&quot;, Bari, Italy; Clinica Medica Frugoni, Department of Interdisciplinary Medicine, University of Bari, Italy. Electronic address: antonio.moschetta@uniba.it.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>REVIEW</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biochim Biophys Acta</MedlineTA>
            <NlmUniqueID>0217513</NlmUniqueID>
            <ISSNLinking>0006-3002</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Bile acid homeostasis</Keyword>
            <Keyword MajorTopicYN="N">Farnesoid X receptor</Keyword>
            <Keyword MajorTopicYN="N">Gut???liver axis</Keyword>
            <Keyword MajorTopicYN="N">Hepatic and colorectal carcinogenesis</Keyword>
            <Keyword MajorTopicYN="N">Selective FXR ligands</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25139561</ArticleId>
            <ArticleId IdType="pii">S1388-1981(14)00160-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbalip.2014.08.005</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139436</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1423-0127</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>21</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of biomedical science</Title>
                <ISOAbbreviation>J. Biomed. Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Enterovirus 71-induced autophagy increases viral replication and pathogenesis in a suckling mouse model.</ArticleTitle>
            <Pagination>
                <MedlinePgn>80</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">BackgroundWe previously reported that Enterovirus 71 (EV71) infection activates autophagy, which promotes viral replication both in vitro and in vivo. In the present study we further investigated whether EV71 infection of neuronal SK-N-SH cells induces an autophagic flux. Furthermore, the effects of autophagy on EV71-related pathogenesis and viral load were evaluated after intracranial inoculation of mouse-adapted EV71 (MP4 strain) into 6-day-old ICR suckling mice.ResultsWe demonstrated that in EV71-infected SK-N-SH cells, EV71 structural protein VP1 and nonstructural protein 2C co-localized with LC3 and mannose-6-phosphate receptor (MPR, endosome marker) proteins by immunofluorescence staining, indicating amphisome formation. Together with amphisome formation, EV71 induced an autophagic flux, which could be blocked by NH4Cl (inhibitor of acidification) and vinblastine (inhibitor of fusion), as demonstrated by Western blotting. Suckling mice intracranially inoculated with EV71 showed EV71 VP1 protein expression (representing EV71 infection) in the cerebellum, medulla, and pons by immunohistochemical staining. Accompanied with these infected brain tissues, increased expression of LC3-II protein as well as formation of LC3 aggregates, autophagosomes and amphisomes were detected. Amphisome formation, which was confirmed by colocalization of EV71-VP1 protein or LC3 puncta and the endosome marker protein MPR. Thus, EV71-infected suckling mice (similar to EV71-infected SK-N-SH cells) also show an autophagic flux. The physiopathological parameters of EV71-MP4 infected mice, including body weight loss, disease symptoms, and mortality were increased compared to those of the uninfected mice. We further blocked EV71-induced autophagy with the inhibitor 3-methyladenine (3-MA), which attenuated the disease symptoms and decreased the viral load in the brain tissues of the infected mice.ConclusionsIn this study, we reveal that EV71 infection of suckling mice induces an amphisome formation accompanied with the autophagic flux in the brain tissues. Autophagy induced by EV71 promotes viral replication and EV71-related pathogenesis.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Ying-Ray</ForeName>
                    <Initials>YR</Initials>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Po-Shun</ForeName>
                    <Initials>PS</Initials>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Jen-Ren</ForeName>
                    <Initials>JR</Initials>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Hsiao-Sheng</ForeName>
                    <Initials>HS</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Biomed Sci</MedlineTA>
            <NlmUniqueID>9421567</NlmUniqueID>
            <ISSNLinking>1021-7770</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">s12929-014-0080-4</ArticleId>
            <ArticleId IdType="doi">10.1186/s12929-014-0080-4</ArticleId>
            <ArticleId IdType="pubmed">25139436</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139423</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-6240</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>17</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Brain research</Title>
                <ISOAbbreviation>Brain Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Polyglutamine-expanded ataxin-3 impairs long-term depression in Purkinje neurons of SCA3 transgenic mouse by inhibiting HAT and impairing histone acetylation.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0006-8993(14)01083-X</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.brainres.2014.08.019</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Our previous study using a transgenic mouse model of spinocerebellar ataxia type 3 (SCA3) reported that disease-causing ataxin-3-Q79 caused cerebellar malfunction by inducing transcriptional downregulation. Long-term depression (LTD) of parallel fiber-Purkinje neuron glutamatergic transmission is believed to be a cellular mechanism for motor learning and motor coordination in the cerebellum. Downregulated mRNA expression of calcineurin B, IP3-R1, myosin Va and PLC ??4, which are required for the induction of cerebellar LTD, led to an impairment of LTD induction in Purkinje neurons of SCA3 transgenic mouse. Our study suggested that ataxin-3-Q79 caused hypoacetylation of cerebellar histone H3 or H4 by inhibiting the activity of histone acetyltransferase (HAT) without affecting the activity of histone deacetylase (HDAC). Consistent with the hypothesis that hypoacetylated H3 or H4 histone associated with promoter regions of downregulated genes is the molecular mechanism underlying ataxin-3-Q79-induced transcriptional repression, chromatin immunoprecipitation-quantitative real-time PCR analysis showed hypoacetylation of H3 or H4 histone associated with the proximal promoter of downregulated calcineurin B, IP3-R1, myosin Va or PLC ??4 gene in the cerebellum of SCA3 mouse. HDAC inhibitor sodium butyrate reversed ataxin-3-Q79-induced hypoacetylation of histone H3 or H4 associated with the proximal promoter of calcineurin B, IP3-R1, myosin Va or PLC ??4 gene. Sodium butyrate also prevented ataxin-3-Q79-induced impairment of LTD induction in Purkinje neurons of SCA3 mice. Our results suggest that polyglutamine-expanded ataxin-3-Q79 impairs HAT activity, leading to histone hypoacetylation, downregulated expression of cerebellar genes required for LTD induction and impaired induction of cerebellar LTD in the SCA3 transgenic mouse.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Chou</LastName>
                    <ForeName>An-Hsun</ForeName>
                    <Initials>AH</Initials>
                    <Affiliation>Department of Anesthesiology, Chang Gung Memorial Hospital, Tao-Yuan, Taiwan, ROC.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Ying-Ling</ForeName>
                    <Initials>YL</Initials>
                    <Affiliation>Chang Gung University of Science and Technology, Tao-Yuan, Taiwan, ROC.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hu</LastName>
                    <ForeName>Su-Huei</ForeName>
                    <Initials>SH</Initials>
                    <Affiliation>Department of Physiology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan, ROC.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chang</LastName>
                    <ForeName>Ya-Ming</ForeName>
                    <Initials>YM</Initials>
                    <Affiliation>Department of Physiology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan, ROC; Graduate Institute of Biomedical Sciences, Chang Gung University, Tao-Yuan, Taiwan, ROC.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Hung-Li</ForeName>
                    <Initials>HL</Initials>
                    <Affiliation>Department of Physiology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan, ROC; Neuroscience Research Center, Chang Gung Memorial Hospital, Tao-Yuan, Taiwan, ROC; Healthy Aging Research Center, Chang Gung University, Kwei-San, Tao-Yuan, Taiwan, ROC. Electronic address: hlwns@mail.cgu.edu.tw.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Brain Res</MedlineTA>
            <NlmUniqueID>0045503</NlmUniqueID>
            <ISSNLinking>0006-8993</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cerebellar long-term depression</Keyword>
            <Keyword MajorTopicYN="N">Histone acetylation</Keyword>
            <Keyword MajorTopicYN="N">Histone acetyltransferase</Keyword>
            <Keyword MajorTopicYN="N">Polyglutamine-expanded ataxin-3</Keyword>
            <Keyword MajorTopicYN="N">Purkinje neuron</Keyword>
            <Keyword MajorTopicYN="N">Spinocerebellar ataxia type 3</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25139423</ArticleId>
            <ArticleId IdType="pii">S0006-8993(14)01083-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.brainres.2014.08.019</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139404</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-2399</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Experimental hematology</Title>
                <ISOAbbreviation>Exp. Hematol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Phosphatase of regenerating liver-3 (PRL-3) is regulated by STAT3 in acute myeloid leukemia.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0301-472X(14)00624-9</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.exphem.2014.08.001</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Over-expression of PRL-3 has been identified in about 50% of patients with acute myeloid leukemia (AML). The mechanism of regulation of PRL-3 remains obscure. Signal transducer and activator of transcription 3 (STAT3), a latent transcriptional factor, has also been often found to be activated in AML. We first identified consensus STAT3 binding sites in the promoter of PRL-3 genes. Then we experimentally validated the direct binding and transcriptional activation. shRNA-mediated knockdown and overexpression approaches were applied in STAT3(-/-) liver cells and leukemic cells to validate the functional regulation of PRL-3 by STAT3. A STAT3 core signature, derived through data mining from publicly available gene expression data, was employed to correlate PRL-3 expression in large AML patient samples. We discovered that STAT3 binds to the -201 to -210 region of PRL-3, which was conserved between human and mouse. Importantly, PRL-3 protein was significantly reduced in mouse STAT3 knockout liver cells compared to STAT3-WT counterparts and ectopic expression of STAT3 in these cells led to a pronounced increase in PRL-3 protein. We demonstrated that STAT3 functionally regulated PRL-3 and STAT3 core signature was enriched in AML with high PRL-3 expression. Targeting either STAT3 or PRL-3 reduced leukemic cell viability. Silencing PRL-3 impaired invasiveness and induced leukemic cell differentiation. In conclusion, PRL-3 was transcriptionally regulated by STAT3. The STAT3/PRL-3 regulatory loop contributes to the pathogenesis of AML and it might represent an attractive therapeutic target for antileukemic therapy.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Jianbiao</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Centre for Translational Medicine, Singapore 117599, Republic of Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chong</LastName>
                    <ForeName>Phyllis Sy</ForeName>
                    <Initials>PS</Initials>
                    <Affiliation>Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Centre for Translational Medicine, Singapore 117599, Republic of Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lu</LastName>
                    <ForeName>Xiao</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Centre for Translational Medicine, Singapore 117599, Republic of Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cheong</LastName>
                    <ForeName>Lip-Lee</ForeName>
                    <Initials>LL</Initials>
                    <Affiliation>Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 5 Lower Kent Ridge Road, Singapore 119074, Republic of Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bi</LastName>
                    <ForeName>Chonglei</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Centre for Translational Medicine, Singapore 117599, Republic of Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Shaw-Cheng</ForeName>
                    <Initials>SC</Initials>
                    <Affiliation>Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Centre for Translational Medicine, Singapore 117599, Republic of Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Yafeng</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Centre for Translational Medicine, Singapore 117599, Republic of Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tan</LastName>
                    <ForeName>Tuan Zea</ForeName>
                    <Initials>TZ</Initials>
                    <Affiliation>Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Centre for Translational Medicine, Singapore 117599, Republic of Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Henry</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Centre for Translational Medicine, Singapore 117599, Republic of Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chung</LastName>
                    <ForeName>Tae-Hoon</ForeName>
                    <Initials>TH</Initials>
                    <Affiliation>Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Centre for Translational Medicine, Singapore 117599, Republic of Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zeng</LastName>
                    <ForeName>Qi</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>Institute of Molecular and Cell Biology, A*STAR (Agency for Science, Technology and Research), 61 Biopolis Drive, Proteos, Singapore 138648, Republic of Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chng</LastName>
                    <ForeName>Wee-Joo</ForeName>
                    <Initials>WJ</Initials>
                    <Affiliation>Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Centre for Translational Medicine, Singapore 117599, Republic of Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 5 Lower Kent Ridge Road, Singapore 119074, Republic of Singapore; Department of Hematology-Oncology, National University Hospital, 1E, Kent Ridge Road, Singapore 119228, Republic of Singapore. Electronic address: dccwj@nus.edu.sg.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Exp Hematol</MedlineTA>
            <NlmUniqueID>0402313</NlmUniqueID>
            <ISSNLinking>0301-472X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Acute myeloid leukemia (AML)</Keyword>
            <Keyword MajorTopicYN="N">Protein tyrosine phosphatase type IVA 3 (PTP4A3)</Keyword>
            <Keyword MajorTopicYN="N">Protein-tyrosine phosphatase of regenerating liver 3 (PRL-3)</Keyword>
            <Keyword MajorTopicYN="N">Signal transducer and activator of transcription 3 (STAT3)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0301-472X(14)00624-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.exphem.2014.08.001</ArticleId>
            <ArticleId IdType="pubmed">25139404</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139400</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1532-2823</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>4</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Prostaglandins, leukotrienes, and essential fatty acids</Title>
                <ISOAbbreviation>Prostaglandins Leukot. Essent. Fatty Acids</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Docosahexaenoic acid supplementation modifies fatty acid incorporation in tissues and prevents hypoxia induced-atherosclerosis progression in apolipoprotein-E deficient mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0952-3278(14)00125-2</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.plefa.2014.07.016</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The n-3 polyunsaturated fatty acid, docosahexaenoic acid (DHA), displays anti-inflammatory properties that may prevent atherosclerosis progression. Exposure of apolipoprotein-E deficient (ApoE(-/-)) mice to chronic intermittent hypoxia (CIH) accelerates atherosclerosis progression. Our aim was to assess DHA-supplementation influence on fatty acid incorporation in different tissues/organs and on atherosclerosis progression in ApoE(-/-) mice exposed to CIH. ApoE(-/-) mice were exposed to CIH or normoxia (N) and randomized to four groups (N control, CIH control, N+DHA, and CIH+DHA). DHA-supplementation enhanced DHA and reduced arachidonic acid (AA) contents in tissues/organs. CIH control mice exhibited increased atherosclerosis lesion sizes compared to N control mice. DHA prevented CIH induced atherosclerosis but did not improve atherosclerosis burden in N mice. Aortic matrix metalloproteinase-2 (MMP-2) expression was decreased in CIH+DHA mice (p=0.007). DHA-supplementation prevented CIH-induced atherosclerosis acceleration. This was associated with a decrease of AA incorporation and of aortic MMP-2 gene expression.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Van Noolen</LastName>
                    <ForeName>Laetitia</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Universit?? Grenoble Alpes, F-38041 Grenoble, France; INSERM U1042, HP2, F-38041 Grenoble, France; CHU, H??pital A. Michalon, D??partement de Biochimie, Toxicologie et Pharmacologie, CS 10217, F-38043 Grenoble cedex 9, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>B??ck</LastName>
                    <ForeName>Magnus</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Medicine, Karolinska Institutet, 17176 Stockholm, Sweden; Department of Cardiology, Karolinska University Hospital, 17176 Stockholm, Sweden.</Affiliation>
                </Author>
                <Author>
                    <LastName>Arnaud</LastName>
                    <ForeName>Claire</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Universit?? Grenoble Alpes, F-38041 Grenoble, France; INSERM U1042, HP2, F-38041 Grenoble, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rey</LastName>
                    <ForeName>Amandine</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>CHU, H??pital A. Michalon, D??partement de Biochimie, Toxicologie et Pharmacologie, CS 10217, F-38043 Grenoble cedex 9, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Petri</LastName>
                    <ForeName>Marcelo H</ForeName>
                    <Initials>MH</Initials>
                    <Affiliation>Department of Medicine, Karolinska Institutet, 17176 Stockholm, Sweden.</Affiliation>
                </Author>
                <Author>
                    <LastName>Levy</LastName>
                    <ForeName>Patrick</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Universit?? Grenoble Alpes, F-38041 Grenoble, France; INSERM U1042, HP2, F-38041 Grenoble, France; CHU, H??pital A. Michalon, D??partement de Biochimie, Toxicologie et Pharmacologie, CS 10217, F-38043 Grenoble cedex 9, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Faure</LastName>
                    <ForeName>Patrice</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Universit?? Grenoble Alpes, F-38041 Grenoble, France; INSERM U1042, HP2, F-38041 Grenoble, France; CHU, H??pital A. Michalon, D??partement de Biochimie, Toxicologie et Pharmacologie, CS 10217, F-38043 Grenoble cedex 9, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Stanke-Labesque</LastName>
                    <ForeName>Fran??oise</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Universit?? Grenoble Alpes, F-38041 Grenoble, France; INSERM U1042, HP2, F-38041 Grenoble, France; CHU, H??pital A. Michalon, D??partement de Biochimie, Toxicologie et Pharmacologie, CS 10217, F-38043 Grenoble cedex 9, France. Electronic address: FStanke@chu-grenoble.fr.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>4</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Prostaglandins Leukot Essent Fatty Acids</MedlineTA>
            <NlmUniqueID>8802730</NlmUniqueID>
            <ISSNLinking>0952-3278</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Atherosclerosis</Keyword>
            <Keyword MajorTopicYN="N">Docosahexaenoic acid</Keyword>
            <Keyword MajorTopicYN="N">Eicosapentaenoic acid</Keyword>
            <Keyword MajorTopicYN="N">Inflammation</Keyword>
            <Keyword MajorTopicYN="N">Intermittent hypoxia</Keyword>
            <Keyword MajorTopicYN="N">Omega 3 polyunsaturated fatty acid</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0952-3278(14)00125-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.plefa.2014.07.016</ArticleId>
            <ArticleId IdType="pubmed">25139400</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139399</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">0022-2275</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of lipid research</Title>
                <ISOAbbreviation>J. Lipid Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">jlr.M051326</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">PCSK9 inhibition is a potential novel strategy for treatment of cardiovascular disease. Alirocumab is a fully human PCSK9 monoclonal antibody in phase III clinical development. We evaluated the antiatherogenic potential of alirocumab in APOE*3Leiden.CETP mice. Mice received a Western-type diet and were treated with alirocumab (3 or 10 mg/kg, weekly subcutaneous dosing) alone and in combination with atorvastatin (3.6 mg/kg/d) for 18 weeks. Alirocumab alone dose-dependently decreased total cholesterol (-37%; -46%, P &lt; 0.001) and triglycerides (-33%; -36%, P &lt; 0.001) and further decreased cholesterol in combination with atorvastatin (-48%; -58%, P &lt; 0.001). Alirocumab increased hepatic LDLR protein levels but did not affect hepatic cholesterol and triglyceride content. Fecal output of bile acids and neutral sterols was not changed. Alirocumab dose-dependently decreased atherosclerotic lesion size (-71%; -88%, P &lt; 0.001) and severity and enhanced these effects when added to atorvastatin (-89%; -98%, P &lt; 0.001). Alirocumab reduced monocyte recruitment and improved the lesion composition by increasing the smooth muscle cell and collagen content and decreasing the macrophage and necrotic core content. Alirocumab dose-dependently decreases plasma lipids and as a result atherosclerosis development, and enhances the beneficial effects of atorvastatin in APOE*3Leiden.CETP mice. In addition, alirocumab improves plaque morphology.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, The American Society for Biochemistry and Molecular Biology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>K??hnast</LastName>
                    <ForeName>Susan</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Leiden University Medical Center, Netherlands;</Affiliation>
                </Author>
                <Author>
                    <LastName>van der Hoorn</LastName>
                    <ForeName>Jose W A</ForeName>
                    <Initials>JW</Initials>
                    <Affiliation>TNO- Metabolic Health Research, Netherlands; jose.vanderhoorn@tno.nl.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pieterman</LastName>
                    <ForeName>Elsbet J</ForeName>
                    <Initials>EJ</Initials>
                    <Affiliation>TNO - Metabolic Health Research, Netherlands;</Affiliation>
                </Author>
                <Author>
                    <LastName>van den Hoek</LastName>
                    <ForeName>Anita M</ForeName>
                    <Initials>AM</Initials>
                    <Affiliation>TNO - Metabolic Health Research, Netherlands;</Affiliation>
                </Author>
                <Author>
                    <LastName>Sasiela</LastName>
                    <ForeName>William J</ForeName>
                    <Initials>WJ</Initials>
                    <Affiliation>Regeneron Pharmaceuticals Inc., United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Gusarova</LastName>
                    <ForeName>Viktoria</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Regeneron Pharmaceuticals Inc., United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Peyman</LastName>
                    <ForeName>Anusch</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Sanofi-Aventis Deutschland GmbH, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sch??fer</LastName>
                    <ForeName>Hans-Ludwig</ForeName>
                    <Initials>HL</Initials>
                    <Affiliation>Sanofi-Aventis Deutschland GmbH, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Schwahn</LastName>
                    <ForeName>Uwe</ForeName>
                    <Initials>U</Initials>
                    <Affiliation>Sanofi-Aventis Deutschland GmbH, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jukema</LastName>
                    <ForeName>J Wouter</ForeName>
                    <Initials>JW</Initials>
                    <Affiliation>Leiden University Medical Center, Netherlands;</Affiliation>
                </Author>
                <Author>
                    <LastName>Princen</LastName>
                    <ForeName>Hans M G</ForeName>
                    <Initials>HM</Initials>
                    <Affiliation>TNO - Metabolic Health Research, Netherlands;</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Lipid Res</MedlineTA>
            <NlmUniqueID>0376606</NlmUniqueID>
            <ISSNLinking>0022-2275</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">APOE*3Leiden.CETP mice</Keyword>
            <Keyword MajorTopicYN="N">Atherosclerosis</Keyword>
            <Keyword MajorTopicYN="N">Cholesterol</Keyword>
            <Keyword MajorTopicYN="N">Drug therapy/Hypolipidemic drugs</Keyword>
            <Keyword MajorTopicYN="N">LDL/Metabolism</Keyword>
            <Keyword MajorTopicYN="N">Lipoproteins/Receptors</Keyword>
            <Keyword MajorTopicYN="N">PCSK9</Keyword>
            <Keyword MajorTopicYN="N">alirocumab</Keyword>
            <Keyword MajorTopicYN="N">atorvastatin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25139399</ArticleId>
            <ArticleId IdType="pii">jlr.M051326</ArticleId>
            <ArticleId IdType="doi">10.1194/jlr.M051326</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139366</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-1063</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Hippocampus</Title>
                <ISOAbbreviation>Hippocampus</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The dynamic impact of repeated stress on the hippocampal spatial map.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/hipo.22348</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Stress alters the function of many physiological processes throughout the body, including in the brain. A neural circuit particularly vulnerable to the effects of stress is the hippocampus, a key component of the episodic and spatial memory system in both humans and rodents. Earlier studies have provided snapshots of morphological, molecular, physiological and behavioral changes in the hippocampus following either acute or repeated stress. However, the cumulative impact of repeated stress on in vivo hippocampal physiology remains unexplored. Here we report the stress-induced modulation of the spatially receptive fields of the hippocampal CA1 'place cells' as mice explore familiar and novel tracks after 5 and 10 days of immobilization stress. We find that similar to what has been observed following acute stress, five days of repeated stress results in decreased excitability of CA1 pyramidal cells. Following ten days of chronic stress, however, this decreased hippocampal excitability is no longer evident, suggesting adaptation may have occurred. In addition to these changes in neuronal excitability, we find deficient context discrimination, wherein both short-term and chronic stress impairs the ability of the hippocampus to unambiguously distinguish novel and familiar environments. These results suggest that a loss of network flexibility may underlie some of the behavioral deficits accompanying chronic stress. ?? 2014 Wiley Periodicals, Inc.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Wiley Periodicals, Inc., a Wiley company.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Tomar</LastName>
                    <ForeName>Anupratap</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>National Centre for Biological Sciences, Bangalore, India, 560065; Manipal University, Manipal, India, 576104; Current address: Laboratory for Circuit and Behavioral Physiology, RIKEN Brain Science Institute, 2-1 Hirosawa, Wakoshi, Saitama, Japan, 351-0198.</Affiliation>
                </Author>
                <Author>
                    <LastName>Polygalov</LastName>
                    <ForeName>Denis</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author>
                    <LastName>Chattarji</LastName>
                    <ForeName>Sumantra</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>McHugh</LastName>
                    <ForeName>Thomas J</ForeName>
                    <Initials>TJ</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Hippocampus</MedlineTA>
            <NlmUniqueID>9108167</NlmUniqueID>
            <ISSNLinking>1050-9631</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CA1</Keyword>
            <Keyword MajorTopicYN="N">chronic stress</Keyword>
            <Keyword MajorTopicYN="N">context discrimination</Keyword>
            <Keyword MajorTopicYN="N">generalization</Keyword>
            <Keyword MajorTopicYN="N">place cell</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hipo.22348</ArticleId>
            <ArticleId IdType="pubmed">25139366</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139358</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1528-0020</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Blood</Title>
                <ISOAbbreviation>Blood</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Donor CD4+ Foxp3+ regulatory T cells are necessary for post-transplantation cyclophosphamide-mediated protection against GVHD in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">blood-2013-10-525873</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Post-transplantation cyclophosphamide (PTCy) is an effective prophylaxis against graft-versus-host disease (GVHD). However, it is unknown whether PTCy works singularly by eliminating alloreactive T cells via DNA alkylation or also by restoring the conventional (Tcon)/regulatory (Treg) T cell balance. We studied the role of Tregs in PTCy-mediated GVHD prophylaxis in murine models of allogeneic blood or marrow transplantation (alloBMT). In two distinct MHC-matched alloBMT models, infusing Treg-depleted allografts abrogated the GVHD-prophylactic activity of PTCy. Using allografts in which Foxp3(+) Tregs could be selectively depleted in vivo, either pre- or post-PTCy ablation of donor thymus-derived Tregs (tTregs) abolished PTCy protection against GVHD. PTCy treatment was associated with relative preservation of donor Tregs. Experiments using combinations of Foxp3(-) Tcons and Foxp3(+) Tregs sorted from different Foxp3 reporter mice indicated that donor Treg persistence after PTCy treatment was predominantly due to survival of functional tTregs that retained Treg-specific demethylation and also induction of peripherally-derived Tregs. Lastly, adoptive transfer of tTregs retrieved from PTCy-treated chimeras rescued PTCy-treated, Treg-depleted recipients from lethal GVHD. Our findings indicate that PTCy-mediated protection against GVHD therefore is not singularly dependent on depletion of donor alloreactive T cells but also requires rapidly recovering donor Tregs to initiate and maintain alloimmune regulation.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 American Society of Hematology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ganguly</LastName>
                    <ForeName>Sudipto</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Ross</LastName>
                    <ForeName>Duncan B</ForeName>
                    <Initials>DB</Initials>
                    <Affiliation>Departments of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Panoskaltsis-Mortari</LastName>
                    <ForeName>Angela</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota Cancer Center, Minneapolis, MN, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kanakry</LastName>
                    <ForeName>Christopher G</ForeName>
                    <Initials>CG</Initials>
                    <Affiliation>Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Blazar</LastName>
                    <ForeName>Bruce R</ForeName>
                    <Initials>BR</Initials>
                    <Affiliation>Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota Cancer Center, Minneapolis, MN, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Levy</LastName>
                    <ForeName>Robert B</ForeName>
                    <Initials>RB</Initials>
                    <Affiliation>Departments of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Luznik</LastName>
                    <ForeName>Leo</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States; luznile@jhmi.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Blood</MedlineTA>
            <NlmUniqueID>7603509</NlmUniqueID>
            <ISSNLinking>0006-4971</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">blood-2013-10-525873</ArticleId>
            <ArticleId IdType="doi">10.1182/blood-2013-10-525873</ArticleId>
            <ArticleId IdType="pubmed">25139358</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139355</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1528-0020</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Blood</Title>
                <ISOAbbreviation>Blood</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Clonal analysis identifies hemogenic endothelium and not hemangioblasts as the source of the blood-endothelial common lineage in the mouse embryo.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">blood-2013-12-545939</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The first blood and endothelial cells of amniote embryos appear in close association in the blood islands of the yolk sac. This association and in vitro lineage analyses have suggested a common origin from mesodermal precursors called hemangioblasts, specified in the primitive streak during gastrulation. Fate mapping and chimera studies, however, failed to provide strong evidence for a common origin in the early mouse yolk sac. Additional in vitro studies suggest instead that mesodermal precursors first generate hemogenic endothelium, which then generate blood cells in a linear sequence. We conducted an in vivo clonal analysis to determine the potential of individual cells in the mouse epiblast, primitive streak and early yolk sac. We found that early yolk sac blood and endothelial lineages mostly derive from independent epiblast populations, specified before gastrulation. Additionally, a subpopulation of the yolk sac endothelium has hemogenic activity and displays characteristics similar to those found later in the embryonic hemogenic endothelium. Our results show that the earliest blood and endothelial cell populations in the mouse embryo are specified independently, and that hemogenic endothelium first appears in the yolk sac and produces blood precursors with markers related to definitive haematopoiesis.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 American Society of Hematology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Padr??n-Barthe</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Departamento de Desarrollo y Reparacion Cardiovascular, Centro Nacional de Investigaciones Cardiovasculares, CNIC, Madrid, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Temi??o</LastName>
                    <ForeName>Susana</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Departamento de Desarrollo y Reparacion Cardiovascular, Centro Nacional de Investigaciones Cardiovasculares, CNIC, Madrid, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Villa Del Campo</LastName>
                    <ForeName>Cristina</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Departamento de Desarrollo y Reparacion Cardiovascular, Centro Nacional de Investigaciones Cardiovasculares, CNIC, Madrid, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Carramolino</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Departamento de Desarrollo y Reparacion Cardiovascular, Centro Nacional de Investigaciones Cardiovasculares, CNIC, Madrid, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Isern</LastName>
                    <ForeName>Joan</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Departamento de Desarrollo y Reparacion Cardiovascular, Centro Nacional de Investigaciones Cardiovasculares, CNIC, Madrid, Spain.</Affiliation>
                </Author>
                <Author>
                    <LastName>Torres</LastName>
                    <ForeName>Miguel</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Departamento de Desarrollo y Reparacion Cardiovascular, Centro Nacional de Investigaciones Cardiovasculares, CNIC, Madrid, Spain mtorres@cnic.es.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Blood</MedlineTA>
            <NlmUniqueID>7603509</NlmUniqueID>
            <ISSNLinking>0006-4971</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">blood-2013-12-545939</ArticleId>
            <ArticleId IdType="doi">10.1182/blood-2013-12-545939</ArticleId>
            <ArticleId IdType="pubmed">25139355</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139353</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1528-0020</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Blood</Title>
                <ISOAbbreviation>Blood</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Phosphoinositide 3-kinase-?? mediates microvascular endothelial repair of thrombotic microangiopathy.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">blood-2014-02-557975</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Thrombotic microangiopathy (TMA) commonly involves injury of kidney glomerular endothelial cells (ECs) and fibrin occlusion of the capillaries. The mechanisms underlying repair of the microvasculature and recovery of kidney function are poorly defined. In the developing vasculature, the phosphoinositide 3-kinase (PI3K) ?? isoform integrates many growth factor cues. However, the role of individual isoforms in repair of the established vasculature is unclear. We found that postnatal endothelial deletion of PI3K?? sensitizes mice to lethal acute kidney failure after TMA injury. In vitro, PI3K?? deficient ECs show reduced angiogenic invasion of fibrin matrix with unaltered sensitivity to pro-apoptotic stress versus wild-type ECs. This correlates with decreased expression of the EC tip cell markers apelin and Dll4, and is associated with a reduction in migration and proliferation. In vivo, PI3K??-knockdown ECs are deficient in assembly of microvessel-like structures. These data identify a critical role for endothelial PI3K?? in microvascular repair following injury.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 American Society of Hematology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Haddad</LastName>
                    <ForeName>George</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Medicine, University of Alberta, Edmonton, AB, Canada;</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhabyeyev</LastName>
                    <ForeName>Pavel</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Medicine, University of Alberta, Edmonton, AB, Canada;</Affiliation>
                </Author>
                <Author>
                    <LastName>Farhan</LastName>
                    <ForeName>Maikel</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Medicine, University of Alberta, Edmonton, AB, Canada;</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhu</LastName>
                    <ForeName>Lin Fu</ForeName>
                    <Initials>LF</Initials>
                    <Affiliation>Department of Surgery, University of Alberta, Edmonton, AB, Canada;</Affiliation>
                </Author>
                <Author>
                    <LastName>Kassiri</LastName>
                    <ForeName>Zamaneh</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department of Physiology, University of Alberta, Edmonton, AB, Canada;</Affiliation>
                </Author>
                <Author>
                    <LastName>Rayner</LastName>
                    <ForeName>David C</ForeName>
                    <Initials>DC</Initials>
                    <Affiliation>Department of Pathology and Laboratory Medicine, University of Alberta, Edmonton, AB, Canada;</Affiliation>
                </Author>
                <Author>
                    <LastName>Vanhaesebroeck</LastName>
                    <ForeName>Bart</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>UCL Cancer Institute, University College London, London, United Kingdom.</Affiliation>
                </Author>
                <Author>
                    <LastName>Oudit</LastName>
                    <ForeName>Gavin Y</ForeName>
                    <Initials>GY</Initials>
                    <Affiliation>Department of Medicine, University of Alberta, Edmonton, AB, Canada;</Affiliation>
                </Author>
                <Author>
                    <LastName>Murray</LastName>
                    <ForeName>Allan G</ForeName>
                    <Initials>AG</Initials>
                    <Affiliation>Department of Medicine, University of Alberta, Edmonton, AB, Canada; allan.murray@ualberta.ca.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Blood</MedlineTA>
            <NlmUniqueID>7603509</NlmUniqueID>
            <ISSNLinking>0006-4971</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">blood-2014-02-557975</ArticleId>
            <ArticleId IdType="doi">10.1182/blood-2014-02-557975</ArticleId>
            <ArticleId IdType="pubmed">25139353</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139351</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1528-0020</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Blood</Title>
                <ISOAbbreviation>Blood</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">blood-2013-07-517219</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The bone marrow niche is thought to act as a permissive microenvironment required for emergence or progression of hematological cancers. We hypothesized that osteoblasts, components of the niche involved in HSC function, influence the fate of leukemic blasts. We show that osteoblast numbers decrease by 55% in myelodysplasia and acute myeloid leukemia patients. Further, genetic depletion of osteoblasts in mouse models of acute leukemia increased circulating blasts and tumor engraftment in the marrow and spleen leading to higher tumor burden and shorter survival. Myelopoiesis increased and was coupled with a reduction in B-lymphopoiesis and compromised erythropoiesis suggesting that hematopoietic lineage/progression was altered. Treatment of mice with acute myeloid or lymphoblastic leukemia with a pharmacological inhibitor of the synthesis of duodenal serotonin, a hormone suppressing osteoblast numbers, inhibited loss of osteoblasts. Maintenance of the osteoblast pool restored normal marrow function, reduced tumor burden and prolonged survival. Leukemia prevention was due to maintenance of osteoblast numbers since inhibition of serotonin receptors alone in leukemic blasts did not affect leukemia progression. These results suggest that osteoblasts play a fundamental role in propagating leukemia in the marrow and may be a therapeutic target to induce hostility of the niche to leukemia blasts.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 American Society of Hematology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Krevvata</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Physiology &amp; Cellular Biophysics, College of Physicians &amp; Surgeons, Columbia University, New York, NY, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Silva</LastName>
                    <ForeName>Barbara C</ForeName>
                    <Initials>BC</Initials>
                    <Affiliation>Department of Physiology &amp; Cellular Biophysics, College of Physicians &amp; Surgeons, Columbia University, New York, NY, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Manavalan</LastName>
                    <ForeName>John S</ForeName>
                    <Initials>JS</Initials>
                    <Affiliation>Department of Physiology &amp; Cellular Biophysics, College of Physicians &amp; Surgeons, Columbia University, New York, NY, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Galan-Diez</LastName>
                    <ForeName>Marta</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Physiology &amp; Cellular Biophysics, College of Physicians &amp; Surgeons, Columbia University, New York, NY, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Kode</LastName>
                    <ForeName>Aruna</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Physiology &amp; Cellular Biophysics, College of Physicians &amp; Surgeons, Columbia University, New York, NY, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Matthews</LastName>
                    <ForeName>Brya Grace</ForeName>
                    <Initials>BG</Initials>
                    <Affiliation>Department of Reconstructive Sciences, University of Connecticut Health Center, Farmington, CT, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Park</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Chiyuan A</ForeName>
                    <Initials>CA</Initials>
                    <Affiliation>Department of Physiology &amp; Cellular Biophysics, College of Physicians &amp; Surgeons, Columbia University, New York, NY, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Galili</LastName>
                    <ForeName>Naomi</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Myelodysplastic Syndromes Center, Columbia University, New York, NY, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Nickolas</LastName>
                    <ForeName>Thomas L</ForeName>
                    <Initials>TL</Initials>
                    <Affiliation>Department of Medicine, Division of Nephrology, College of Physicians &amp; Surgeons, Columbia University, New York, NY, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Dempster</LastName>
                    <ForeName>David W</ForeName>
                    <Initials>DW</Initials>
                    <Affiliation>Regional Bone Center, Helen Hayes Hospital, New York, NY, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Dougall</LastName>
                    <ForeName>William</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Amgen, Inc., Seattle, WA, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Teruya-Feldstein</LastName>
                    <ForeName>Julie</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Economides</LastName>
                    <ForeName>A N</ForeName>
                    <Initials>AN</Initials>
                    <Affiliation>Bone &amp; Cartilage Biology Group, Genome Engineering Technologies Group Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Kalajzic</LastName>
                    <ForeName>Ivo</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Department of Reconstructive Sciences, University of Connecticut Health Center, Farmington, CT, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Raza</LastName>
                    <ForeName>Azra</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Myelodysplastic Syndromes Center, Columbia University, New York, NY, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Berman</LastName>
                    <ForeName>Ellin</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Mukherjee</LastName>
                    <ForeName>Siddhartha</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Departments of Medicine Hematology &amp; Oncology, Columbia University, New York, NY, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Bhagat</LastName>
                    <ForeName>Govind</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Depatment of Pathology and Cell Biology, College of Physicians &amp; Surgeons, Columbia University, New York, NY, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kousteni</LastName>
                    <ForeName>Stavroula</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Physiology &amp; Cellular Biophysics, College of Physicians &amp; Surgeons, Columbia University, New York, NY, United States; sk2836@columbia.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Blood</MedlineTA>
            <NlmUniqueID>7603509</NlmUniqueID>
            <ISSNLinking>0006-4971</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">blood-2013-07-517219</ArticleId>
            <ArticleId IdType="doi">10.1182/blood-2013-07-517219</ArticleId>
            <ArticleId IdType="pubmed">25139351</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139304</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-230X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>14</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC gastroenterology</Title>
                <ISOAbbreviation>BMC Gastroenterol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pharmacologic cholinesterase inhibition improves survival in acetaminophen-induced acute liver failure in the mouse.</ArticleTitle>
            <Pagination>
                <MedlinePgn>148</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Acetaminophen (APAP) is one of the most widely used analgesic and antipyretic pharmaceutical substances in the world and accounts for most cases of drug induced liver injury resulting in acute liver failure. Acute liver failure initiates a sterile inflammatory response with release of cytokines and innate immune cell infiltration in the liver. This study investigates, whether pharmacologic acetylcholinesterase inhibition with neostigmine diminishes liver damage in acute liver failure via the cholinergic anti-inflammatory pathway.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Acute liver failure was induced in BALB/c mice by a toxic dose of acetaminophen (APAP). Neostigmine and/or N-acetyl-cysteine (NAC) were applied therapeutically at set time points and the survival was investigated. Liver damage was assessed by serum parameters, histopathology and serum cytokine assays 12 h after initiation of acute liver failure.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Serum parameters, histopathology and serum cytokine assays showed pronounced features of acute liver failure 12 h after application of acetaminophen (APAP). Neostigmine treatment led to significant reduction of serum liver enzymes (LDH (47,147 +/- 12,726 IU/l vs. 15,822 +/- 10,629 IU/l, p = 0.0014) and ALT (18,048 +/- 4,287 IU/l vs. 7,585 +/- 5,336 IU/l, p = 0.0013), APAP-alone-treated mice vs. APAP + neostigmine-treated mice), inflammatory cytokine levels (IL-1beta (147 +/- 19 vs. 110 +/- 25, p = 0.0138) and TNF-alpha (184 +/- 23 vs. 130 +/- 33, p = 0.0086), APAP-alone-treated mice vs. APAP + neostigmine-treated mice) and histopathological signs of damage.Animals treated with NAC in combination with the peripheral cholinesterase inhibitor neostigmine showed prolonged survival and improved outcome.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Neostigmine is an acetylcholinesterase inhibitor that ameliorates the effects of APAP-induced acute liver failure in the mouse and therefore may provide new treatment options for affected patients.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Steinebrunner</LastName>
                    <ForeName>Niels</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author>
                    <LastName>Mogler</LastName>
                    <ForeName>Carolin</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Vittas</LastName>
                    <ForeName>Spiros</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Hoyler</LastName>
                    <ForeName>Birgit</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author>
                    <LastName>Sandig</LastName>
                    <ForeName>Catharina</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Stremmel</LastName>
                    <ForeName>Wolfgang</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author>
                    <LastName>Eisenbach</LastName>
                    <ForeName>Christoph</ForeName>
                    <Initials>C</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>BMC Gastroenterol</MedlineTA>
            <NlmUniqueID>100968547</NlmUniqueID>
            <ISSNLinking>1471-230X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1471-230X-14-148</ArticleId>
            <ArticleId IdType="doi">10.1186/1471-230X-14-148</ArticleId>
            <ArticleId IdType="pubmed">25139304</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139293</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-4367</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>12</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Colloids and surfaces. B, Biointerfaces</Title>
                <ISOAbbreviation>Colloids Surf B Biointerfaces</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A simple and effective approach for the treatment of dyslipidemia using anionic nanoliposomes.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0927-7765(14)00418-4</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.colsurfb.2014.07.045</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The present study was undertaken to evaluate the anti-dyslipidemic effects of nanoliposomes with different phospholipid compositions. Three sets of liposomal formulations (20Mm; 100nM in size) were prepared with low (SPC), medium (POPC) and high (HSPC) phase transition temperature values with and without cholesterol and anionic phosphatidyl glycerol (HSPC/DSPG; POPC/DMPG; SPC/EPG). The liposomal preparations were characterized for their size and zeta potential (dynamic light scattering), J774A.1 macrophages uptake (flow cytometry) and lipid-modifying effects (tyloxapol-induced hyperlipidemic mouse model). Anionic formulations displayed the highest rate of uptake by macrophages. Among them, HSPC/DSPG and SPC/EPG liposomes had the best lipid-modifying activity. These two formulations exerted favorable impact on all lipid profile parameters by reducing LDL-C (by up to 76% [HSPC/DSPG] and 86% [SPC/EPG]), total cholesterol (by up to 52% [HSPC/DSPG] and 68% [SPC/EPG]), triglycerides (by up to 88% [HSPC/DSPG] and 73% [SPC/EPG]), apoB (by up to 44% [HSPC/DSPG] and 35% [SPC/EPG]) and elevating HDL-C (by up to 85% [HSPC/DSPG] and 75% [SPC/EPG]) concentrations. Atherogenic indices were also effectively reduced following HSPC/DSPG (by up to 69%) and SPC/EPG (by up to 79%) injections. Empty, cholesterol-free nanoliposomal formulations containing 75% anionic phospholipid (PG) might serve as effective and rapid acting anti-dyslipidemic agents. Further research is warranted to confirm the observed anti-dyslipidemic effects of anionic nanoliposomes in diet-induced hyperlipidemic models, and also to evaluate the potential protective effects in regressing atheromatous lesions.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Sahebkar</LastName>
                    <ForeName>Amirhossein</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Research Centre, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia; Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation>
                </Author>
                <Author>
                    <LastName>Badiee</LastName>
                    <ForeName>Ali</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ghayour-Mobarhan</LastName>
                    <ForeName>Majid</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation>
                </Author>
                <Author>
                    <LastName>Goldouzian</LastName>
                    <ForeName>Seyed Reza</ForeName>
                    <Initials>SR</Initials>
                    <Affiliation>Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jaafari</LastName>
                    <ForeName>Mahmoud Reza</ForeName>
                    <Initials>MR</Initials>
                    <Affiliation>Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran; Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: jafarimr@mums.ac.ir.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Colloids Surf B Biointerfaces</MedlineTA>
            <NlmUniqueID>9315133</NlmUniqueID>
            <ISSNLinking>0927-7765</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Atherosclerosis</Keyword>
            <Keyword MajorTopicYN="N">Hyperlipidemia</Keyword>
            <Keyword MajorTopicYN="N">Liposome</Keyword>
            <Keyword MajorTopicYN="N">Nanomedicine</Keyword>
            <Keyword MajorTopicYN="N">Phospholipid</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0927-7765(14)00418-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.colsurfb.2014.07.045</ArticleId>
            <ArticleId IdType="pubmed">25139293</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139290</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1938-3673</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of leukocyte biology</Title>
                <ISOAbbreviation>J. Leukoc. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The mucosal expression pattern of interferon-?? in rhesus macaques.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">jlb.3A0214-088RRR</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Type I IFNs play an important role in innate and adaptive immunity against viral infections. A novel type I IFN, namely IFN-??, which can protect against vaginal transmission of HSV2 and Chlamydia muridarum bacterial infection, has been described in mice and humans. Nevertheless, the principle cell type and the expression pattern of IFN-?? in tissues remain uncertain. In addition, the expression of IFN-?? in Indian rhesus macaques (Macaca mulatta) has not been reported. Here, we analyzed IFN-?? expression in multiple mucosal sites of uninfected or SIV-infected Indian rhesus macaques using IHCS. We report for the first time the detection of IFN-?? expression in situ in the lung, foreskin, vaginal, cervical, and small and large intestinal mucosae of rhesus macaques. We found that the expression of IFN-?? was exclusive to the epithelial cells in all of the aforementioned mucosal tissues. Furthermore, the macaque IFN-?? sequence in this study revealed that macaque IFN-?? is highly conserved among human and other nonhuman primates. Lastly, SIV rectal infection did not significantly alter the expression of IFN-?? in rectal mucosae. Together, these findings indicate that IFN-?? may function as the first line of defense against the invasion of mucosal pathogens. Further studies should be conducted to examine IFN-?? protection against gastrointestinal as well as respiratory infections.</AbstractText>
                <CopyrightInformation>?? 2014 Society for Leukocyte Biology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Demers</LastName>
                    <ForeName>Andrew</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Nebraska Center for Virology, School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, Nebraska, USA;</Affiliation>
                </Author>
                <Author>
                    <LastName>Kang</LastName>
                    <ForeName>Guobin</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Nebraska Center for Virology, School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, Nebraska, USA;</Affiliation>
                </Author>
                <Author>
                    <LastName>Ma</LastName>
                    <ForeName>Fungrui</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Nebraska Center for Virology, School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, Nebraska, USA;</Affiliation>
                </Author>
                <Author>
                    <LastName>Lu</LastName>
                    <ForeName>Wuxun</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Nebraska Center for Virology, School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, Nebraska, USA;</Affiliation>
                </Author>
                <Author>
                    <LastName>Yuan</LastName>
                    <ForeName>Zhe</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Nebraska Center for Virology, School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, Nebraska, USA;</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Yue</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Nebraska Center for Virology, School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, Nebraska, USA; College of Life Sciences, Nankai University, Tianjin, China;</Affiliation>
                </Author>
                <Author>
                    <LastName>Lewis</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Bioqual, Rockville, Maryland, USA;</Affiliation>
                </Author>
                <Author>
                    <LastName>Kraiselburd</LastName>
                    <ForeName>Edmundo N</ForeName>
                    <Initials>EN</Initials>
                    <Affiliation>Department of Microbiology and Zoology, University of Puerto Rico-School of Medicine, San Juan, Puerto Rico; and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Montaner</LastName>
                    <ForeName>Luis</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>The Wistar Institute, Philadelphia, Pennsylvania, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Qingsheng</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>Nebraska Center for Virology, School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, Nebraska, USA; qli@unl.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Leukoc Biol</MedlineTA>
            <NlmUniqueID>8405628</NlmUniqueID>
            <ISSNLinking>0741-5400</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">IFN-I</Keyword>
            <Keyword MajorTopicYN="N">SIV</Keyword>
            <Keyword MajorTopicYN="N">Simian Immunodeficiency Virus</Keyword>
            <Keyword MajorTopicYN="N">mucosal immunity</Keyword>
            <Keyword MajorTopicYN="N">type I interferons</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">jlb.3A0214-088RRR</ArticleId>
            <ArticleId IdType="doi">10.1189/jlb.3A0214-088RRR</ArticleId>
            <ArticleId IdType="pubmed">25139290</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139265</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">0219-1032</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecules and cells</Title>
                <ISOAbbreviation>Mol. Cells</ISOAbbreviation>
            </Journal>
            <ArticleTitle>2-(Trimethylammonium) Ethyl (R)-3-Methoxy-3-oxo-2-Stearamidopropyl Phosphate Suppresses Osteoclast Maturation and Bone Resorption by Targeting Macrophage-Colony Stimulating Factor Signaling.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.14348/molcells.2014.0190</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">2-(Trimethylammonium) ethyl (R)-3-methoxy-3-oxo-2-stearamidopropyl phosphate [(R)-TEMOSPho], a derivative of an organic chemical identified from a natural product library, promotes highly efficient megakaryopoiesis. Here, we show that (R)-TEMOSPho blocks osteoclast maturation from progenitor cells of hematopoietic origin, as well as blocking the resorptive function of mature osteoclasts. The inhibitory effect of (R)-TEMOSPho on osteoclasts was due to a disruption of the actin cytoskeleton, resulting from impaired downstream signaling of c-Fms, a receptor for macrophage- colony stimulating factor linked to c-Cbl, phosphoinositol- 3-kinase (PI3K), Vav3, and Rac1. In addition, (R)- TEMOSPho blocked inflammation-induced bone destruction by reducing the numbers of osteoclasts produced in mice. Thus, (R)-TEMOSPho may represent a promising new class of antiresorptive drugs for the treatment of bone loss associated with increased osteoclast maturation and activity.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Park</LastName>
                    <ForeName>So Jeong</ForeName>
                    <Initials>SJ</Initials>
                    <Affiliation>Department of Life Science and the Research Center for Cellular Homeostasis, Ewha Womans University, Seoul 120-750, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Park</LastName>
                    <ForeName>Doo Ri</ForeName>
                    <Initials>DR</Initials>
                </Author>
                <Author>
                    <LastName>Bhattarai</LastName>
                    <ForeName>Deepak</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>BK21 Plus R-FIND Team, College of Pharmacy, Dongguk University, Goyang 410-820, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Kyeong</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Jaesang</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Bae</LastName>
                    <ForeName>Yun Soo</ForeName>
                    <Initials>YS</Initials>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Soo Young</ForeName>
                    <Initials>SY</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Mol Cells</MedlineTA>
            <NlmUniqueID>9610936</NlmUniqueID>
            <ISSNLinking>1016-8478</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">molcells.2014.0190</ArticleId>
            <ArticleId IdType="doi">10.14348/molcells.2014.0190</ArticleId>
            <ArticleId IdType="pubmed">25139265</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139234</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1090-2104</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>17</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochemical and biophysical research communications</Title>
                <ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mammalian target of rapamycin is essential for cardiomyocyte survival and heart development in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0006-291X(14)01461-2</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.bbrc.2014.08.046</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Mammalian target of rapamycin (mTOR) is a critical regulator of protein synthesis, cell proliferation and energy metabolism. As constitutive knockout of Mtor leads to embryonic lethality, the in vivo function of mTOR in perinatal development and postnatal growth of heart is not well defined. In this study, we established a muscle-specific mTOR conditional knockout mouse model (mTOR-mKO) by crossing MCK-Cre and Mtor(flox/flox) mice. Although the mTOR-mKO mice survived embryonic and perinatal development, they exhibited severe postnatal growth retardation, cardiac muscle pathology and premature death. At the cellular level, the cardiac muscle of mTOR-mKO mice had fewer cardiomyocytes due to apoptosis and necrosis, leading to dilated cardiomyopathy. At the molecular level, the cardiac muscle of mTOR-mKO mice expressed lower levels of fatty acid oxidation and glycolysis related genes compared to the WT littermates. In addition, the mTOR-mKO cardiac muscle had reduced Myh6 but elevated Myh7 expression, indicating cardiac muscle degeneration. Furthermore, deletion of Mtor dramatically decreased the phosphorylation of S6 and AKT, two key targets downstream of mTORC1 and mTORC2 mediating the normal function of mTOR. These results demonstrate that mTOR is essential for cardiomyocyte survival and cardiac muscle function.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Pengpeng</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Key Laboratory of Swine Genetics and Breeding, Ministry of Agriculture, College of Animal Science and Technology, Huazhong Agricultural University, Wuhan 430070, China; Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction, Ministry of Education, College of Animal Science and Technology, Huazhong Agricultural University, Wuhan 430070, China; Department of Animal Sciences, Purdue University, West Lafayette, IN 47907, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shan</LastName>
                    <ForeName>Tizhong</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Animal Sciences, Purdue University, West Lafayette, IN 47907, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liang</LastName>
                    <ForeName>Xinrong</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Animal Sciences, Purdue University, West Lafayette, IN 47907, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Deng</LastName>
                    <ForeName>Changyan</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Key Laboratory of Swine Genetics and Breeding, Ministry of Agriculture, College of Animal Science and Technology, Huazhong Agricultural University, Wuhan 430070, China; Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction, Ministry of Education, College of Animal Science and Technology, Huazhong Agricultural University, Wuhan 430070, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kuang</LastName>
                    <ForeName>Shihuan</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Animal Sciences, Purdue University, West Lafayette, IN 47907, USA. Electronic address: skuang@purdue.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
            <NlmUniqueID>0372516</NlmUniqueID>
            <ISSNLinking>0006-291X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cardiomyocyte</Keyword>
            <Keyword MajorTopicYN="N">Heart failure</Keyword>
            <Keyword MajorTopicYN="N">mTOR</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25139234</ArticleId>
            <ArticleId IdType="pii">S0006-291X(14)01461-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbrc.2014.08.046</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139227</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1524-475X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society</Title>
                <ISOAbbreviation>Wound Repair Regen</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The Therapeutic Potential of a C-X-C Chemokine Receptor type 4 (CXCR-4) Antagonist on Hypertrophic Scarring in vivo.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1111/wrr.12208</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Effective prevention and treatment of hypertrophic scars (HTS), a dermal form of fibrosis that frequently occurs following thermal injury to deep dermis, is an unsolved significant clinical problem. Previously, we have found that SDF-1/CXCR4 signaling is up-regulated during wound healing in burn patients and HTS tissue after thermal injury. We hypothesize that blood-borne mononuclear cells are recruited into wound sites after burn injury through the chemokine pathway of stromal cell-derived factor 1 (SDF-1) and its receptor CXCR4. Deep dermal injuries to the skin are often accompanied by prolonged inflammation, which leads to chemotaxis of mononuclear cells into the wounds by chemokine signaling where fibroblast activation occurs and ultimately HTS are formed. Blocking mononuclear cell recruitment and fibroblast activation, CXCR4 antagonism is expected to reduce or minimize scar formation. In this study, the inhibitory effect of CXCR4 antagonist CTCE-9908 on dermal fibrosis was determined in vivo using a human HTS-like nude mouse model, in which split-thickness human skin is transplanted into full thickness dorsal excisional wounds in athymic mice, where these wounds subsequently develop fibrotic scars that resemble human HTS as previously described. CTCE-9908 significantly attenuated scar formation and contraction, reduced the accumulation of macrophages and myofibroblasts, enhanced the remodeling of collagen fibers, and down-regulated the gene and protein expression of fibrotic growth factors in the human skin tissues. These findings support the potential therapeutic value of CXCR4 antagonist in dermal fibrosis and possibly other fibroproliferative disorders.</AbstractText>
                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ding</LastName>
                    <ForeName>Jie</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Wound Healing Research Group, Division of Plastic and Reconstructive Surgery, University of Alberta, Edmonton, Alberta, Canada.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ma</LastName>
                    <ForeName>Zengshuan</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Hongbin</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Kwan</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author>
                    <LastName>Iwashina</LastName>
                    <ForeName>Takashi</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Shankowsky</LastName>
                    <ForeName>Heather A</ForeName>
                    <Initials>HA</Initials>
                </Author>
                <Author>
                    <LastName>Wong</LastName>
                    <ForeName>Donald</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author>
                    <LastName>Tredget</LastName>
                    <ForeName>Edward E</ForeName>
                    <Initials>EE</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Wound Repair Regen</MedlineTA>
            <NlmUniqueID>9310939</NlmUniqueID>
            <ISSNLinking>1067-1927</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">SDF-1/CXCR4 signal pathway</Keyword>
            <Keyword MajorTopicYN="N">and CXCR4 antagonist</Keyword>
            <Keyword MajorTopicYN="N">hypertrophic scar</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1111/wrr.12208</ArticleId>
            <ArticleId IdType="pubmed">25139227</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139222</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1460-9568</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The European journal of neuroscience</Title>
                <ISOAbbreviation>Eur. J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of the volatile anesthetic sevoflurane on tonic GABA currents in the mouse striatum during postnatal development.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1111/ejn.12691</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The volatile anesthetic sevoflurane, which is widely used in pediatric surgery, has proposed effects on GABAA receptor-mediated extrasynaptic tonic inhibition. In the developing striatum, medium-sized spiny projection neurons have tonic GABA currents, which function in the excitatory/inhibitory balance and maturation of striatal neural circuits. In this study, we examined the effects of sevoflurane on the tonic GABA currents of medium spiny neurons in developing striatal slices. Sevoflurane strongly increased GABAA receptor-mediated tonic conductance at postnatal days 3-35. The antagonist of the GABA transporter-1, 1-[2-[[(diphenylmethylene)imino]oxy]ethyl]-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid hydrochloride further increased tonic GABA conductance during the application of sevoflurane, thereby increasing the total magnitude of tonic currents. Both GABA (5????m) and 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridine-3-ol hydrochloride, the ??-subunit-containing GABAA receptor agonist, induced tonic GABA currents in medium spiny neurons but not in cholinergic neurons. However, sevoflurane additively potentiated the tonic GABA currents in both cells. Interestingly, 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridine-3-ol hydrochloride-sensitive neurons made a large current response to sevoflurane, indicating the contribution of the ??-subunit on sevoflurane-enhanced tonic GABA currents. Our findings suggest that sevoflurane can affect the tone of tonic GABA inhibition in a developing striatal neural network.</AbstractText>
                <CopyrightInformation>?? 2014 Federation of European Neuroscience Societies and John Wiley &amp; Sons Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ando</LastName>
                    <ForeName>Nozomi</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Department of Anesthesiology and Pain Management, Juntendo University School of Medicine, Tokyo, Japan; Neurophysiology Research Group, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakae-cho, Itabashi-ku, Tokyo, 173-0015, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sugasawa</LastName>
                    <ForeName>Yusuke</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Inoue</LastName>
                    <ForeName>Ritsuko</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author>
                    <LastName>Aosaki</LastName>
                    <ForeName>Toshihiko</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Miura</LastName>
                    <ForeName>Masami</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Nishimura</LastName>
                    <ForeName>Kinya</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Eur J Neurosci</MedlineTA>
            <NlmUniqueID>8918110</NlmUniqueID>
            <ISSNLinking>0953-816X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">GABAA receptors</Keyword>
            <Keyword MajorTopicYN="N">ambient GABA</Keyword>
            <Keyword MajorTopicYN="N">basal ganglia</Keyword>
            <Keyword MajorTopicYN="N">development</Keyword>
            <Keyword MajorTopicYN="N">striatum</Keyword>
            <Keyword MajorTopicYN="N">volatile anesthetics</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ejn.12691</ArticleId>
            <ArticleId IdType="pubmed">25139222</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139191</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-2013</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Pflugers Archiv : European journal of physiology</Title>
                <ISOAbbreviation>Pflugers Arch.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Carbachol-induced colonic mucus formation requires transport via NKCC1, K(+) channels and CFTR.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The colonic mucosa protects itself from the luminal content by secreting mucus that keeps the bacteria at a distance from the epithelium. For this barrier to be effective, the mucus has to be constantly replenished which involves exocytosis and expansion of the secreted mucins. Mechanisms involved in regulation of mucus exocytosis and expansion are poorly understood, and the aim of this study was to investigate whether epithelial anion secretion regulates mucus formation in the colon. The muscarinic agonist carbachol was used to induce parallel secretion of anions and mucus, and by using established inhibitors of ion transport, we studied how inhibition of epithelial transport affected mucus formation in mouse colon. Anion secretion and mucin exocytosis were measured by changes in membrane current and epithelial capacitance, respectively. Mucus thickness measurements were used to determine the carbachol effect on mucus growth. The results showed that the carbachol-induced increase in membrane current was dependent on NKCC1 co-transport, basolateral K(+) channels and Cftr activity. In contrast, the carbachol-induced increase in capacitance was partially dependent on NKCC1 and K(+) channel activity, but did not require Cftr activity. Carbachol also induced an increase in mucus thickness that was inhibited by the NKCC1 blocker bumetanide. However, mice that lacked a functional Cftr channel did not respond to carbachol with an increase in mucus thickness, suggesting that carbachol-induced mucin expansion requires Cftr channel activity. In conclusion, these findings suggest that colonic epithelial transport regulates mucus formation by affecting both exocytosis and expansion of the mucin molecules.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Gustafsson</LastName>
                    <ForeName>Jenny K</ForeName>
                    <Initials>JK</Initials>
                    <Affiliation>Department of Medical Biochemistry, University of Gothenburg, Medicinaregatan 9A, Box 440, Gothenburg, 405 30, Sweden, jenny.gustafsson@gu.se.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lind??n</LastName>
                    <ForeName>Sara K</ForeName>
                    <Initials>SK</Initials>
                </Author>
                <Author>
                    <LastName>Alwan</LastName>
                    <ForeName>Ala H</ForeName>
                    <Initials>AH</Initials>
                </Author>
                <Author>
                    <LastName>Scholte</LastName>
                    <ForeName>Bob J</ForeName>
                    <Initials>BJ</Initials>
                </Author>
                <Author>
                    <LastName>Hansson</LastName>
                    <ForeName>Gunnar C</ForeName>
                    <Initials>GC</Initials>
                </Author>
                <Author>
                    <LastName>Sj??vall</LastName>
                    <ForeName>Henrik</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Pflugers Arch</MedlineTA>
            <NlmUniqueID>0154720</NlmUniqueID>
            <ISSNLinking>0031-6768</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00424-014-1595-y</ArticleId>
            <ArticleId IdType="pubmed">25139191</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139148</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2159-8290</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer discovery</Title>
                <ISOAbbreviation>Cancer Discov</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Brain Tumor Cells in Circulation are Enriched for Mesenchymal Gene Expression.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">CD-14-0471</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Glioblastoma (GBM) is a highly aggressive brain cancer characterized by local invasion and angiogenic recruitment, yet metastatic dissemination is extremely rare. Here, we adapted a microfluidic device to deplete hematopoietic cells from blood specimens of patients with GBM, uncovering evidence of circulating brain tumor cells (CTCs). Staining and scoring criteria for GBM CTCs were first established using orthotopic patient-derived xenografts (PDX), and then applied clinically: CTCs were identified in at least one blood specimen from 13/33 patients (39%; 26/87 samples). Single GBM CTCs isolated from both patients and mouse PDX models demonstrated enrichment for mesenchymal over neural differentiation markers, compared with primary GBMs. Within primary GBMs, RNA-in-situ hybridization identifies a subpopulation of highly migratory mesenchymal tumor cells, and in a rare patient with disseminated GBM, systemic lesions were exclusively mesenchymal. Thus, a mesenchymal subset of GBM cells invades into the vasculature, and may proliferate outside the brain.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Sullivan</LastName>
                    <ForeName>James P</ForeName>
                    <Initials>JP</Initials>
                    <Affiliation>Massachusetts General Hospital Cancer Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nahed</LastName>
                    <ForeName>Brian V</ForeName>
                    <Initials>BV</Initials>
                    <Affiliation>Massachusetts General Hospital Cancer Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Madden</LastName>
                    <ForeName>Marissa W</ForeName>
                    <Initials>MW</Initials>
                    <Affiliation>Massachusetts General Hospital Cancer Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Oliveira</LastName>
                    <ForeName>Samantha M</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>Massachusetts General Hospital Cancer Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Springer</LastName>
                    <ForeName>Simeon</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Massachusetts General Hospital Cancer Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bhere</LastName>
                    <ForeName>Deepak</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Neurology, Harvard Medical School.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chi</LastName>
                    <ForeName>Andrew S</ForeName>
                    <Initials>AS</Initials>
                    <Affiliation>Massachusetts General Hospital Cancer Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wakimoto</LastName>
                    <ForeName>Hiroaki</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Massachusetts General Hospital Cancer Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rothenberg</LastName>
                    <ForeName>S Michael</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>Massachusetts General Hospital Cancer Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sequist</LastName>
                    <ForeName>Lecia V</ForeName>
                    <Initials>LV</Initials>
                    <Affiliation>Massachusetts General Hospital Cancer Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kapur</LastName>
                    <ForeName>Ravi</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Center for Engineering in Medicine, Harvard Medical School.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shah</LastName>
                    <ForeName>Khalid</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Neurology, Harvard Medical School.</Affiliation>
                </Author>
                <Author>
                    <LastName>Iafrate</LastName>
                    <ForeName>A John</ForeName>
                    <Initials>AJ</Initials>
                    <Affiliation>Massachusetts General Hospital Cancer Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Curry</LastName>
                    <ForeName>William T</ForeName>
                    <Initials>WT</Initials>
                    <Affiliation>Massachusetts General Hospital Cancer Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Loeffler</LastName>
                    <ForeName>Jay S</ForeName>
                    <Initials>JS</Initials>
                    <Affiliation>Massachusetts General Hospital Cancer Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Batchelor</LastName>
                    <ForeName>Tracy T</ForeName>
                    <Initials>TT</Initials>
                    <Affiliation>Massachusetts General Hospital Cancer Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Louis</LastName>
                    <ForeName>David N</ForeName>
                    <Initials>DN</Initials>
                    <Affiliation>Massachusetts General Hospital Cancer Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Toner</LastName>
                    <ForeName>Mehmet</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Center for Engineering in Medicine, Harvard Medical School.</Affiliation>
                </Author>
                <Author>
                    <LastName>Maheswaran</LastName>
                    <ForeName>Shyamala</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Massachusetts General Hospital Cancer Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Haber</LastName>
                    <ForeName>Daniel A</ForeName>
                    <Initials>DA</Initials>
                    <Affiliation>Massachusetts General Hospital Cancer Center haber@helix.mgh.harvard.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <GrantList>
                <Grant>
                    <GrantID>K12 CA090354</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P50 CA165962</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Cancer Discov</MedlineTA>
            <NlmUniqueID>101561693</NlmUniqueID>
            <ISSNLinking>2159-8274</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">2159-8290.CD-14-0471</ArticleId>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-14-0471</ArticleId>
            <ArticleId IdType="pubmed">25139148</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139109</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1756-6606</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>7</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular brain</Title>
                <ISOAbbreviation>Mol Brain</ISOAbbreviation>
            </Journal>
            <ArticleTitle>TLR4 enhances histamine-mediated pruritus by potentiating TRPV1 activity.</ArticleTitle>
            <Pagination>
                <MedlinePgn>59</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">BackgroundRecent studies have indicated that Toll-like receptor 4 (TLR4), a pathogen-recognition receptor that triggers inflammatory signals in innate immune cells, is also expressed on sensory neurons, implicating its putative role in sensory signal transmission. However, the possible function of sensory neuron TLR4 has not yet been formally addressed. In this regard, we investigated the role of TLR4 in itch signal transmission.ResultsTLR4 was expressed on a subpopulation of dorsal root ganglia (DRG) sensory neurons that express TRPV1. In TLR4-knockout mice, histamine-induced itch responses were compromised while TLR4 activation by LPS did not directly elicit an itch response. Histamine-induced intracellular calcium signals and inward currents were comparably reduced in TLR4-deficient sensory neurons. Reduced histamine sensitivity in the TLR4-deficient neurons was accompanied by a decrease in TRPV1 activity. Heterologous expression experiments in HEK293T cells indicated that TLR4 expression enhanced capsaicin-induced intracellular calcium signals and inward currents.ConclusionsOur data show that TLR4 on sensory neurons enhances histamine-induced itch signal transduction by potentiating TRPV1 activity. The results suggest that TLR4 could be a novel target for the treatment of enhanced itch sensation.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Min</LastName>
                    <ForeName>Hyunjung</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Hyunkyoung</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Lim</LastName>
                    <ForeName>Hyoungsub</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Jang</LastName>
                    <ForeName>Yong</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Chung</LastName>
                    <ForeName>Sung</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Sung</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Mol Brain</MedlineTA>
            <NlmUniqueID>101468876</NlmUniqueID>
            <ISSNLinking>1756-6606</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">s13041-014-0059-9</ArticleId>
            <ArticleId IdType="doi">10.1186/s13041-014-0059-9</ArticleId>
            <ArticleId IdType="pubmed">25139109</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139092</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1420-9071</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cellular and molecular life sciences : CMLS</Title>
                <ISOAbbreviation>Cell. Mol. Life Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Regulation of male sex determination: genital ridge formation and Sry activation in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Sex determination is essential for the sexual reproduction to generate the next generation by the formation of functional male or female gametes. In mammals, primary sex determination is commenced by the presence or absence of the Y chromosome, which controls the fate of the gonadal primordium. The somatic precursor of gonads, the genital ridge is formed at the mid-gestation stage and gives rise to one of two organs, a testis or an ovary. The fate of the genital ridge, which is governed by the differentiation of somatic cells into Sertoli cells in the testes or granulosa cells in the ovaries, further determines the sex of an individual and their germ cells. Mutation studies in human patients with disorders of sex development and mouse models have revealed factors that are involved in mammalian sex determination. In most of mammals, a single genetic trigger, the Y-linked gene Sry (sex determination region on Y chromosome), regulates testicular differentiation. Despite identification of Sry in 1990, precise mechanisms underlying the sex determination of bipotential genital ridges are still largely unknown. Here, we review the recent progress that has provided new insights into the mechanisms underlying genital ridge formation as well as the regulation of Sry expression and its functions in male sex determination of mice.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Tanaka</LastName>
                    <ForeName>Satomi S</ForeName>
                    <Initials>SS</Initials>
                    <Affiliation>Department of Kidney Development, Institute of Molecular Embryology and Genetics, Kumamoto University, 2-2-1 Honjo, Kumamoto, 860-0811, Japan, stanaka@kumamoto-u.ac.jp.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nishinakamura</LastName>
                    <ForeName>Ryuichi</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Cell Mol Life Sci</MedlineTA>
            <NlmUniqueID>9705402</NlmUniqueID>
            <ISSNLinking>1420-682X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-014-1703-3</ArticleId>
            <ArticleId IdType="pubmed">25139092</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139079</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1521-3773</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Angewandte Chemie (International ed. in English)</Title>
                <ISOAbbreviation>Angew. Chem. Int. Ed. Engl.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Phosphonated Near-Infrared Fluorophores for Biomedical Imaging of Bone.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/anie.201404930</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The conventional method for creating targeted contrast agents is to conjugate separate targeting and fluorophore domains. A new strategy is based on the incorporation of targeting moieties into the non-delocalized structure of pentamethine and heptamethine indocyanines. Using the known affinity of phosphonates for bone minerals in a model system, two families of bifunctional molecules that target bone without requiring a traditional bisphosphonate are synthesized. With peak fluorescence emissions at approximately 700 or 800 nm, these molecules can be used for fluorescence-assisted resection and exploration (FLARE) dual-channel imaging. Longitudinal FLARE studies in mice demonstrate that phosphonated near-infrared fluorophores remain stable in bone for over five weeks, and histological analysis confirms their incorporation into the bone matrix. Taken together, a new strategy for creating ultra-compact, targeted near-infrared fluorophores for various bioimaging applications is described.</AbstractText>
                <CopyrightInformation>?? 2014 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hyun</LastName>
                    <ForeName>Hoon</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Division of Hematology/Oncology, Department of Medicine and Department of Radiology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, SL436A, Boston, MA 02215 (USA).</Affiliation>
                </Author>
                <Author>
                    <LastName>Wada</LastName>
                    <ForeName>Hideyuki</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Bao</LastName>
                    <ForeName>Kai</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Gravier</LastName>
                    <ForeName>Julien</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Yadav</LastName>
                    <ForeName>Yogesh</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Laramie</LastName>
                    <ForeName>Matt</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Henary</LastName>
                    <ForeName>Maged</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Frangioni</LastName>
                    <ForeName>John V</ForeName>
                    <Initials>JV</Initials>
                </Author>
                <Author>
                    <LastName>Choi</LastName>
                    <ForeName>Hak Soo</ForeName>
                    <Initials>HS</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Angew Chem Int Ed Engl</MedlineTA>
            <NlmUniqueID>0370543</NlmUniqueID>
            <ISSNLinking>1433-7851</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">fluorophores</Keyword>
            <Keyword MajorTopicYN="N">imaging agents</Keyword>
            <Keyword MajorTopicYN="N">medicinal chemistry</Keyword>
            <Keyword MajorTopicYN="N">near-infrared fluorescence</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/anie.201404930</ArticleId>
            <ArticleId IdType="pubmed">25139079</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139051</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-1555</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Endocrinology and metabolism</Title>
                <ISOAbbreviation>Am. J. Physiol. Endocrinol. Metab.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>SUMOylation protects against IL-1??-induced apoptosis in INS-1 832/13 and human islets.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ajpendo.00168.2014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Post-translational modification by the small ubiquitin-like modifier (SUMO) peptides, known as SUMOylation, is reversed by the sentrin/SUMO-specific proteases (SENPs). While increased SUMOylation reduces ??-cell exocytosis, insulin secretion, and responsiveness to GLP-1, the impact of SUMOylation on islet cell survival is unknown. Mouse islets, INS-1 832/13 cells, or human islets were transduced with adenoviruses to increase either SENP1 or SUMO1, or were transfected with siRNA duplexes to knockdown SENP1. We examined insulin secretion, intracellular Ca(2+) responses, induction of ER stress markers and inducible nitric oxide synthase (iNOS) expression, and apoptosis by TUNEL and caspase 3 cleavage. Surprisingly, up-regulation of SENP1 reduces insulin secretion and impairs intracellular Ca(2+) handling. This secretory dysfunction is due to SENP1-induced cell death. Indeed, the detrimental effect of SENP1 on secretory function is diminished when two mediators of ??-cell death, iNOS and NF??B, are pharmacologically inhibited. Conversely, enhanced SUMOylation protects against IL-1??-induced cell death. This is associated with reduced iNOS expression, cleavage of caspase 3, and nuclear translocation of NF??B. Taken together, these findings identify SUMO1 as a novel anti-apoptotic protein in islets and demonstrate that reduced viability accounts for impaired islet function following SENP1 up-regulation.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Journal of Physiology - Endocrinology and Metabolism.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hajmrle</LastName>
                    <ForeName>Catherine</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>University of Alberta.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ferdaoussi</LastName>
                    <ForeName>Mourad</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>University of Alberta.</Affiliation>
                </Author>
                <Author>
                    <LastName>Plummer</LastName>
                    <ForeName>Gregory</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>University of Alberta.</Affiliation>
                </Author>
                <Author>
                    <LastName>Spigelman</LastName>
                    <ForeName>Aliya F</ForeName>
                    <Initials>AF</Initials>
                    <Affiliation>University of Alberta.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lai</LastName>
                    <ForeName>Krista</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>University of Alberta.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fox</LastName>
                    <ForeName>Jocelyn E Manning</ForeName>
                    <Initials>JE</Initials>
                    <Affiliation>University of Alberta.</Affiliation>
                </Author>
                <Author>
                    <LastName>MacDonald</LastName>
                    <ForeName>Patrick E</ForeName>
                    <Initials>PE</Initials>
                    <Affiliation>University of Alberta pmacdonald@ualberta.ca.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Am J Physiol Endocrinol Metab</MedlineTA>
            <NlmUniqueID>100901226</NlmUniqueID>
            <ISSNLinking>0193-1849</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Islets of Langerhans</Keyword>
            <Keyword MajorTopicYN="N">SENP1</Keyword>
            <Keyword MajorTopicYN="N">SUMOylation</Keyword>
            <Keyword MajorTopicYN="N">iNOS</Keyword>
            <Keyword MajorTopicYN="N">insulin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ajpendo.00168.2014</ArticleId>
            <ArticleId IdType="doi">10.1152/ajpendo.00168.2014</ArticleId>
            <ArticleId IdType="pubmed">25139051</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139050</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-1555</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Endocrinology and metabolism</Title>
                <ISOAbbreviation>Am. J. Physiol. Endocrinol. Metab.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Loss of Vitamin D Receptor Signaling from the Mammary Epithelium or Adipose Tissue Alters Pubertal Glandular Development.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ajpendo.00200.2014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Vitamin D3 receptor (VDR) signaling within the mammary gland regulates various postnatal stages of glandular development including puberty, pregnancy, involution, and tumorigenesis. Previous studies have shown that vitamin D3 treatment induces cell autonomous growth inhibition and differentiation of mammary epithelial cells in culture. Further, mammary adipose tissue serves as a depot for vitamin D3 storage, and both epithelial cells and adipocytes are capable of bioactivating vitamin D3. Despite the pervasiveness of VDR in mammary tissue, individual contributions of epithelial cells and adipocytes, as well as the VDR-regulated crosstalk between these two cell types during pubertal mammary development have yet to be investigated. To assess the cell-type specific effect of VDR signaling during pubertal mammary development, novel mouse models with mammary epithelial- or adipocyte-specific loss of VDR were generated. Interestingly, loss of VDR in either cellular compartment accelerated ductal morphogenesis with increased epithelial cell proliferation and decreased apoptosis within terminal end buds. Conversely, VDR signaling specifically in the mammary epithelium modulated hormone-induced alveolar growth as ablation of VDR in this cell type resulted in precocious alveolar development. In examining cellular cross-talk ex vivo, we show that ligand-dependent VDR signaling in adipocytes significantly inhibits mammary epithelial cell growth, in part, through the vitamin D3 dependent production of the cytokine IL-6. Collectively, these studies delineate independent roles for vitamin D3-dependent VDR signaling in mammary adipocytes and epithelial cells in controlling pubertal mammary gland development.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Journal of Physiology - Endocrinology and Metabolism.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Johnson</LastName>
                    <ForeName>Abby L</ForeName>
                    <Initials>AL</Initials>
                    <Affiliation>University of Cincinnati.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zinser</LastName>
                    <ForeName>Glendon M</ForeName>
                    <Initials>GM</Initials>
                    <Affiliation>University of Cincinnati.</Affiliation>
                </Author>
                <Author>
                    <LastName>Waltz</LastName>
                    <ForeName>Susan E</ForeName>
                    <Initials>SE</Initials>
                    <Affiliation>University of Cincinnati College of Medicine susan.waltz@uc.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Am J Physiol Endocrinol Metab</MedlineTA>
            <NlmUniqueID>100901226</NlmUniqueID>
            <ISSNLinking>0193-1849</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Vitamin D receptor</Keyword>
            <Keyword MajorTopicYN="N">cell cross talk</Keyword>
            <Keyword MajorTopicYN="N">mammary gland development</Keyword>
            <Keyword MajorTopicYN="N">paracrine signaling</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ajpendo.00200.2014</ArticleId>
            <ArticleId IdType="doi">10.1152/ajpendo.00200.2014</ArticleId>
            <ArticleId IdType="pubmed">25139050</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139048</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-1555</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Endocrinology and metabolism</Title>
                <ISOAbbreviation>Am. J. Physiol. Endocrinol. Metab.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Detection of insulin granule exocytosis by an electrophysiology method with high temporal resolution reveals enlarged insulin granule pool in BIG3 knockout mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ajpendo.00208.2014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">We recently identified BIG3 as a negative regulator of insulin granule biogenesis, and reported increased insulin secretion in BIG3 KO (BKO) mice. To pinpoint the site of action for BIG3, we investigated whether BIG3 regulates quantal insulin granule exocytosis. We established an assay to detect insulin granule exocytosis by recording ATP-elicited currents at high temporal resolution by patch clamp. Similar to insulin, ATP release was increased in BKO ??-cells. Although the frequency of insulin granule exocytosis was increased in BKO ??-cells, quantal size or release kinetics remained unchanged. EM studies showed that the number of insulin granules was increased by &gt;60% in BKO ??-cells. However, the number of morphologically docked granules was unaltered. The number of insulin granules having significant distances away from plasma membrane was greatly increased in BKO ??-cells. Thus, BIG3 negatively regulates insulin granule exocytosis by restricting insulin granule biogenesis, without affecting the release kinetics of individual granules at the final exocytotic steps. Depletion of BIG3 leads to enlarged releasable pool of insulin granules, which accounts for increased release frequency and consequently, increased insulin secretion.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Journal of Physiology - Endocrinology and Metabolism.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Tao</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Singapore Bioimaging Consortium.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Hongyu</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Singapore Bioimaging Consortium.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gounko</LastName>
                    <ForeName>Natalia V</ForeName>
                    <Initials>NV</Initials>
                    <Affiliation>Singapore Bioimaging Consortium.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Zhuan</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Peking University.</Affiliation>
                </Author>
                <Author>
                    <LastName>Xu</LastName>
                    <ForeName>Aimin</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>University of Hong Kong.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hong</LastName>
                    <ForeName>Wanjin</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Singapore Bioimaging Consortium.</Affiliation>
                </Author>
                <Author>
                    <LastName>Han</LastName>
                    <ForeName>Weiping</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Singapore Bioimaging Consortium weiping_han@sbic.a-star.edu.sg.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Am J Physiol Endocrinol Metab</MedlineTA>
            <NlmUniqueID>100901226</NlmUniqueID>
            <ISSNLinking>0193-1849</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">calcium</Keyword>
            <Keyword MajorTopicYN="N">diabetes</Keyword>
            <Keyword MajorTopicYN="N">exocytosis</Keyword>
            <Keyword MajorTopicYN="N">fusion</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ajpendo.00208.2014</ArticleId>
            <ArticleId IdType="doi">10.1152/ajpendo.00208.2014</ArticleId>
            <ArticleId IdType="pubmed">25139048</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139020</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1537-6613</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of infectious diseases</Title>
                <ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Two Borrelia burgdorferi proteins - BB0323 and novel virulence determinant BB0238 - that interact with and stabilize each other are critical for infectivity.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">jiu460</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">We have shown that Borrelia burgdorferi gene product BB0323 is essential for cell fission and pathogen persistence in vivo. Here we describe characterization of a conserved hypothetical protein annotated as BB0238, which specifically interacts with the N-terminal region of BB0323. We show that BB0238 is a subsurface protein, and similar to BB0323, exists in the periplasm and as a membrane-bound protein. Deletion of bb0238 in infectious B. burgdorferi did not affect microbial growth in vitro or survival in ticks, but the mutant was unable to persist in mice or transmit from ticks - defects that are restored upon genetic complementation. Remarkably, BB0238 and BB0323 contribute to mutual post-translational stability, as deletion of one causes dramatic reduction in the protein level of the other partner. Interference with the function of BB0238 or BB0323 and their interaction may provide novel strategies to combat B. burgdorferi infection.</AbstractText>
                <CopyrightInformation>?? The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kariu</LastName>
                    <ForeName>Toru</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Veterinary Medicine and Virginia-Maryland Regional College of Veterinary Medicine, University of Maryland, College Park, MD 20742, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sharma</LastName>
                    <ForeName>Kavita</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Veterinary Medicine and Virginia-Maryland Regional College of Veterinary Medicine, University of Maryland, College Park, MD 20742, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Singh</LastName>
                    <ForeName>Preeti</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Veterinary Medicine and Virginia-Maryland Regional College of Veterinary Medicine, University of Maryland, College Park, MD 20742, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Smith</LastName>
                    <ForeName>Alexis A</ForeName>
                    <Initials>AA</Initials>
                    <Affiliation>Department of Veterinary Medicine and Virginia-Maryland Regional College of Veterinary Medicine, University of Maryland, College Park, MD 20742, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Backstedt</LastName>
                    <ForeName>Brian</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Department of Veterinary Medicine and Virginia-Maryland Regional College of Veterinary Medicine, University of Maryland, College Park, MD 20742, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Buyuktanir</LastName>
                    <ForeName>Ozlem</ForeName>
                    <Initials>O</Initials>
                    <Affiliation>Department of Veterinary Medicine and Virginia-Maryland Regional College of Veterinary Medicine, University of Maryland, College Park, MD 20742, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pal</LastName>
                    <ForeName>Utpal</ForeName>
                    <Initials>U</Initials>
                    <Affiliation>Department of Veterinary Medicine and Virginia-Maryland Regional College of Veterinary Medicine, University of Maryland, College Park, MD 20742, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Infect Dis</MedlineTA>
            <NlmUniqueID>0413675</NlmUniqueID>
            <ISSNLinking>0022-1899</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">jiu460</ArticleId>
            <ArticleId IdType="doi">10.1093/infdis/jiu460</ArticleId>
            <ArticleId IdType="pubmed">25139020</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139019</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1537-6613</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of infectious diseases</Title>
                <ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dietary Pectin-Derived Acidic Oligosaccharides Improve the Pulmonary Bacterial Clearance of Pseudomonas aeruginosa Lung Infection in Mice by Modulating Intestinal Microbiota and Immunity.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">jiu391</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">???A predominantly T-helper type 2 (Th2) immune response is critical in the prognosis of pulmonary Pseudomonas aeruginosa infection. But the mucosal and systemic immune responses can be influenced by the intestinal microbiota.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">???We assessed the effect of microbiota compositional changes induced by a diet enriched in 5% acidic oligosaccharides derived from pectin (pAOS) on the immune response and outcome of chronic pulmonary P. aeruginosa infection in mice.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">???pAOS promoted Th1 polarization by increasing interferon ?? release, upregulating t-bet gene expression, decreasing interleukin 4 secretion, and downregulating gata3 gene expression. pAOS also sustained the release of keratinocyte chemoattractant, recruited polynuclear leukocytes and macrophages, stimulated M1 macrophage activation and interleukin 10 release, and decreased tumor necrosis factor ?? release in the lung. These effects led to increased bacterial clearance after the first and second P. aeruginosa infections. pAOS modified the intestinal microbiota by stimulating the growth of species involved in immunity development, such as Bifidobacterium species, Sutturella wadsworthia, and Clostridium cluster XIVa organisms, and at the same time increased the production of butyrate and propionate.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">???These results suggest that pAOS may have beneficial effects by limiting the number and severity of pulmonary exacerbations in patients chronically infected with P. aeruginosa, such as individuals with cystic fibrosis.</AbstractText>
                <CopyrightInformation>?? The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Bernard</LastName>
                    <ForeName>Henry</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Unit?? INSERM 995, Facult?? de m??decine, Universit?? Lille 2, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Desseyn</LastName>
                    <ForeName>Jean-Luc</ForeName>
                    <Initials>JL</Initials>
                    <Affiliation>Unit?? INSERM 995, Facult?? de m??decine, Universit?? Lille 2, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bartke</LastName>
                    <ForeName>Nana</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Nutricia Research, Utrecht.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kleinjans</LastName>
                    <ForeName>Lennart</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Laboratory of Microbiology, Wageningen University, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Stahl</LastName>
                    <ForeName>Bernd</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Nutricia Research, Utrecht.</Affiliation>
                </Author>
                <Author>
                    <LastName>Belzer</LastName>
                    <ForeName>Clara</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Laboratory of Microbiology, Wageningen University, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Knol</LastName>
                    <ForeName>Jan</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Nutricia Research, Utrecht Laboratory of Microbiology, Wageningen University, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gottrand</LastName>
                    <ForeName>Fr??d??ric</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Unit?? INSERM 995, Facult?? de m??decine, Universit?? Lille 2, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Husson</LastName>
                    <ForeName>Marie-Odile</ForeName>
                    <Initials>MO</Initials>
                    <Affiliation>Unit?? INSERM 995, Facult?? de m??decine, Universit?? Lille 2, France.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Infect Dis</MedlineTA>
            <NlmUniqueID>0413675</NlmUniqueID>
            <ISSNLinking>0022-1899</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">P. aeruginosa lung infection</Keyword>
            <Keyword MajorTopicYN="N">Th1 and M1 polarization</Keyword>
            <Keyword MajorTopicYN="N">intestinal microbiota</Keyword>
            <Keyword MajorTopicYN="N">prebiotics</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">jiu391</ArticleId>
            <ArticleId IdType="doi">10.1093/infdis/jiu391</ArticleId>
            <ArticleId IdType="pubmed">25139019</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25139013</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-8421</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>8</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of neuroimmunology</Title>
                <ISOAbbreviation>J. Neuroimmunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Enhanced resistance of CXCR3 deficient mice to ocular HSV-1 infection is due to control of replication in the brain ependyma.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0165-5728(14)00238-0</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.jneuroim.2014.08.005</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">CXCR3 deficient (CXCR3(-/-)) mice are resistant to ocular HSV-1 infection in that less mice develop encephalitis and succumb to infection in comparison to wild type (WT) animals. A region of the brain previously identified to be crucial for development of encephalitis was evaluated in HSV-1-infected CXCR3(-/-) and WT mice. In this region, known as the ependyma, viral titer, infiltrating leukocyte populations, and key anti-viral cytokine message levels were evaluated. We found that CXCR3(-/-) mice possessed significantly less HSV-1 and expressed significantly more IFN-?? mRNA in the brain ependyma compared to WT animals during the development of encephalitis.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kroll</LastName>
                    <ForeName>Chandra M</ForeName>
                    <Initials>CM</Initials>
                    <Affiliation>Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zheng</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Carr</LastName>
                    <ForeName>Daniel J J</ForeName>
                    <Initials>DJ</Initials>
                    <Affiliation>Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; Department of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA. Electronic address: dan-carr@ouhsc.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Neuroimmunol</MedlineTA>
            <NlmUniqueID>8109498</NlmUniqueID>
            <ISSNLinking>0165-5728</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Brain ependyma</Keyword>
            <Keyword MajorTopicYN="N">CXCR3</Keyword>
            <Keyword MajorTopicYN="N">Herpes simplex virus type 1</Keyword>
            <Keyword MajorTopicYN="N">Interferon-??</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0165-5728(14)00238-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2014.08.005</ArticleId>
            <ArticleId IdType="pubmed">25139013</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138991</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1744-7593</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Expert opinion on drug delivery</Title>
                <ISOAbbreviation>Expert Opin Drug Deliv</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1-16</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Introduction: Biologic drugs are large molecules that do not cross the blood- brain barrier (BBB). Brain penetration is possible following the re-engineering of the biologic drug as an IgG fusion protein. The IgG domain is a MAb against an endogenous BBB receptor such as the transferrin receptor (TfR). The TfRMAb acts as a molecular Trojan horse to ferry the fused biologic drug into the brain via receptor-mediated transport on the endogenous BBB TfR. Areas covered: This review discusses TfR isoforms, models of BBB transport of transferrin and TfRMAbs, and the genetic engineering of TfRMAb fusion proteins, including BBB penetrating IgG-neurotrophins, IgG-decoy receptors, IgG-lysosomal enzyme therapeutics and IgG-avidin fusion proteins, as well as BBB transport of bispecific antibodies formed by fusion of a therapeutic antibody to a TfRMAb targeting antibody. Also discussed are quantitative aspects of the plasma pharmacokinetics and brain uptake of TfRMAb fusion proteins, as compared to the brain uptake of small molecules, and therapeutic applications of TfRMAb fusion proteins in mouse models of neural disease, including Parkinson's disease, stroke, Alzheimer's disease and lysosomal storage disorders. The review covers the engineering of TfRMAb-avidin fusion proteins for BBB targeted delivery of biotinylated peptide radiopharmaceuticals, low-affinity TfRMAb Trojan horses and the safety pharmacology of chronic administration of TfRMAb fusion proteins. Expert opinion: The BBB delivery of biologic drugs is possible following re-engineering as a fusion protein with a molecular Trojan horse such as a TfRMAb. The efficacy of this technology will be determined by the outcome of future clinical trials.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Pardridge</LastName>
                    <ForeName>William M</ForeName>
                    <Initials>WM</Initials>
                    <Affiliation>ArmaGen Technologies, Inc. , 26679 Agoura Road, Calabasas, CA 91302 , USA +1 818 252 8202 ; +1 818 252 8214 ; wpardrid@ucla.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Expert Opin Drug Deliv</MedlineTA>
            <NlmUniqueID>101228421</NlmUniqueID>
            <ISSNLinking>1742-5247</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">biologic drugs</Keyword>
            <Keyword MajorTopicYN="N">blood???brain barrier</Keyword>
            <Keyword MajorTopicYN="N">fusion proteins</Keyword>
            <Keyword MajorTopicYN="N">monoclonal antibody</Keyword>
            <Keyword MajorTopicYN="N">transferrin receptor</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1517/17425247.2014.952627</ArticleId>
            <ArticleId IdType="pubmed">25138991</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138963</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1559-0100</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Endocrine</Title>
                <ISOAbbreviation>Endocrine</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Adipogenic changes of hepatocytes in a high-fat diet-induced fatty liver mice model and non-alcoholic fatty liver disease patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Non-alcoholic fatty liver disease (NAFLD) is characterized by steatosis associated with liver inflammation. As NAFLD progresses, triglycerides increase within hepatocytes, causing typical vacuoles that resemble adipocytes. However, whether these morphological changes in hepatocytes indicate potential functional changes is unclear. C57BL/6J mice were fed a high-fat diet (HFD) containing 42??% fat. Markers for adipocytes in the liver were measured using real-time PCR, Western blot, and double immunofluorescent labeling. Cytokines in cell culture supernatants were quantified with ELISA. To determine the macrophage phenotype, hepatic classical M1 markers and alternative M2 markers were analyzed. After a 24-week feeding period, adipocyte markers aP2 and PPAR?? increased at both the mRNA and protein level in the liver of HFD-fed mice. FITC-labeled aP2 and rhodamine-labeled albumin were both stained in the cytoplasm of steatotic hepatocytes as observed under confocal laser scanning microscopy. Cell membrane-bound E-cadherin and albumin expression were reduced in steatotic hepatocytes compared to controls. However, hepatic adiponectin and adiponectin receptor-2 expression decreased with upregulation of hepatic CD36, suggesting impaired adiponectin activity in livers of HFD-fed mice. Moreover, steatotic primary hepatocytes not only released pro-inflammatory cytokines such as TNF??, MCP-1, IL-6, and IL-18, but also could activate macrophages when co-cultured in vitro. In vivo, hepatic expression of M1 genes such as iNOS and TNF?? was markedly increased in HFD-fed mice. In contrast, hepatic expression of M2 genes such as Arg1 and CD206 was significantly reduced. Specifically, the ratio of TNF?? to CD206 in HFD-fed mice was notably upregulated. Overexpression of adipocyte-specific genes in hepatocytes and their secretory function and epithelial phenotype impairment in NAFLD cause functional changes in steatotic hepatocytes aside from morphological changes. This suggests that adipogenic changes in hepatocytes are involved in pathogenesis of NAFLD.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Pan</LastName>
                    <ForeName>Xiaoli</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Gastroenterology and Hepatology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan, 430022, Hubei, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Pei</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author>
                    <LastName>Luo</LastName>
                    <ForeName>Jinzhuo</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Zhijun</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author>
                    <LastName>Song</LastName>
                    <ForeName>Yuhu</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Ye</LastName>
                    <ForeName>Jin</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Hou</LastName>
                    <ForeName>Xiaohua</ForeName>
                    <Initials>X</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Endocrine</MedlineTA>
            <NlmUniqueID>9434444</NlmUniqueID>
            <ISSNLinking>1355-008X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-014-0384-x</ArticleId>
            <ArticleId IdType="pubmed">25138963</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25138790</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCompleted>
        <Article PubModel="Electronic-Print">
            <Journal>
                <ISSN IssnType="Electronic">2051-817X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>2</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>1</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Physiological reports</Title>
                <ISOAbbreviation>Physiol Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Identification of the pre-B??tzinger complex inspiratory center in calibrated &quot;sandwich&quot; slices from newborn mice with fluorescent Dbx1 interneurons.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.14814/phy2.12111</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">e12111</ELocationID>
            <Abstract>
                <AbstractText>Inspiratory active pre-B??tzinger complex (preB??tC) networks produce the neural rhythm that initiates and controls breathing movements. We previously identified the preB??tC in the newborn rat brainstem and established anatomically defined transverse slices in which the preB??tC remains active when exposed at one surface. This follow-up study uses a neonatal mouse model in which the preB??tC as well as a genetically defined class of respiratory interneurons can be identified and selectively targeted for physiological recordings. The population of glutamatergic interneurons whose precursors express the transcription factor Dbx1 putatively comprises the core respiratory rhythmogenic circuit. Here, we used intersectional mouse genetics to identify the brainstem distribution of Dbx1-derived neurons in the context of observable respiratory marker structures. This reference brainstem atlas enabled online histology for generating calibrated sandwich slices to identify the preB??tC location, which was heretofore unspecified for perinatal mice. Sensitivity to opioids ensured that slice rhythms originated from preB??tC neurons and not parafacial respiratory group/retrotrapezoid nucleus (pFRG/RTN) cells because opioids depress preB??tC, but not pFRG/RTN rhythms. We found that the preB??tC is centered ~0.4 mm caudal to the facial motor nucleus in this Cre/lox reporter mouse during postnatal days 0-4. Our findings provide the essential basis for future optically guided electrophysiological and fluorescence imaging-based studies, as well as the application of other Cre-dependent tools to record or manipulate respiratory rhythmogenic neurons. These resources will ultimately help elucidate the mechanisms that promote respiratory-related oscillations of preB??tC Dbx1-derived neurons and thus breathing.</AbstractText>
                <CopyrightInformation>?? 2014 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of the American Physiological Society and The Physiological Society.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ruangkittisakul</LastName>
                    <ForeName>Araya</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Physiology, Faculty of Medicine &amp; Dentistry, University of Alberta, Edmonton, Alberta, Canada.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kottick</LastName>
                    <ForeName>Andrew</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Applied Science, The College of William &amp; Mary, Williamsburg, Virginia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Picardo</LastName>
                    <ForeName>Maria C D</ForeName>
                    <Initials>MC</Initials>
                    <Affiliation>Department of Applied Science, The College of William &amp; Mary, Williamsburg, Virginia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ballanyi</LastName>
                    <ForeName>Klaus</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Physiology, Faculty of Medicine &amp; Dentistry, University of Alberta, Edmonton, Alberta, Canada.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Del Negro</LastName>
                    <ForeName>Christopher A</ForeName>
                    <Initials>CA</Initials>
                    <Affiliation>Department of Applied Science, The College of William &amp; Mary, Williamsburg, Virginia.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Physiol Rep</MedlineTA>
            <NlmUniqueID>101607800</NlmUniqueID>
            <ISSNLinking>2051-817X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breathing</Keyword>
            <Keyword MajorTopicYN="N">central pattern generator</Keyword>
            <Keyword MajorTopicYN="N">respiration</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ppublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">2/8/e12111</ArticleId>
            <ArticleId IdType="doi">10.14814/phy2.12111</ArticleId>
            <ArticleId IdType="pubmed">25138790</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25138789</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCompleted>
        <Article PubModel="Electronic-Print">
            <Journal>
                <ISSN IssnType="Electronic">2051-817X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>2</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>1</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Physiological reports</Title>
                <ISOAbbreviation>Physiol Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Regulation of angiopoietin-like protein 4 production during and after exercise.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.14814/phy2.12109</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">e12109</ELocationID>
            <Abstract>
                <AbstractText>Angiopoietin-like protein 4 (ANGPTL4) may regulate lipoprotein lipase-dependent plasma clearance of triacylglycerol from skeletal muscle during exercise. The aim of this study was to examine the importance of muscle in regulating ANGPTL4 in response to exercise. We sampled muscle biopsies and serum before, immediately after, and 2 h after 45 min of ergometer cycling. Sampling was done before and after a 12-week training intervention in controls and dysglycemic subjects. Moreover, fat biopsies were taken before and after the training intervention. The regulation of ANGPTL4 was also investigated in several tissues of exercising mice, and in cultured myotubes. ANGPTL4 levels in serum and expression in muscle were highest 2 h after exercise in both groups. Whereas ANGPTL4 was higher in muscle of exercising controls as compared to dysglycemic subjects, the opposite was observed in serum. In exercising mice, Angptl4 mRNA showed both higher basal expression and induction in liver compared to muscle. Angptl4 mRNA was much higher in adipose tissue than muscle and was also induced by exercise. We observed two mRNA isoforms of ANGPTL4 in muscle and fat in humans. Both were induced by exercise in muscle; one isoform was expressed 5- to 10-fold higher than the other. Studies in mice and cultured myotubes showed that both fatty acids and cortisol have the potential to increase ANGPTL4 expression in muscle during exercise. In conclusion, ANGPTL4 is markedly induced in muscle in response to exercise. However, liver and adipose tissue may contribute more than muscle to the exercise-induced increase in circulating ANGPTL4.</AbstractText>
                <CopyrightInformation>?? 2014 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of the American Physiological Society and The Physiological Society.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Norheim</LastName>
                    <ForeName>Frode</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Nutrition, Faculty of Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hjorth</LastName>
                    <ForeName>Marit</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Nutrition, Faculty of Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Langleite</LastName>
                    <ForeName>Torgrim M</ForeName>
                    <Initials>TM</Initials>
                    <Affiliation>Department of Nutrition, Faculty of Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Sindre</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Nutrition, Faculty of Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Holen</LastName>
                    <ForeName>Torgeir</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Nutrition, Faculty of Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bindesb??ll</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Nutrition, Faculty of Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stadheim</LastName>
                    <ForeName>Hans K</ForeName>
                    <Initials>HK</Initials>
                    <Affiliation>Department of Physical Performance, Norwegian School of Sport Sciences, Oslo, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gulseth</LastName>
                    <ForeName>Hanne L</ForeName>
                    <Initials>HL</Initials>
                    <Affiliation>Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Birkeland</LastName>
                    <ForeName>K??re I</ForeName>
                    <Initials>KI</Initials>
                    <Affiliation>Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway Faculty of medicine, University of Oslo, Oslo, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kielland</LastName>
                    <ForeName>Anders</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Nutrition, Faculty of Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jensen</LastName>
                    <ForeName>J??rgen</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Physical Performance, Norwegian School of Sport Sciences, Oslo, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dalen</LastName>
                    <ForeName>Knut T</ForeName>
                    <Initials>KT</Initials>
                    <Affiliation>Department of Nutrition, Faculty of Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Drevon</LastName>
                    <ForeName>Christian A</ForeName>
                    <Initials>CA</Initials>
                    <Affiliation>Department of Nutrition, Faculty of Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Physiol Rep</MedlineTA>
            <NlmUniqueID>101607800</NlmUniqueID>
            <ISSNLinking>2051-817X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ANGPTL4</Keyword>
            <Keyword MajorTopicYN="N">Adipose tissue</Keyword>
            <Keyword MajorTopicYN="N">exercise</Keyword>
            <Keyword MajorTopicYN="N">skeletal muscle</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ppublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">2/8/e12109</ArticleId>
            <ArticleId IdType="doi">10.14814/phy2.12109</ArticleId>
            <ArticleId IdType="pubmed">25138789</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138774</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1559-0267</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical reviews in allergy &amp; immunology</Title>
                <ISOAbbreviation>Clin Rev Allergy Immunol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>TGR5: Pathogenetic Role and/or Therapeutic Target in Fibrosing Cholangitis?</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease affecting the intrahepatic and extrahepatic biliary tree leading to bile duct strictures, progressive cholestasis, and development of liver fibrosis and cirrhosis. The pathogenesis of PSC is still elusive; however, both an immune-mediated injury of the bile ducts as well as increased recruitment of intestinal-primed T lymphocytes to the biliary tracts seem to contribute to disease development and progression. TGR5 (Gpbar-1) is a G-protein-coupled receptor responsive to bile acids, which is expressed in cholangiocytes, intestinal epithelial cells, and macrophages of the liver and intestine as well as in CD14-positive monocytes of the peripheral blood. Activation of TGR5 in biliary epithelial cells promotes chloride and bicarbonate secretion, triggers cell proliferation, and prevents apoptotic cell death. In immune cells, stimulation of TGR5 inhibits cytokine expression and secretion, thus reducing systemic as well as hepatic and intestinal inflammation. The expression pattern of TGR5 in the liver and intestine as well as the potential protective functions of TGR5 suggest a role for this receptor in the pathogenesis of PSC. While mutations in the coding region of the TGR5 gene are too rare to contribute to overall disease susceptibility, the expression and localization of the receptor have not been studied in PSC livers. Pharmacological activation of TGR5 in mice promotes protective mechanisms in biliary epithelial cells and reduces hepatic and systemic inflammation; however, it also provokes pruritus. Further studies are needed to predict the potential benefits as well as side effects of TGR5 agonist treatment in PSC patients.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Keitel</LastName>
                    <ForeName>Verena</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Clinic for Gastroenterology, Hepatology and Infectious Diseases, Heinrich-Heine-University, Moorenstrasse 5, 40225, D??sseldorf, Germany, verena.keitel@med.uni-duesseldorf.de.</Affiliation>
                </Author>
                <Author>
                    <LastName>Reich</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>H??ussinger</LastName>
                    <ForeName>Dieter</ForeName>
                    <Initials>D</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Clin Rev Allergy Immunol</MedlineTA>
            <NlmUniqueID>9504368</NlmUniqueID>
            <ISSNLinking>1080-0549</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12016-014-8443-x</ArticleId>
            <ArticleId IdType="pubmed">25138774</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138705</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7603</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                        <Day>30</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of reproductive immunology</Title>
                <ISOAbbreviation>J. Reprod. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hormonal regulation of the cytokine microenvironment in the mammary gland.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0165-0378(14)00065-5</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.jri.2014.07.002</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The mammary gland is a unique organ that undergoes hormone-driven developmental changes over the course of the ovarian cycle during adult life. Macrophages play a role in regulating cellular turnover in the mammary gland and may affect cancer susceptibility. However, the immune microenvironment that regulates macrophage function has not been described. Hormonal regulation of the cytokine microenvironment across the ovarian cycle was explored using microbead multiplex assay for 15 cytokines in mammary glands from C57Bl/6 mice at different stages of the oestrous cycle, and in ovariectomised mice administered oestradiol and progesterone. The cytokines that were found to fluctuate over the course of the oestrous cycle were colony-stimulating factor (CSF)1, CSF2, interferon gamma (IFNG) and tumour necrosis factor alpha (TNFA), all of which were significantly elevated at oestrus compared with other phases. The concentration of serum progesterone during the oestrus phase negatively correlated with the abundance of cytokines CSF3, IL12p40, IFNG and leukaemia inhibitory factor (LIF). In ovariectomised mice, exogenous oestradiol administration increased mammary gland CSF1, CSF2, IFNG and LIF, compared with ovariectomised control mice. Progesterone administration together with oestradiol resulted in reduced CSF1, CSF3 and IFNG compared with oestradiol administration alone. This study suggests that the cytokine microenvironment in the mammary gland at the oestrus phase of the ovarian cycle is relatively pro-inflammatory compared with other stages of the cycle, and that the oestradiol-induced cytokine microenvironment is significantly attenuated by progesterone. A continuously fluctuating cytokine microenvironment in the mammary gland presumably regulates the phenotypes of resident leukocytes and may affect mammary gland cancer susceptibility.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ireland Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Dasari</LastName>
                    <ForeName>Pallave</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Discipline of Surgery, School of Medicine, The Queen Elizabeth Hospital, University of Adelaide, Woodville, Australia; School of Paediatrics and Reproductive Health, University of Adelaide, Australia; Research Centre for Reproductive Health, The Robinson Institute, University of Adelaide, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sharkey</LastName>
                    <ForeName>David J</ForeName>
                    <Initials>DJ</Initials>
                    <Affiliation>School of Paediatrics and Reproductive Health, University of Adelaide, Australia; Research Centre for Reproductive Health, The Robinson Institute, University of Adelaide, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Noordin</LastName>
                    <ForeName>Effarina</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>School of Paediatrics and Reproductive Health, University of Adelaide, Australia; Research Centre for Reproductive Health, The Robinson Institute, University of Adelaide, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Glynn</LastName>
                    <ForeName>Danielle J</ForeName>
                    <Initials>DJ</Initials>
                    <Affiliation>Discipline of Surgery, School of Medicine, The Queen Elizabeth Hospital, University of Adelaide, Woodville, Australia; School of Paediatrics and Reproductive Health, University of Adelaide, Australia; Research Centre for Reproductive Health, The Robinson Institute, University of Adelaide, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hodson</LastName>
                    <ForeName>Leigh J</ForeName>
                    <Initials>LJ</Initials>
                    <Affiliation>Discipline of Surgery, School of Medicine, The Queen Elizabeth Hospital, University of Adelaide, Woodville, Australia; School of Paediatrics and Reproductive Health, University of Adelaide, Australia; Research Centre for Reproductive Health, The Robinson Institute, University of Adelaide, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chin</LastName>
                    <ForeName>Peck Y</ForeName>
                    <Initials>PY</Initials>
                    <Affiliation>School of Paediatrics and Reproductive Health, University of Adelaide, Australia; Research Centre for Reproductive Health, The Robinson Institute, University of Adelaide, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Evdokiou</LastName>
                    <ForeName>Andreas</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Discipline of Surgery, School of Medicine, The Queen Elizabeth Hospital, University of Adelaide, Woodville, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Robertson</LastName>
                    <ForeName>Sarah A</ForeName>
                    <Initials>SA</Initials>
                    <Affiliation>School of Paediatrics and Reproductive Health, University of Adelaide, Australia; Research Centre for Reproductive Health, The Robinson Institute, University of Adelaide, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ingman</LastName>
                    <ForeName>Wendy V</ForeName>
                    <Initials>WV</Initials>
                    <Affiliation>Discipline of Surgery, School of Medicine, The Queen Elizabeth Hospital, University of Adelaide, Woodville, Australia; School of Paediatrics and Reproductive Health, University of Adelaide, Australia; Research Centre for Reproductive Health, The Robinson Institute, University of Adelaide, Australia. Electronic address: wendy.ingman@adelaide.edu.au.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>30</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Reprod Immunol</MedlineTA>
            <NlmUniqueID>8001906</NlmUniqueID>
            <ISSNLinking>0165-0378</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cytokines</Keyword>
            <Keyword MajorTopicYN="N">Inflammation</Keyword>
            <Keyword MajorTopicYN="N">Mammary gland</Keyword>
            <Keyword MajorTopicYN="N">Oestrogen</Keyword>
            <Keyword MajorTopicYN="N">Progesterone</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0165-0378(14)00065-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jri.2014.07.002</ArticleId>
            <ArticleId IdType="pubmed">25138705</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138704</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-4919</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular and cellular biochemistry</Title>
                <ISOAbbreviation>Mol. Cell. Biochem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Epigenetic modifications and NF-??B pathway activity in Cu,Zn-SOD-deficient mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The aim of this study was to examine the possible impact of Cu,Zn-SOD deficiency on the level of epigenetic modifications in different mouse tissues, and the relationship between these modifications and the NF-??B transcription factor activity. Cu,Zn-SOD deficiency did not influence the level of 5mdC or 5hmdC in the analyzed tissues. Statistically significant organ-/tissue-specific differences between the levels of 5mdC and 5hmdC were demonstrated within each genotype. Also correlations between analyzed parameters pointed to wide tissue/genotype variety; we observed a positive correlation between 5mdC and NF-??B proteins, p50 and RelA, in the liver of wild mice, as well as an inverse correlation between 5mdC and p65 in the brain of Cu,Zn-SOD-deficient animals. Moreover, a positive correlation was revealed between 5mdC and 5hmdC in the liver and brain of knockout mice. As the highest levels of both 5mdC and 5hmdC were observed in the brains of analyzed animals regardless of their genotype, and lower, comparable to each other, levels of these modifications were shown in the kidney and liver, active demethylation process seems to be tissue-/organ-specific and does not necessarily rely solely on the redox/oxidation state of cells. According to the most likely scenario, various tissues may differ in terms of their metabolic rates, which has potential influence on cofactors, and consequently on the activity of TET enzymes or activation of TET-independent mechanisms.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Siomek</LastName>
                    <ForeName>Agnieszka</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Clinical Biochemistry, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, ul. Karlowicza 24, 85-092, Bydgoszcz, Poland, asiomek@cm.umk.pl.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gackowski</LastName>
                    <ForeName>Daniel</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author>
                    <LastName>Szpila</LastName>
                    <ForeName>Anna</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Brz??ska</LastName>
                    <ForeName>Kamil</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Guz</LastName>
                    <ForeName>Jolanta</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Sochanowicz</LastName>
                    <ForeName>Barbara</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author>
                    <LastName>Kruszewski</LastName>
                    <ForeName>Marcin</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Mol Cell Biochem</MedlineTA>
            <NlmUniqueID>0364456</NlmUniqueID>
            <ISSNLinking>0300-8177</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11010-014-2186-0</ArticleId>
            <ArticleId IdType="pubmed">25138704</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138700</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-4919</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular and cellular biochemistry</Title>
                <ISOAbbreviation>Mol. Cell. Biochem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Decreased BMP2 signal in GIT1 knockout mice slows bone healing.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Endochondral ossification, an important stage of fracture healing, is regulated by a variety of signaling pathways. Transforming growth factor ?? (TGF??) superfamily plays important roles and comprises TGF??s, bone morphogenetic proteins (BMPs), and growth differentiation factors. TGF??s primarily regulate cartilage formation and endochondral ossification. BMP2 shows diverse efficacy, from the formation of skeleton and extraskeletal organs to the osteogenesis and remodeling of bone. G-protein-coupled receptor kinase 2-interacting protein-1 (GIT1), a shuttle protein in osteoblasts, facilitates fracture healing by promoting bone formation and increasing the secretion of vascular endothelial growth factor. Our study examined whether GIT1 regulates fracture healing through the BMP2 signaling pathway and/or through the TGF?? signaling pathway. GIT1 knockout (KO) mice exhibited delayed fracture healing, chondrocyte accumulation in the fracture area, and reduced staining intensity of phosphorylated Smad1/5/8 (pSmad1/5/8) and Runx2. Endochondral mineralization diminished while the staining intensity of phosphorylated Smad2/3 (pSmad2/3) showed no significant change. Bone marrow mesenchymal stem cells extracted from GIT1 KO mice showed a decline of pSmad1/5/8 levels and of pSmad1/5/8 translocated into the cell nucleus after BMP2 stimulus. We detected no significant change in the pSmad2/3 level after TGF??1 stimulus. Data obtained from reporter gene analysis of C3H10T1/2 cells cultured in vitro confirmed these findings. GIT1-siRNA inhibited transcription in the cell nucleus via pSmad1/5/8 after BMP2 stimulus but had no significant effect on transcription via pSmad2/3 after TGF??1 stimulus. Our results indicate that GIT1 regulates Smad1/5/8 phosphorylation and mediates BMP2 regulation of Runx2 expression, thus affecting endochondral ossification at the fracture site.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Sheu</LastName>
                    <ForeName>T J</ForeName>
                    <Initials>TJ</Initials>
                    <Affiliation>Center for Musculoskeletal Research, University of Rochester, Rochester, NY, 14642, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author>
                    <LastName>Fan</LastName>
                    <ForeName>Jin</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Hao</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Zuscik</LastName>
                    <ForeName>Michael J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author>
                    <LastName>Xie</LastName>
                    <ForeName>Chao</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Yin</LastName>
                    <ForeName>Guoyong</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author>
                    <LastName>Berk</LastName>
                    <ForeName>Bradford C</ForeName>
                    <Initials>BC</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Mol Cell Biochem</MedlineTA>
            <NlmUniqueID>0364456</NlmUniqueID>
            <ISSNLinking>0300-8177</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11010-014-2173-5</ArticleId>
            <ArticleId IdType="pubmed">25138700</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138666</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1935-3456</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Mucosal immunology</Title>
                <ISOAbbreviation>Mucosal Immunol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>CCR2(+)CD103(-) intestinal dendritic cells develop from DC-committed precursors and induce interleukin-17 production by T cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1038/mi.2014.70</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The identification of intestinal macrophages (m??s) and dendritic cells (DCs) is a matter of intense debate. Although CD103(+) mononuclear phagocytes (MPs) appear to be genuine DCs, the nature and origins of CD103(-) MPs remain controversial. We show here that intestinal CD103(-)CD11b(+) MPs can be separated clearly into DCs and m??s based on phenotype, gene profile, and kinetics. CD64(-)CD103(-)CD11b(+) MPs are classical DCs, being derived from Flt3 ligand-dependent, DC-committed precursors, not Ly6C(hi) monocytes. Surprisingly, a significant proportion of these CD103(-)CD11b(+) DCs express CCR2 and there is a selective decrease in CD103(-)CD11b(+) DCs in mice lacking this chemokine receptor. CCR2(+)CD103(-) DCs are present in both the murine and human intestine, drive interleukin (IL)-17a production by T cells in vitro, and show constitutive expression of IL-12/IL-23p40. These data highlight the heterogeneity of intestinal DCs and reveal a bona fide population of CCR2(+) DCs that is involved in priming mucosal T helper type 17 (Th17) responses.Mucosal Immunology advance online publication, 20 August 2014; doi:10.1038/mi.2014.70.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Scott</LastName>
                    <ForeName>C L</ForeName>
                    <Initials>CL</Initials>
                    <Affiliation>1] Institute of Infection, Immunity and Inflammation, College of Veterinary, Medical and Life Science, University of Glasgow, Glasgow, Scotland, UK [2] VIB Ghent University, Inflammation Research Centre (IRC), Laboratory of Immunoregulation, Ghent (Zwijnaarde), Belgium.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bain</LastName>
                    <ForeName>C C</ForeName>
                    <Initials>CC</Initials>
                    <Affiliation>Institute of Infection, Immunity and Inflammation, College of Veterinary, Medical and Life Science, University of Glasgow, Glasgow, Scotland, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wright</LastName>
                    <ForeName>P B</ForeName>
                    <Initials>PB</Initials>
                    <Affiliation>Institute of Infection, Immunity and Inflammation, College of Veterinary, Medical and Life Science, University of Glasgow, Glasgow, Scotland, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sichien</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>VIB Ghent University, Inflammation Research Centre (IRC), Laboratory of Immunoregulation, Ghent (Zwijnaarde), Belgium.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kotarsky</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Immunology Section, Lund University, Lund, Sweden.</Affiliation>
                </Author>
                <Author>
                    <LastName>Persson</LastName>
                    <ForeName>E K</ForeName>
                    <Initials>EK</Initials>
                    <Affiliation>Immunology Section, Lund University, Lund, Sweden.</Affiliation>
                </Author>
                <Author>
                    <LastName>Luda</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Immunology Section, Lund University, Lund, Sweden.</Affiliation>
                </Author>
                <Author>
                    <LastName>Guilliams</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>VIB Ghent University, Inflammation Research Centre (IRC), Laboratory of Immunoregulation, Ghent (Zwijnaarde), Belgium.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lambrecht</LastName>
                    <ForeName>B N</ForeName>
                    <Initials>BN</Initials>
                    <Affiliation>VIB Ghent University, Inflammation Research Centre (IRC), Laboratory of Immunoregulation, Ghent (Zwijnaarde), Belgium.</Affiliation>
                </Author>
                <Author>
                    <LastName>Agace</LastName>
                    <ForeName>W W</ForeName>
                    <Initials>WW</Initials>
                    <Affiliation>1] Immunology Section, Lund University, Lund, Sweden [2] Department of International Health, Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
                </Author>
                <Author>
                    <LastName>Milling</LastName>
                    <ForeName>S Wf</ForeName>
                    <Initials>SW</Initials>
                    <Affiliation>Institute of Infection, Immunity and Inflammation, College of Veterinary, Medical and Life Science, University of Glasgow, Glasgow, Scotland, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mowat</LastName>
                    <ForeName>A M</ForeName>
                    <Initials>AM</Initials>
                    <Affiliation>Institute of Infection, Immunity and Inflammation, College of Veterinary, Medical and Life Science, University of Glasgow, Glasgow, Scotland, UK.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Mucosal Immunol</MedlineTA>
            <NlmUniqueID>101299742</NlmUniqueID>
            <ISSNLinking>1933-0219</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">mi201470</ArticleId>
            <ArticleId IdType="doi">10.1038/mi.2014.70</ArticleId>
            <ArticleId IdType="pubmed">25138666</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138637</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1421-9859</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Developmental neuroscience</Title>
                <ISOAbbreviation>Dev. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>G-Protein-Coupled Receptor Cell Signaling Pathways Mediating Embryonic Chick Retinal Growth Cone Collapse Induced by Lysophosphatidic Acid and Sphingosine-1-Phosphate.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">In the development of the nervous system, one of the critical aspects is the proper navigation of axons to their targets, i.e. the problem of axonal guidance. We used the chick visual system as a model to investigate the role of the lysophospholipids lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) as potential axon guidance cues. We showed that both LPA and S1P cause a specific, dose-dependent growth cone collapse of retinal neurons in vitro in the chick model system, with slight differences compared to the mouse but very similar to observations in Xenopus. Because LPA and S1P receptors are G-protein-coupled receptors, we analyzed the intracellular signaling pathways using pharmacological inhibitors in chick retinal neurons. Blocking rho kinase (ROCK) prevented growth cone collapse by LPA and S1P, while blocking PLC or chelating calcium had no effect on growth cone collapse. Inhibition of Gi/o with pertussis toxin resulted in a partial reduction of growth cone collapse, both with LPA and with S1P. Inhibition of p38 blocked growth cone collapse mediated by LPA but not S1P. Thus, in addition to the involvement of the G12/13-ROCK pathway, LPA- and S1P-induced collapse of chick retinal growth cones has a partial requirement for Gi/o. ?? 2014 S. Karger AG, Basel.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Fincher</LastName>
                    <ForeName>Jarod</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Biology, Winthrop University, Rock Hill, S.C., USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Whiteneck</LastName>
                    <ForeName>Canaan</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Birgbauer</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <GrantList>
                <Grant>
                    <GrantID>P20 GM103499</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P20 RR016461</GrantID>
                    <Acronym>RR</Acronym>
                    <Agency>NCRR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Dev Neurosci</MedlineTA>
            <NlmUniqueID>7809375</NlmUniqueID>
            <ISSNLinking>0378-5866</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">000364858</ArticleId>
            <ArticleId IdType="doi">10.1159/000364858</ArticleId>
            <ArticleId IdType="pubmed">25138637</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138636</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1537-6524</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicology mechanisms and methods</Title>
                <ISOAbbreviation>Toxicol. Mech. Methods</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Zinc Oxide nanoparticles induced oxidative stress in mouse bone marrow mesenchymal stem cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1-31</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Abstract Engineered nanoparticles are developed for various applications in industrial, electrical, agricultural, pharmaceutical and medical fields due to their unique properties. Nanoparticles such as TiO2 and ZnO are widely used in cosmetics for UV protection. The toxicological investigations of ZnO NPs are highly recommended because of the increasing use in various industrial and consumer products. The toxic potential of ZnO NPs was assumed to be caused by the release of free Zn+ ions in the medium. Many of the in??vivo studies suggest the toxic nature of ZnO NPs, the in??vitro studies are certainly important to elucidate the mechanism of toxicity. The present study examined the toxicity of ZnO NPs with the average size of 6-8nm on the isolated mice bone marrow mesenchymal stem cells (BMSCs). The study focuses on the cytotoxicity and oxidative stress mediated cellular responses upon exposure to ZnO NPs. The results indicated that the exposure to ZnO NPs significantly affects cellular viability in a dose dependent manner. Formation of reactive oxygen species (ROS) was found to be the mechanism of cellular toxicity. The release of Zn(+) ions from the nanoparticles, due to the instability of ZnO NPs in the acidic compartment of lysosomes also increases the ROS generation. In addition to increased ROS production, damage of lysosomal membrane and the activation of executioner caspase-3 and caspase-7 were observed which eventually ends in apoptosis.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>S</LastName>
                    <ForeName>Syama</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Toxicology Division.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pj</LastName>
                    <ForeName>Sreekanth</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Hk</LastName>
                    <ForeName>Varma</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author>
                    <LastName>Pv</LastName>
                    <ForeName>Mohanan</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Toxicol Mech Methods</MedlineTA>
            <NlmUniqueID>101134521</NlmUniqueID>
            <ISSNLinking>1537-6516</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Apoptosis</Keyword>
            <Keyword MajorTopicYN="N">Caspase</Keyword>
            <Keyword MajorTopicYN="N">Cytotoxicity</Keyword>
            <Keyword MajorTopicYN="N">Lysosome</Keyword>
            <Keyword MajorTopicYN="N">Reactive oxygen species</Keyword>
            <Keyword MajorTopicYN="N">Zinc oxide nanoparticles</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3109/15376516.2014.956914</ArticleId>
            <ArticleId IdType="pubmed">25138636</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138634</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-1220</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>17</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of steroid biochemistry and molecular biology</Title>
                <ISOAbbreviation>J. Steroid Biochem. Mol. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Metabolism of 20-hydroxyvitamin D3 by mouse liver microsomes.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0960-0760(14)00188-5</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.jsbmb.2014.08.009</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">20-Hydroxyvitamin D3 [20(OH)D3], the major product of CYP11A1 action on vitamin D3, is biologically active and like 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] can inhibit proliferation and promote differentiation of a range of cells, and has anti-inflammatory properties. However, unlike 1,25(OH)2D3, it does not cause toxic hypercalcemia at high doses and is therefore a good candidate for therapeutic use to treat hyperproliferative and autoimmune disorders. In this study we analyzed the ability of mouse liver microsomes to metabolize 20(OH)D3. The two major products were identified from authentic standards as 20,24-dihydroxyvitamin D3 [20,24(OH)2D3] and 20,25-dihydroxyvitamin D3 [20,25(OH)2D3]. The reactions for synthesis of these two products from 20(OH)D3 displayed similar Km values suggesting that they were catalyzed by the same cytochrome P450. Some minor metabolites were produced by reactions with higher Km values for 20(OH)D3. Some metabolites gave mass spectra suggesting that they were the result of hydroxylation followed by dehydrogenation. One product had an increase in the wavelength for maximum absorbance from 263nm seen for 20(OH)D3, to 290nm, suggesting a new double bond was interacting with the vitamin D-triene chromophore. The two major products, 20,24(OH)2D3 and 20,25(OH)2D3 have both previously been shown to have higher potency for inhibition of colony formation by melanoma cells than 20(OH)D3, thus it appears that metabolism of 20(OH)D3 by mouse liver microsomes can generate products with enhanced activity.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Cheng</LastName>
                    <ForeName>Chloe Y S</ForeName>
                    <Initials>CY</Initials>
                    <Affiliation>School of Chemistry and Biochemistry, The University of Western Australia, Crawley, WA 6009, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Slominski</LastName>
                    <ForeName>Andrzej T</ForeName>
                    <Initials>AT</Initials>
                    <Affiliation>Department of Pathology and Laboratory Medicine, Center for Adult Cancer Research, University of Tennessee Health Science Center, Memphis, TN, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tuckey</LastName>
                    <ForeName>Robert C</ForeName>
                    <Initials>RC</Initials>
                    <Affiliation>School of Chemistry and Biochemistry, The University of Western Australia, Crawley, WA 6009, Australia. Electronic address: robert.tuckey@uwa.edu.au.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Steroid Biochem Mol Biol</MedlineTA>
            <NlmUniqueID>9015483</NlmUniqueID>
            <ISSNLinking>0960-0760</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">20-Hydroxyvitamin D3</Keyword>
            <Keyword MajorTopicYN="N">Cytochrome P450</Keyword>
            <Keyword MajorTopicYN="N">Hydroxylation</Keyword>
            <Keyword MajorTopicYN="N">Liver</Keyword>
            <Keyword MajorTopicYN="N">Microsomes</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25138634</ArticleId>
            <ArticleId IdType="pii">S0960-0760(14)00188-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jsbmb.2014.08.009</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138596</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1097-0177</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Developmental dynamics : an official publication of the American Association of Anatomists</Title>
                <ISOAbbreviation>Dev. Dyn.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Spatiotemporal Mapping of Vascularization and Innervation in the Fetal Murine Intestine.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/dvdy.24178</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Background In mice, the intestinal tube develops from the splanchopleure prior to embryonic day 9.5. Subsequent patterning of nerves and blood vessels is critical for normal digestive function. A hierarchical branching vascular network allows for efficient nutrient absorption, while the complex enteric nervous system regulates intestinal motility as well as secretion, absorption, and blood flow. Despite the well-recognized significance of these systems, the precise mechanisms by which they develop have not been clearly established in mammals. Results Using a novel whole-mount immunohistochemical protocol, we visualize the pattern of intestinal neurovascular development in mice between embryonic day 10.5 and birth. In particular, we focus on the development and remodeling of the enteric vascular plexus, the migration and organization of enteric neural crest-derived cells, and the integration of peripheral sympathetic nerves with the enteric nervous system. These correlative data lead us to hypothesize a functional interaction between migrating neural crest-derived cells and endothelial cells of the primary capillary plexus, as well as a subsequent interaction between developing peripheral autonomic nerves and differentiated neural crest-derived cells. Conclusions These studies provide useful anatomical data for continuing investigations on the functional mechanisms underlying intestinal organogenesis. Developmental Dynamics, 2014. ?? 2014 Wiley Periodicals, Inc.</AbstractText>
                <CopyrightInformation>??2014. Wiley Periodicals, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hatch</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Laboratory of Stem Cell and Neuro-Vascular Biology, Genetics and Developmental Biology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Building 10/6C103, 10 Center Drive, Bethesda, MD, 20892.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mukouyama</LastName>
                    <ForeName>Yoh-Suke</ForeName>
                    <Initials>YS</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Dev Dyn</MedlineTA>
            <NlmUniqueID>9201927</NlmUniqueID>
            <ISSNLinking>1058-8388</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Enteric development</Keyword>
            <Keyword MajorTopicYN="N">enteric nervous system</Keyword>
            <Keyword MajorTopicYN="N">enteric vasculature</Keyword>
            <Keyword MajorTopicYN="N">whole-mount imaging</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dvdy.24178</ArticleId>
            <ArticleId IdType="pubmed">25138596</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138581</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1554-527X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of orthopaedic research : official publication of the Orthopaedic Research Society</Title>
                <ISOAbbreviation>J. Orthop. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Fluorescence-guided surgery improves outcome in an orthotopic osteosarcoma nude-mouse model.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/jor.22706</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">In order to develop a model for fluorescence-guided surgery (FGS), 143B human osteosarcoma cells expressing red fluorescent protein (RFP) were injected into the intramedullary cavity of the tibia in nude mice. The fluorescent areas of residual tumors after bright-light surgery (BLS) and FGS were 10.2????????2.4???mm(2) and 0.1????????0.1???mm(2) , respectively (p???&lt;???0.001). The BLS-treated mice and BLS???+???cisplatinum (CDDP)-treated mice had significant recurrence. In contrast, the FGS mice and FGS???+???CDDP mice had very little recurring tumor growth. Disease-free survival (DFS) in the BLS-, BLS???+???CDDP-, FGS-, and FGS???+???CDDP-treated mice was 12.5%, 37.5%, 75.0%, and 87.5%, respectively. The FGS-treated mice had a significantly higher DFS rate than the BLS-treated mice (p???=???0.021). The FGS???+???CDDP-treated mice had significantly higher DFS rate than the BLS???+???CDDP-treated mice (p???=???0.043). Although chemotherapy significantly reduced multiple metastases (p???=???0.033), there was no significant correlation between FGS and lung metastasis. FGS significantly reduced the recurrence of the primary tumor but did not reduce lung metastasis. The combination of FGS and adjuvant CDDP reduced tumor recurrence and prevented multiple metastases. FGS and adjuvant chemotherapy should be performed as early as possible in the disease to prevent both recurrence and metastatic development. ?? 2014 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 9999:XX-XX, 2014.</AbstractText>
                <CopyrightInformation>?? 2014 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Miwa</LastName>
                    <ForeName>Shinji</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>AntiCancer, Inc., San Diego, CA; Department of Surgery, University of California, San Diego, San Diego, CA; Department of Orthopedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hiroshima</LastName>
                    <ForeName>Yukihiko</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Yano</LastName>
                    <ForeName>Shuya</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Yong</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Matsumoto</LastName>
                    <ForeName>Yasunori</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Uehara</LastName>
                    <ForeName>Fuminari</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author>
                    <LastName>Yamamoto</LastName>
                    <ForeName>Mako</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Kimura</LastName>
                    <ForeName>Hiroaki</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Hayashi</LastName>
                    <ForeName>Katsuhiro</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Bouvet</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Tsuchiya</LastName>
                    <ForeName>Hiroyuki</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Hoffman</LastName>
                    <ForeName>Robert M</ForeName>
                    <Initials>RM</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Orthop Res</MedlineTA>
            <NlmUniqueID>8404726</NlmUniqueID>
            <ISSNLinking>0736-0266</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">RFP</Keyword>
            <Keyword MajorTopicYN="N">chemotherapy</Keyword>
            <Keyword MajorTopicYN="N">cisplatinum (CDDP)</Keyword>
            <Keyword MajorTopicYN="N">fluorescence-guided surgery</Keyword>
            <Keyword MajorTopicYN="N">orthotopic mouse model</Keyword>
            <Keyword MajorTopicYN="N">osteosarcoma</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jor.22706</ArticleId>
            <ArticleId IdType="pubmed">25138581</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138575</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-1912</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Naunyn-Schmiedeberg's archives of pharmacology</Title>
                <ISOAbbreviation>Naunyn Schmiedebergs Arch. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A therapeutic approach to treat prostate cancer by targeting Nm23-H1/h-Prune interaction.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Nm23-H1 is a metastasis suppressor gene whose overexpression is associated with both reduced cell motility in various cancers and increased metastatic potential in neuroblastomas, osteosarcomas, and hematological malignances. We previously reported that Nm23-H1 exerts tumor suppressor action in prostate cancer cells and that h-Prune, which is overexpressed in various tumor types, binds Nm23-H1. Moreover, blockage of the Nm23-H1/h-Prune interaction with a competitive permeable peptide (CPP) attenuates migration of breast and neuroblastoma cells. This series of events suggests that the Nm23-H1/h-Prune protein complex regulates cancer progression and that its specific impairment could be a new therapeutic strategy in oncology. We found that CPP leads to inhibition of the AKT/mTORv and NF-kBv signaling pathways and also activates apoptosis. To obtain a proof-of-concept of our hypothesis, we used a xenograft model of prostate cancer to evaluate whether impairment of this complex using CPP results in an anti-tumoral effect. Using a mouse orthotopic model with bioluminescent imaging, we show evidences that CPP reduces prostate cancer metastases formation. In conclusion, CPP being able to impair formation of the h-Prune/Nm23-H1 complex holds promise for the treatment of prostate cancer.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Carotenuto</LastName>
                    <ForeName>Marianeve</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Centro di Ingegneria Genetica e Biotecnologia Avanzate (CEINGE), Naples, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>de Antonellis</LastName>
                    <ForeName>Pasqualino</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author>
                    <LastName>Chiarolla</LastName>
                    <ForeName>Cristina Maria</ForeName>
                    <Initials>CM</Initials>
                </Author>
                <Author>
                    <LastName>Attanasio</LastName>
                    <ForeName>Carmela</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Damiani</LastName>
                    <ForeName>Valentina</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author>
                    <LastName>Boffa</LastName>
                    <ForeName>Iolanda</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author>
                    <LastName>Aiese</LastName>
                    <ForeName>Nadia</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author>
                    <LastName>Pedone</LastName>
                    <ForeName>Emilia</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author>
                    <LastName>Accordi</LastName>
                    <ForeName>Benedetta</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author>
                    <LastName>Basso</LastName>
                    <ForeName>Giuseppe</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author>
                    <LastName>Navas</LastName>
                    <ForeName>Luigi</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author>
                    <LastName>Imbimbo</LastName>
                    <ForeName>Ciro</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Zollo</LastName>
                    <ForeName>Massimo</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Naunyn Schmiedebergs Arch Pharmacol</MedlineTA>
            <NlmUniqueID>0326264</NlmUniqueID>
            <ISSNLinking>0028-1298</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00210-014-1035-8</ArticleId>
            <ArticleId IdType="pubmed">25138575</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138561</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1937-335X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Tissue engineering. Part A</Title>
                <ISOAbbreviation>Tissue Eng Part A</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Differential Effect of Water-Soluble Chitin on Collagen Synthesis of Human Bone Marrow Stem Cells and Human Periodontal Ligament Stem Cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Human bone marrow mesenchymal stem cells (hBMSCs) represent a promising regenerative material because of their mutipotency, including their ability to regenerate collagenous soft tissues. We previously found that water-soluble chitin (WSC) enhances the ability of human periodontal ligament stem cells (hPDLSCs) to synthesize collagen tissue. The aim of the present study was to determine the effects of WSC on hBMSCs and hPDLSCs for the collagen synthesis in vitro and in vivo. hBMSCs and hPDLSCs were isolated and expanded without or with 0.3 mg/ml WSC. A series of in vitro and in vivo analyses were performed to evaluate their characteristics as stem cell populations. Then, collagen and hydroxyproline assays were conducted using in vitro and in vivo assay models, and the real-time polymerase chain reaction was performed to analyze the expression of collagen-related markers. WSC-treated and nontreated hBMSCs and hPDLSCs were transplanted into immunocompromised mice and histology and immunohistochemistry analyses were conducted after 8 weeks. The in vitro results showed that those cells possessed the characteristics of mesenchymal stem cells. The amount of soluble collagen synthesized was significantly greater in WSC-treated hBMSCs than in the nontreated group; conversely, treatment of hPDLSCs with WSC decreased the formation of soluble collagen. The amount of insoluble collagen synthesized was greater in the WSC-treated groups than in the nontreated groups for both hBMSCs and hPDLSCs. The hydroxyproline contents of the regenerated soluble and insoluble collagens were similar. The expressions of mRNA for collagen types I-V, HAS1, HAS2, and HAS3, and the LOX family were higher in WSC-treated hPDLSCs than in the non-treated group, whereas WSC increased the expression of collagen type III and decreased that of collagen type I in hBMSCs. The histology and immunohistochemistry results revealed that WSC significantly increased the amount of collagen formed in vivo by both types of stem cells. Collectively, treatment with WSC significantly enhanced the collagen-forming potentials of hBMSCs and hPDLSCs, but the collagen they produced exhibited distinctively different characteristics. These findings suggest that the appropriate stem-cell source should be chosen based on the purpose of the required regenerated tissue.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Park</LastName>
                    <ForeName>So-Yon</ForeName>
                    <Initials>SY</Initials>
                    <Affiliation>Research Institute for Periodontal Regeneration, College of Dentistry, Yonsei University, Department of Periodontology , 134 Shinchon-Dong, Seodaemun-gu , Seoul, Korea, Republic of , 120-752 , +82-2-2228-3125 , +82-2-392-0398 , BK21 PLUS Project, College of Dentistry, Yonsei University, Department of Applied Life Science , 134 Shinchon-Dong, Seodaemun-gu , Seoul, Korea, Republic of , 120-752 , +82-2-2228-3125 , +82-2-392-0398 ; SOYONP@yuhs.ac.</Affiliation>
                </Author>
                <Author>
                    <LastName>Park</LastName>
                    <ForeName>Jung-Chul</ForeName>
                    <Initials>JC</Initials>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Min-Soo</ForeName>
                    <Initials>MS</Initials>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Sung-Eun</ForeName>
                    <Initials>SE</Initials>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Ki-Joon</ForeName>
                    <Initials>KJ</Initials>
                </Author>
                <Author>
                    <LastName>Jung</LastName>
                    <ForeName>Byung-Joo</ForeName>
                    <Initials>BJ</Initials>
                </Author>
                <Author>
                    <LastName>Park</LastName>
                    <ForeName>Wonse</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author>
                    <LastName>Jeon</LastName>
                    <ForeName>Dong-Won</ForeName>
                    <Initials>DW</Initials>
                </Author>
                <Author>
                    <LastName>Cho</LastName>
                    <ForeName>Kyoo Sung</ForeName>
                    <Initials>KS</Initials>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Chang Sung</ForeName>
                    <Initials>CS</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Tissue Eng Part A</MedlineTA>
            <NlmUniqueID>101466659</NlmUniqueID>
            <ISSNLinking>1937-3341</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ten.TEA.2014.0156</ArticleId>
            <ArticleId IdType="pubmed">25138561</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138545</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1756-0500</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>7</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC research notes</Title>
                <ISOAbbreviation>BMC Res Notes</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Characterization of adipose-derived stem cells of anatomical region from mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>552</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Stem cells constitute a group of great capacity for self-renewal, long-term viability, and multi-lineage potential. Several studies have provided evidence that adipose tissue represents an alternative source of stem cells, with the main benefit of adipose-derived stem cells being that they can be easily harvested from patients by a simple minimally invasive method and can be easily cultured. The aim of this study was to establish a culture protocol for obtaining and characterizing adipose-derived stem cells (ADSCs) from C57BL/6 J mice.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The results showed that the yield, viability, and cell morphology obtained differ according to the age of isolated anatomic regions of the adipose tissue from ovarian and epididymis. The results of determination of cyclin D1 showed uniformity in the expression between different populations of ADSCs. A significant increase in the expression of caspase-3 active, was also observed in large cell populations from mice after 120 days. ADSCs were positive for mesenchymal markers CD90 and CD105, Nanog, SSEA-1, CD106, and VEGFR-1, and negative for hematopoietic markers CD34 and CD45. A large number of cells in S + G2/M phases was also observed for both sexes, demonstrating high proliferative capacity of ADSCs.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We observed that the adipose tissue of C57BL/6 J mice, isolated from the studied anatomic regions, is a promising source for obtaining pluripotent mesenchymal stem cells with high viability and proliferative response.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Luna</LastName>
                    <ForeName>Arthur Cl</ForeName>
                    <Initials>AC</Initials>
                </Author>
                <Author>
                    <LastName>Madeira</LastName>
                    <ForeName>Maria Ep</ForeName>
                    <Initials>ME</Initials>
                </Author>
                <Author>
                    <LastName>Concei????o</LastName>
                    <ForeName>Thais O</ForeName>
                    <Initials>TO</Initials>
                </Author>
                <Author>
                    <LastName>Moreira</LastName>
                    <ForeName>Jos?? Alc</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author>
                    <LastName>Laiso</LastName>
                    <ForeName>Rosa An</ForeName>
                    <Initials>RA</Initials>
                </Author>
                <Author>
                    <LastName>Maria</LastName>
                    <ForeName>Durvanei A</ForeName>
                    <Initials>DA</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>BMC Res Notes</MedlineTA>
            <NlmUniqueID>101462768</NlmUniqueID>
            <ISSNLinking>1756-0500</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1756-0500-7-552</ArticleId>
            <ArticleId IdType="doi">10.1186/1756-0500-7-552</ArticleId>
            <ArticleId IdType="pubmed">25138545</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138526</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1421-9859</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Developmental neuroscience</Title>
                <ISOAbbreviation>Dev. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Structural Abnormalities of Corpus Callosum and Cortical Axonal Tracts Accompanied by Decreased Anxiety-Like Behavior and Lowered Sociability in Spock3- Mutant Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Spock3/Testican-3 is a nervous system-expressed heparan sulfate proteoglycan belonging to a subgroup of the BM-40/SPARC/osteonectin family, the role of which in brain development is unclear. Because Spock1, a member of the Spock family, inhibits their attachment to substrates and the neurite outgrowth of cultured neuronal cells, Spock3 is also thought to be similarly involved in the neuronal development. In the present study, we established a Spock3-mutant mouse harboring a deletion extending from the presumptive upstream regulatory region to exon 4 of the Spock3 locus and performed histological and behavioral studies on these mutant mice. In wild-type (WT) mice, all Spock members were clearly expressed during brain development. In adults, intense Spock1 and Spock2 expressions were observed throughout the entire brain; whereas, Spock3 expression was no longer visible except in the thalamic nuclei. Thus, Spock3 expression is mostly confined to the developmental stage of the brain. In adult mutant mice, the cells of all cortical layers were swollen. The corpus callosum was narrowed around the central region along the rostral-caudal axis and many small spaces were observed without myelin sheaths throughout the entire corpus callosum. In addition, the cortical input and output fibers did not form into thick bundled fibers as well as the WT counterparts did. Moreover, a subpopulation of corticospinal axonal fibers penetrated into the dorsal striatum with moderately altered orientations. Consistent with these modifications of brain structures, the mutant mice exhibited decreased anxiety-like behavior and lowered sociability. Together, these results demonstrate that Spock3 plays an important role in the formation or maintenance of major neuronal structures in the brain. ?? 2014 S. Karger AG, Basel.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Yamamoto</LastName>
                    <ForeName>Ayako</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Nutritional Sciences, Faculty of Health and Welfare Science, Nayoro City University, Nayoro, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Uchiyama</LastName>
                    <ForeName>Koji</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Nara</LastName>
                    <ForeName>Tomoka</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Nishimura</LastName>
                    <ForeName>Naomichi</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author>
                    <LastName>Hayasaka</LastName>
                    <ForeName>Michiko</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Hanaoka</LastName>
                    <ForeName>Kazunori</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Yamamoto</LastName>
                    <ForeName>Tatsuro</ForeName>
                    <Initials>T</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Dev Neurosci</MedlineTA>
            <NlmUniqueID>7809375</NlmUniqueID>
            <ISSNLinking>0378-5866</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">000363101</ArticleId>
            <ArticleId IdType="doi">10.1159/000363101</ArticleId>
            <ArticleId IdType="pubmed">25138526</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138435</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1423-0291</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>81</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Pathobiology : journal of immunopathology, molecular and cellular biology</Title>
                <ISOAbbreviation>Pathobiology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Role of Two Types of Angiotensin II Receptors in Colorectal Carcinoma Progression.</ArticleTitle>
            <Pagination>
                <MedlinePgn>169-175</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Angiotensin II (Ang-II) is a bioactive peptide associated closely with the progression and metastasis of colorectal cancer (CRC). We examined the expression and role of 2 Ang-II receptor types in 20 cases of CRC. Ang-II type 1 receptor (AT1R) protein was localized to the plasma membrane, whereas Ang-II type 2 receptor (AT2R) protein was localized to the nuclei. AT1R expression showed a direct correlation with tumor stage and liver metastasis, whereas AT2R expression showed an inverse correlation. A knockdown study of the AT1R or AT2R with Ang-II treatment was performed to reveal their individual roles in a mouse rectal cell line CMT93, which expresses both Ang-II receptor types. AT2R knockdown showed that the AT1R was associated with tumor growth, survival, invasion and VEGF-A secretion in CMT93 cells in a dose-dependent manner. In contrast, AT1R knockdown showed that the AT2R was associated with increased VEGF-A secretion at low Ang-II concentrations, whereas high concentrations of Ang-II inhibited tumor growth, survival, invasion and VEGF-A secretion. Thus, the AT1R showed a monophasic protumoral effect, while the AT2R showed a biphasic amphitumoral effect. Our findings suggest that a high angiotensinogen condition in the liver might evoke the antitumoral role of the AT2R in CRC cells. ?? 2014 S. Karger AG, Basel.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Linyan</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Molecular Pathology, Nara Medical University, Kashihara, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Luo</LastName>
                    <ForeName>Yi</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Sato</LastName>
                    <ForeName>Seiya</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Tanabe</LastName>
                    <ForeName>Eriko</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author>
                    <LastName>Kitayoshi</LastName>
                    <ForeName>Misaho</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Fujiwara</LastName>
                    <ForeName>Rina</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author>
                    <LastName>Sasaki</LastName>
                    <ForeName>Takamitsu</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Fujii</LastName>
                    <ForeName>Kiyomu</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Ohmori</LastName>
                    <ForeName>Hitoshi</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Kuniyasu</LastName>
                    <ForeName>Hiroki</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Pathobiology</MedlineTA>
            <NlmUniqueID>9007504</NlmUniqueID>
            <ISSNLinking>1015-2008</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">000362092</ArticleId>
            <ArticleId IdType="doi">10.1159/000362092</ArticleId>
            <ArticleId IdType="pubmed">25138435</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138434</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-0738</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Archives of toxicology</Title>
                <ISOAbbreviation>Arch. Toxicol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Quercetin induces mitochondrial-derived apoptosis via reactive oxygen species-mediated ERK activation in HL-60 leukemia cells and xenograft.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Quercetin is a plant-derived bioflavonoid that was recently shown to have multiple anticancer activities in various solid tumors. Here, novel molecular mechanisms through which quercetin exerts its anticancer effects in acute myeloid leukemia (AML) cells were investigated. Results from Western blot and flow cytometric assays revealed that quercetin significantly induced caspase-8, caspase-9, and caspase-3 activation, poly ADP-ribose polymerase (PARP) cleavage, and mitochondrial membrane depolarization in HL-60 AML cells. The induction of PARP cleavage by quercetin was also observed in other AML cell lines: THP-1, MV4-11, and U937. Moreover, treatment of HL-60 cells with quercetin induced sustained activation of extracellular signal-regulated kinase (ERK), and inhibition of ERK by an ERK inhibitor significantly abolished quercetin-induced cell apoptosis. MitoSOX red and 2',7'-dichlorofluorescin fluorescence, respectively, showed that mitochondrial superoxide and intracellular peroxide levels were higher in quercetin-treated HL-60 cells compared with the control group. Moreover, both N-acetylcysteine and the superoxide dismutase mimetic, MnTBAP, reversed quercetin-induced intracellular reactive oxygen species production, ERK activation, and subsequent cell death. The in vivo xenograft mice experiments revealed that quercetin significantly reduced tumor growth through inducing intratumoral oxidative stress while activating the ERK pathway and subsequent cell apoptosis in mice with HL-60 tumor xenografts. In conclusions, our results indicated that quercetin induced cell death of HL-60 cells in vitro and in vivo through induction of intracellular oxidative stress following activation of an ERK-mediated apoptosis pathway.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Wei-Jiunn</ForeName>
                    <Initials>WJ</Initials>
                    <Affiliation>Department of Urology, Wan Fang Hospital, Taipei Medical University, 111 Hsing Long Road, Section??3, Taipei, 116, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hsiao</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Chang</LastName>
                    <ForeName>Junn-Liang</ForeName>
                    <Initials>JL</Initials>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Shun-Fa</ForeName>
                    <Initials>SF</Initials>
                </Author>
                <Author>
                    <LastName>Tseng</LastName>
                    <ForeName>Tsui-Hwa</ForeName>
                    <Initials>TH</Initials>
                </Author>
                <Author>
                    <LastName>Cheng</LastName>
                    <ForeName>Chao-Wen</ForeName>
                    <Initials>CW</Initials>
                </Author>
                <Author>
                    <LastName>Chow</LastName>
                    <ForeName>Jyh-Ming</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author>
                    <LastName>Lin</LastName>
                    <ForeName>Ke-Hsun</ForeName>
                    <Initials>KH</Initials>
                </Author>
                <Author>
                    <LastName>Lin</LastName>
                    <ForeName>Yung-Wei</ForeName>
                    <Initials>YW</Initials>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Chung-Chi</ForeName>
                    <Initials>CC</Initials>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Liang-Ming</ForeName>
                    <Initials>LM</Initials>
                </Author>
                <Author>
                    <LastName>Chien</LastName>
                    <ForeName>Ming-Hsien</ForeName>
                    <Initials>MH</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Arch Toxicol</MedlineTA>
            <NlmUniqueID>0417615</NlmUniqueID>
            <ISSNLinking>0340-5761</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00204-014-1300-0</ArticleId>
            <ArticleId IdType="pubmed">25138434</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138378</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1878-1705</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International immunopharmacology</Title>
                <ISOAbbreviation>Int. Immunopharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ganoderic acid Me induces the apoptosis of competent T cells and increases the proportion of Treg cells through enhancing the expression and activation of indoleamine 2,3-dioxygenase in mouse lewis lung cancer cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S1567-5769(14)00315-4</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.intimp.2014.08.001</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The indoleamine 2,3-dioxygenase-(IDO-) mediated microenvironment plays an important role in tumor immune escape. It is known that ganoderic acid Me can enhance IFN-?? expression and IDO is preferentially induced by IFN-??. However, whether GA-Me can induce IDO expression has not been clarified yet. We established stable clones of IDO-overexpressing 2LL cells (2LL-EGFP-IDO). After co-culturing with IDO expressing or control vector-transfected 2LL-EGFP cells, T cell apoptosis was determined and the proportion of the regulatory T cells (Tregs) and CD8+ T cell subset was measured. The total cellular protein samples of 2LL-EGFP-IDO cells were isolated for detecting JAK-STAT1 signalling pathway. Co-culture supernatants were used to detect amino acids and cytokines. IDO transfected 2LL cells yielded high level of IDO enzymatic activity, resulting in complete depletion of tryptophan from the culture medium. We found that apoptosis occurred in T cells after cocultured with IDO+2LL cells and the proportion of CD4+CD25+ cells and FoxP3+ cells increased while CD8+ cells decreased. The specific inhibitor of IDO, 1-D-MT and GA-Me efficiently enhanced T cell apoptosis, increased Tregs, and reduced CD8+ T cells in vitro. Increased expression of IDO, p-JAK1 and p-STAT1 were confirmed by Western blot analysis. The levels of IFN-??, IL-10, LDH and kynurenine in co-culture supernatant correspondingly increased, while tryptophan reduced. These results suggest that GA-Me contributing to IDO helps to create a tolerogenic milieu in lung tumors by directly inducing T cell apoptosis, restraining CD8+ T cell activation, and enhancing Treg-mediated immunosuppression.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Que</LastName>
                    <ForeName>Zujun</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department of Molecular &amp; Cellular Pharmacology, Biomedical Nanotechnology Center, State Key Laboratory of Bioreactor Engineering &amp; Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zou</LastName>
                    <ForeName>Fangyuan</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Molecular &amp; Cellular Pharmacology, Biomedical Nanotechnology Center, State Key Laboratory of Bioreactor Engineering &amp; Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Anle</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Molecular &amp; Cellular Pharmacology, Biomedical Nanotechnology Center, State Key Laboratory of Bioreactor Engineering &amp; Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>xZheng</LastName>
                    <ForeName>Yuanhong</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Molecular &amp; Cellular Pharmacology, Biomedical Nanotechnology Center, State Key Laboratory of Bioreactor Engineering &amp; Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bi</LastName>
                    <ForeName>Ling</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhong</LastName>
                    <ForeName>Jianjiang</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>State Key Laboratory of Microbial Metabolism, and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, 800 Dong-Chuan Road, Shanghai 200240, PR China; Shanghai Collaborative Innovation Center for Biomanufacturing Technology (SCICBT), East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tian</LastName>
                    <ForeName>Jianhui</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, PR China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Jianwen</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Molecular &amp; Cellular Pharmacology, Biomedical Nanotechnology Center, State Key Laboratory of Bioreactor Engineering &amp; Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, PR China. Electronic address: liujian@ecust.edu.cn.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Int Immunopharmacol</MedlineTA>
            <NlmUniqueID>100965259</NlmUniqueID>
            <ISSNLinking>1567-5769</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Co-culture</Keyword>
            <Keyword MajorTopicYN="N">GA-Me</Keyword>
            <Keyword MajorTopicYN="N">IDO1</Keyword>
            <Keyword MajorTopicYN="N">Mouse lewis lung cancer cells</Keyword>
            <Keyword MajorTopicYN="N">Treg</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1567-5769(14)00315-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.intimp.2014.08.001</ArticleId>
            <ArticleId IdType="pubmed">25138378</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138356</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1742-2094</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>11</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of neuroinflammation</Title>
                <ISOAbbreviation>J Neuroinflammation</ISOAbbreviation>
            </Journal>
            <ArticleTitle>FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination.</ArticleTitle>
            <Pagination>
                <MedlinePgn>138</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">BackgroundFTY720 (fingolimod) is the first oral drug approved by the Food and Drug Administration for treatment of patients with the relapsing-remitting form of the human demyelinating disease multiple sclerosis. Evidence suggests that the therapeutic benefit of FTY720 occurs by preventing the egress of lymphocytes from lymph nodes thereby inhibiting the infiltration of disease-causing lymphocytes into the central nervous system (CNS). We hypothesized that FTY720 treatment would affect lymphocyte migration to the CNS and influence disease severity in a mouse model of viral-induced neurologic disease.MethodsMice were infected intracranially with the neurotropic JHM strain of mouse hepatitis virus. Infected animals were treated with increasing doses (1, 3 and 10??mg/kg) of FTY720 and morbidity and mortality recorded. Infiltration of inflammatory virus-specific T cells (tetramer staining) into the CNS of FTY720-treated mice was determined using flow cytometry. The effects of FTY720 treatment on virus-specific T cell proliferation, cytokine production and cytolytic activity were also determined. The severity of neuroinflammation and demyelination in FTY720-treated mice was examined by flow cytometry and histopathologically, respectively, in the spinal cords of the mice.ResultsAdministration of FTY720 to JHMV-infected mice resulted in increased clinical disease severity and mortality. These results correlated with impaired ability to control viral replication (P??&lt;??0.05) within the CNS at days 7 and 14 post-infection, which was associated with diminished accumulation of virus-specific CD4+ and CD8+ T cells (P??&lt;??0.05) into the CNS. Reduced neuroinflammation in FTY720-treated mice correlated with increased retention of T lymphocytes within draining cervical lymph nodes (P??&lt;??0.05). Treatment with FTY720 did not affect virus-specific T cell proliferation, expression of IFN-??, TNF-?? or cytolytic activity. FTY720-treated mice exhibited a reduction in the severity of demyelination associated with dampened neuroinflammation.ConclusionThese findings indicate that FTY720 mutes effective anti-viral immune responses through impacting migration and accumulation of virus-specific T cells within the CNS during acute viral-induced encephalomyelitis. FTY720 treatment reduces the severity of neuroinflammatory-mediated demyelination by restricting the access of disease-causing lymphocytes into the CNS but is not associated with viral recrudescence in this model.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Blanc</LastName>
                    <ForeName>Caroline A</ForeName>
                    <Initials>CA</Initials>
                </Author>
                <Author>
                    <LastName>Rosen</LastName>
                    <ForeName>Hugh</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Lane</LastName>
                    <ForeName>Thomas E</ForeName>
                    <Initials>TE</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Neuroinflammation</MedlineTA>
            <NlmUniqueID>101222974</NlmUniqueID>
            <ISSNLinking>1742-2094</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">s12974-014-0138-y</ArticleId>
            <ArticleId IdType="doi">10.1186/s12974-014-0138-y</ArticleId>
            <ArticleId IdType="pubmed">25138356</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138349</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1520-5762</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Drug development and industrial pharmacy</Title>
                <ISOAbbreviation>Drug Dev Ind Pharm</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Preparation and evaluation of SEDDS of simvastatin by in vivo, in vitro and ex vivo technique.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Abstract The objective of this work was to formulate a Self Emulsifying Drug Delivery System (SEDDS) of simvastatin, a poorly soluble drug and to evaluate by in vivo, in vitro and ex vivo techniques. Oils and surfactants were screened out depending upon their solubilizing capacity. Among all of the solvents, Capryol 90 showed good solubilizing capacity. It dissolved 105???mg/ml of simvastatin. Tween-80 also showed good solubilizing capacity which was 117???mg/ml. The two excipients were used to prepare simvastatin SEDDS. Formulations were initially checked for the color, clarity and sedimentation. The SEDDS formulations were transparent and clear. Formulation F2 containing 7:3 (m/m) mixture of Capryol 90/Tween-80 produced smallest micro-emulsion with particles size of 0.074?????m and drug release was higher than other formulation (102% within 20???min). Ex vivo study of the SEDDS formulation was evaluated using guinea pig intestinal sac. Drug diffused from F2 formulation was significantly higher than pure drug (p???&lt;???0.001). In vivo study of SEDDS was performed in albino mice using plasma cholesterol level as a pharmacodynamic marker parameter. The test formulation (F2) appeared remarkable reduction in plasma cholesterol level, after oral administration which showed that SEDDS may be an effective technique for the oral administration of simvastatin.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Karim</LastName>
                    <ForeName>Fahim Tamzeedul</ForeName>
                    <Initials>FT</Initials>
                    <Affiliation>Department of Pharmaceutical Technology and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kalam</LastName>
                    <ForeName>Azad</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Anwar</LastName>
                    <ForeName>Rafi</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author>
                    <LastName>Miah</LastName>
                    <ForeName>Muhammad Masum</ForeName>
                    <Initials>MM</Initials>
                </Author>
                <Author>
                    <LastName>Rahman</LastName>
                    <ForeName>Md Shamim</ForeName>
                    <Initials>MS</Initials>
                </Author>
                <Author>
                    <LastName>Islam</LastName>
                    <ForeName>S M Ashraful</ForeName>
                    <Initials>SM</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Drug Dev Ind Pharm</MedlineTA>
            <NlmUniqueID>7802620</NlmUniqueID>
            <ISSNLinking>0363-9045</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Capryol 90</Keyword>
            <Keyword MajorTopicYN="N">SEDDS</Keyword>
            <Keyword MajorTopicYN="N">Tween-80</Keyword>
            <Keyword MajorTopicYN="N">micro-emulsion</Keyword>
            <Keyword MajorTopicYN="N">oral administration</Keyword>
            <Keyword MajorTopicYN="N">simvastatin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3109/03639045.2014.950271</ArticleId>
            <ArticleId IdType="pubmed">25138349</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138294</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1559-064X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of exposure science &amp; environmental epidemiology</Title>
                <ISOAbbreviation>J Expo Sci Environ Epidemiol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cow allergen (Bos d2) and endotoxin concentrations are higher in the settled dust of homes proximate to industrial-scale dairy operations.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1038/jes.2014.57</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Airborne contaminants produced by industrial agricultural facilities contain chemical and biological compounds that can impact the health of residents living in close proximity. Settled dust can be a reservoir for these contaminants and can influence long-term exposures. In this study, we sampled the indoor- and outdoor-settled dust from 40 homes that varied in proximity to industrial-scale dairies (ISD; industrial-scale dairy, a term used in this paper to describe a large dairy farm and adjacent waste sprayfields, concentrated animal feeding operation or animal feeding operation, that uses industrial processes) in the Yakima Valley, Washington. We analyzed settled dust samples for cow allergen (Bos d2, a cow allergen associated with dander, hair, sweat and urine, it is a member of the lipocalin family of allergens associated with mammals), mouse allergen (Mus m1; major mouse allergen, a mouse urinary allergen, in the lipocalin family), dust mite allergens (Der p1 (Dermatophagoides pteronissinus 1) and Der f1 (Dermatophagoides farinae 1)), and endotoxin (a component of the cell walls of gram negative bacteria, lipopolysaccharide, which can be found in air and dust and can produce a strong inflammatory response). A concentration gradient was observed for Bos d2 and endotoxin measured in outdoor-settled dust samples based on proximity to ISD. Indoor-settled dust concentrations of Bos d2 and endotoxin were also highest in proximal homes. While the associated health effects of exposure to cow allergen in settled dust is unknown, endotoxin at concentrations observed in these proximal homes (100???EU/mg) has been associated with increased negative respiratory health effects. These findings document that biological contaminants emitted from ISDs are elevated in indoor- and outdoor-settled dust samples at homes close to these facilities and extend to as much as three miles (4.8???km) away.Journal of Exposure Science and Environmental Epidemiology advance online publication, 20 August 2014; doi:10.1038/jes.2014.57.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Williams</LastName>
                    <ForeName>D' Ann L</ForeName>
                    <Initials>DA</Initials>
                    <Affiliation>Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>McCormack</LastName>
                    <ForeName>Meredith C</ForeName>
                    <Initials>MC</Initials>
                    <Affiliation>Johns Hopkins School of Medicine, Baltimore, Maryland, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Matsui</LastName>
                    <ForeName>Elizabeth C</ForeName>
                    <Initials>EC</Initials>
                    <Affiliation>Johns Hopkins School of Medicine, Baltimore, Maryland, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Diette</LastName>
                    <ForeName>Gregory B</ForeName>
                    <Initials>GB</Initials>
                    <Affiliation>1] Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA [2] Johns Hopkins School of Medicine, Baltimore, Maryland, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>McKenzie</LastName>
                    <ForeName>Shawn E</ForeName>
                    <Initials>SE</Initials>
                    <Affiliation>Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Geyh</LastName>
                    <ForeName>Alison S</ForeName>
                    <Initials>AS</Initials>
                    <Affiliation>Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Breysse</LastName>
                    <ForeName>Patrick N</ForeName>
                    <Initials>PN</Initials>
                    <Affiliation>Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Expo Sci Environ Epidemiol</MedlineTA>
            <NlmUniqueID>101262796</NlmUniqueID>
            <ISSNLinking>1559-0631</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>9</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">jes201457</ArticleId>
            <ArticleId IdType="doi">10.1038/jes.2014.57</ArticleId>
            <ArticleId IdType="pubmed">25138294</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138275</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1083-351X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of biological chemistry</Title>
                <ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Endogenous Glucuronyltransferase Activity of LARGE or LARGE2 Required for Functional Modification of ??-dystroglycan in Cells and Tissues.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">jbc.M114.597831</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Mutations in the LARGE gene have been identified in congenital muscular dystrophy (CMD) patients with brain abnormalities. Both LARGE and its paralog, LARGE2 (also referred to as GYLTL1B) are bifunctional glycosyltransferases with xylosyltransferase (Xyl-T) and glucuronyltransferase (GlcA-T) activities, and are capable of forming polymers consisting of [-3Xyl-??1,3GlcA??1-] repeats. LARGE-dependent modification of ??-dystroglycan (??-DG) with these polysaccharides is essential for the ability of ??-DG to act as a receptor for ligands in the extracellular matrix. Here we report on the endogenous enzymatic activities of LARGE and LARGE2 in mice and humans, using a newly developed assay for GlcA-T activity. We show that normal mouse and human cultured cells have endogenous LARGE GlcA-T, and that this activity is absent in cells from the Largemyd (Large-deficient) mouse model of muscular dystrophy, as well as in cells from CMD patients with mutations in the LARGE gene. We also demonstrate that GlcA-T activity is significant in the brain, heart, and skeletal muscle of wild-type and Large2-/- mice, but negligible in the corresponding tissues of the Largemyd mice. Notably, GlcA-T activity is substantial, though reduced, in the kidneys of both the Largemyd and Large2-/- mice, consistent with the observation of ??-DG/laminin binding in these contexts. This study is the first to test LARGE activity in samples as small as cryosections and, moreover, provides the first direct evidence that not only LARGE, but also LARGE2, is vital to effective functional modification of ??-DG in vivo.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, The American Society for Biochemistry and Molecular Biology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Inamori</LastName>
                    <ForeName>Kei-Ichiro</ForeName>
                    <Initials>KI</Initials>
                    <Affiliation>Tohoku Pharmaceutical University, Japan;</Affiliation>
                </Author>
                <Author>
                    <LastName>Willer</LastName>
                    <ForeName>Tobias</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>University of Iowa Carver College of Medicine, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Hara</LastName>
                    <ForeName>Yuji</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Kyoto University Graduate School of Engineering, Japan;</Affiliation>
                </Author>
                <Author>
                    <LastName>Venzke</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>University of Iowa Carver College of Medicine, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Anderson</LastName>
                    <ForeName>Mary E</ForeName>
                    <Initials>ME</Initials>
                    <Affiliation>University of Iowa Carver College of Medicine, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Clarke</LastName>
                    <ForeName>Nigel F</ForeName>
                    <Initials>NF</Initials>
                    <Affiliation>University of Sydney, Australia;</Affiliation>
                </Author>
                <Author>
                    <LastName>Guicheney</LastName>
                    <ForeName>Pascale</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>INSERM Institut de Myologie, France;</Affiliation>
                </Author>
                <Author>
                    <LastName>B??nnemann</LastName>
                    <ForeName>Carsten G</ForeName>
                    <Initials>CG</Initials>
                    <Affiliation>National Institute of Neurological Disorders and Stroke, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Moore</LastName>
                    <ForeName>Steven A</ForeName>
                    <Initials>SA</Initials>
                    <Affiliation>University of Iowa Carver College of Medicine, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Campbell</LastName>
                    <ForeName>Kevin P</ForeName>
                    <Initials>KP</Initials>
                    <Affiliation>University of Iowa Carver College of Medicine, United States; kevin-campbell@uiowa.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Biol Chem</MedlineTA>
            <NlmUniqueID>2985121R</NlmUniqueID>
            <ISSNLinking>0021-9258</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">LARGE</Keyword>
            <Keyword MajorTopicYN="N">dystroglycan</Keyword>
            <Keyword MajorTopicYN="N">extracellular matrix</Keyword>
            <Keyword MajorTopicYN="N">glucuronyltransferase</Keyword>
            <Keyword MajorTopicYN="N">glycosyltransferase</Keyword>
            <Keyword MajorTopicYN="N">laminin</Keyword>
            <Keyword MajorTopicYN="N">muscular dystrophy</Keyword>
            <Keyword MajorTopicYN="N">post-translational modification (PTM)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25138275</ArticleId>
            <ArticleId IdType="pii">M114.597831</ArticleId>
            <ArticleId IdType="doi">10.1074/jbc.M114.597831</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
        <PMID Version="1">25138272</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1742-2094</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>11</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of neuroinflammation</Title>
                <ISOAbbreviation>J Neuroinflammation</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Etanercept restores normal insulin signal transduction in ??2-adrenergic receptor knockout mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>137</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12974-014-0137-z</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Inhibition of TNF?? protects the retina against diabetic-like changes in rodent models. The mechanism by which TNF?? induces deleterious retinal changes is not known. Previously, we have shown that TNF?? can inhibit normal insulin signal transduction, leading to increased apoptosis in both retinal endothelial cells (REC) and M??ller cells. Additionally, ??2-adrenergic receptor knockout mice (??2KO) have increased TNF?? levels and decreased insulin receptor activity. In this study, we hypothesized that inhibition of TNF?? in ??2KO mice would increase normal insulin signaling, leading to improved retinal function.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">C57BL6 or ??2KO mice were left untreated or treated with etanercept (0.3 mg/kg subcutaneously, 3?? a week) for 2 months. Electroretinogram analyses were done before treatment was initiated and after two months of treatment with etanercept on all mice. Western blot or ELISA analyses were done on whole retinal lysates from all four groups of mice for TNF??, suppressor of cytokine signaling 3 (SOCS3), insulin receptor, and apoptotic proteins.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Etanercept significantly reduced TNF?? levels in ??2KO mice, leading to increased insulin receptor phosphorylation on tyrosine 1150/1151. SOCS3 levels were increased in ??2KO mice, which were reduced after etanercept treatment. Pro-apoptotic proteins were reduced in etanercept-treated ??2KO mice. Etanercept improved ERG amplitudes in ??2KO mice.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Inhibition of TNF?? by etanercept protects the retina likely through reduced TNF??-mediated insulin resistance, leading to reduced apoptosis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jiang</LastName>
                    <ForeName>Youde</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Qiuhua</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ye</LastName>
                    <ForeName>Eun-Ah</ForeName>
                    <Initials>EA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Steinle</LastName>
                    <ForeName>Jena J</ForeName>
                    <Initials>JJ</Initials>
                    <Affiliation>Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, TN, USA. jsteinl1@uthsc.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>3P30 EY013080</GrantID>
                    <Acronym>EY</Acronym>
                    <Agency>NEI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01-EY022330</GrantID>
                    <Acronym>EY</Acronym>
                    <Agency>NEI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Neuroinflammation</MedlineTA>
            <NlmUniqueID>101222974</NlmUniqueID>
            <ISSNLinking>1742-2094</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">s12974-014-0137-z</ArticleId>
            <ArticleId IdType="doi">10.1186/s12974-014-0137-z</ArticleId>
            <ArticleId IdType="pubmed">25138272</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138253</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-3476</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of pharmaceutics</Title>
                <ISOAbbreviation>Int J Pharm</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hydroxypropyl-??-cyclodextrin grafted polyethyleneimine used as transdermal penetration enhancer of sodium diclofenac.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0378-5173(14)00587-0</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.ijpharm.2014.08.021</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The objective of this investigation was to develop a novel cationic polymer, hydroxypropyl-??-cyclodextrin grafted polyethyleneimine (HP-??-CD-PEI1800), as a penetration enhancer, and evaluate its viability on improving transdermal delivery of sodium diclofenac. In this study, HP-??-CD-PEI1800 was characterized by (1)H-NMR and DSC methods, respectively. The hydrophilic drug sodium diclofenac was chosen as model drug, and the transdermal permeation enhancement of HP-??-CD-PEI1800 was estimated in vitro by using Franz diffusion cells fitted with mouse dorsal skins, the in vivo kinetics of sodium diclofenac was analyzed by high-performance liquid chromatography (HPLC). The cumulative drug content deposited in epidermis and dermis was measured at the pre-determined time point of 3, 6, and 9h, and the permeation profile was significantly higher than that of the control groups. In addition, the cytotoxicity and skin irritation of enhancer was evaluated by MTT assay and histological examination, respectively, and the results indicated that the polymer we prepared were non-toxic and non-irritant after exposure to skins .All results suggested that HP-??-CD-PEI1800 could be a safe and efficient penetration enhancer of sodium diclofenac.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Yan</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>School of Pharmacy, Health Science Center, Xi' an Jiaotong University, Xi'an, 710061, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Xing</LastName>
                    <ForeName>Jianfeng</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>School of Pharmacy, Health Science Center, Xi' an Jiaotong University, Xi'an, 710061, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Xu</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>School of Pharmacy, Health Science Center, Xi' an Jiaotong University, Xi'an, 710061, China. Electronic address: perpetual1003@mail.xjtu.edu.cn.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhao</LastName>
                    <ForeName>Guilan</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>School of Pharmacy, Health Science Center, Xi' an Jiaotong University, Xi'an, 710061, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dong</LastName>
                    <ForeName>Kai</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>School of Pharmacy, Health Science Center, Xi' an Jiaotong University, Xi'an, 710061, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Lu</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>School of Pharmacy, Health Science Center, Xi' an Jiaotong University, Xi'an, 710061, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Ke</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>School of Pharmacy, Health Science Center, Xi' an Jiaotong University, Xi'an, 710061, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Int J Pharm</MedlineTA>
            <NlmUniqueID>7804127</NlmUniqueID>
            <ISSNLinking>0378-5173</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Transdermal drug delivery</Keyword>
            <Keyword MajorTopicYN="N">cytotoxicity</Keyword>
            <Keyword MajorTopicYN="N">irritation of the skin</Keyword>
            <Keyword MajorTopicYN="N">penetration enhancer</Keyword>
            <Keyword MajorTopicYN="N">sodium diclofenac</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0378-5173(14)00587-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2014.08.021</ArticleId>
            <ArticleId IdType="pubmed">25138253</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138219</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1083-351X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of biological chemistry</Title>
                <ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Nod-like receptor protein 3 (NLRP3) Inflammasome Activation and Podocyte Injury via Thioredoxin-Interacting Protein during Hyperhomocysteinemia.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">jbc.M114.567537</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">NADPH oxidase-derived reactive oxygen species (ROS) have been reported to activate NLRP3 inflammasomes resulting in podocyte and glomerular injury during hyperhomocysteinemia (hHcys). However, the mechanism by which the inflammasome senses ROS is still unknown in podocytes upon hHcys stimulation. The current study explored whether thioredoxin-interacting protein (TXNIP), an endogenous inhibitor of the antioxidant thioredoxin (TRX) and ROS sensor, mediates hHcys-induced NLRP3 inflammasome activation and consequent glomerular injury. In cultured podocytes, size exclusion chromatography and confocal microscopy showed that inhibition of TXNIP by siRNA or verapamil prevented Hcys-induced TXNIP protein recruitment to form NLRP3 inflammasomes and abolished Hcys-induced increases in caspase-1 activity and IL-1?? production. TXNIP inhibition protected podocytes from injury as shown by normal expression levels of podocyte markers, podocin and desmin. In vivo, adult C57BL/6J male mice were fed a folate-free (FF) diet for 4 weeks to induce hHcys, and TXNIP was inhibited by verapamil (1 mg/mL in drinking water) or by local microbubble-ultrasound TXNIP shRNA transfection. Evidenced by immunofluorescence and co-immunoprecipitation studies, glomerular inflammasome formation and TXNIP binding to NLRP3 were markedly increased in mice with hHcys but not in TXNIP shRNA-transfected mice or those receiving verapamil. Furthermore, TXNIP inhibition significantly reduced caspase-1 activity and IL-1?? production in glomeruli of mice with hHcys. Correspondingly, TXNIP shRNA transfection and verapamil attenuated hHcys-induced proteinuria, albuminuria, glomerular damage, and podocyte injury. In conclusion, our results demonstrate that TXNIP binding to NLRP3 is a key signaling mechanism necessary for hHcys-induced NLRP3 inflammasome formation and activation, and subsequent glomerular injury.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, The American Society for Biochemistry and Molecular Biology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Abais</LastName>
                    <ForeName>Justine M</ForeName>
                    <Initials>JM</Initials>
                    <Affiliation>Virginia Commonwealth University, United States abaisjm@vcu.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Xia</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Virginia Commonwealth University, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Guangbi</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Virginia Commonwealth University, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Yang</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Virginia Commonwealth University, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Conley</LastName>
                    <ForeName>Sabena M</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>Virginia Commonwealth University, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gehr</LastName>
                    <ForeName>Todd W B</ForeName>
                    <Initials>TW</Initials>
                    <Affiliation>Virginia Commonwealth University, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Boini</LastName>
                    <ForeName>Krishna M</ForeName>
                    <Initials>KM</Initials>
                    <Affiliation>Virginia Commonwealth University, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Pin-Lan</ForeName>
                    <Initials>PL</Initials>
                    <Affiliation>Virginia Commonwealth University, United States.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Biol Chem</MedlineTA>
            <NlmUniqueID>2985121R</NlmUniqueID>
            <ISSNLinking>0021-9258</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">glomerulosclerosis</Keyword>
            <Keyword MajorTopicYN="N">homocysteine</Keyword>
            <Keyword MajorTopicYN="N">inflammation</Keyword>
            <Keyword MajorTopicYN="N">kidney</Keyword>
            <Keyword MajorTopicYN="N">podocyte</Keyword>
            <Keyword MajorTopicYN="N">redox signaling</Keyword>
            <Keyword MajorTopicYN="N">thioredoxin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25138219</ArticleId>
            <ArticleId IdType="pii">M114.567537</ArticleId>
            <ArticleId IdType="doi">10.1074/jbc.M114.567537</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138215</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1083-351X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of biological chemistry</Title>
                <ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Transcriptional regulation of the intestinal nuclear bile acid farnesoid X receptor (FXR) by the caudal related homeobox 2 (CDX2).</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">jbc.M114.571513</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Farnesoid X receptor (FXR, NR1H4) is a bile acid-activated transcription factor that belongs to the nuclear receptor super-family. It is highly expressed in the entero-hepatic system, where it senses bile acid levels to consequently reduce their synthesis while inducing their detoxification. Bile acids are intestinal tumor promoters and their concentrations have to be tightly regulated. Indeed, reduced expression of FXR in the intestine increases colorectal cancer susceptibility in mice, while its activation can promote apoptosis in genetically modified cells. Notably, despite the broad knowledge of the FXR entero-hepatic transcriptional activity, the molecular mechanisms regulating FXR expression in the intestine are still unknown. Herein, by combining both gain and loss of function approaches and FXR and promoter activity studies on FXR promoter, we identified caudal-related homeobox 2 (CDX2) transcription factor as a positive regulator of FXR expression in the enterocytes. Our results provide a putative novel tool for modulating FXR expression against bile acid-related colorectal cancer progression.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, The American Society for Biochemistry and Molecular Biology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Modica</LastName>
                    <ForeName>Salvatore</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>negrisud, Italy;</Affiliation>
                </Author>
                <Author>
                    <LastName>Cariello</LastName>
                    <ForeName>Marica</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>IRCCS Oncologico Bari, Italy;</Affiliation>
                </Author>
                <Author>
                    <LastName>Morgano</LastName>
                    <ForeName>Annalisa</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>negrisud, Italy;</Affiliation>
                </Author>
                <Author>
                    <LastName>Gross</LastName>
                    <ForeName>Isabelle</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>University of Strasbourg, France;</Affiliation>
                </Author>
                <Author>
                    <LastName>Vegliante</LastName>
                    <ForeName>Maria Carmela</ForeName>
                    <Initials>MC</Initials>
                    <Affiliation>IRCCS Oncologico Bari, Italy;</Affiliation>
                </Author>
                <Author>
                    <LastName>Murzilli</LastName>
                    <ForeName>Stefania</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>negrisud, Italy;</Affiliation>
                </Author>
                <Author>
                    <LastName>Salvatore</LastName>
                    <ForeName>Lorena</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>negrisud, Italy;</Affiliation>
                </Author>
                <Author>
                    <LastName>Freund</LastName>
                    <ForeName>Jean-Noel</ForeName>
                    <Initials>JN</Initials>
                    <Affiliation>University of Strasbourg INSERM, France;</Affiliation>
                </Author>
                <Author>
                    <LastName>Sabba'</LastName>
                    <ForeName>Carlo</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>University of Bari, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Moschetta</LastName>
                    <ForeName>Antonio</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>University of Bari, Italy antonio.moschetta@uniba.it.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Biol Chem</MedlineTA>
            <NlmUniqueID>2985121R</NlmUniqueID>
            <ISSNLinking>0021-9258</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">bile acid</Keyword>
            <Keyword MajorTopicYN="N">gene transcription</Keyword>
            <Keyword MajorTopicYN="N">intestine</Keyword>
            <Keyword MajorTopicYN="N">lipid metabolism</Keyword>
            <Keyword MajorTopicYN="N">nuclear receptor</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25138215</ArticleId>
            <ArticleId IdType="pii">M114.571513</ArticleId>
            <ArticleId IdType="doi">10.1074/jbc.M114.571513</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138159</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1530-6860</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</Title>
                <ISOAbbreviation>FASEB J.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The CAP1/Prss8 catalytic triad is not involved in PAR2 activation and protease nexin-1 (PN-1) inhibition.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">fj.14-253781</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Serine proteases, serine protease inhibitors, and protease-activated receptors (PARs) are responsible for several human skin disorders characterized by impaired epidermal permeability barrier function, desquamation, and inflammation. In this study, we addressed the consequences of a catalytically dead serine protease on epidermal homeostasis, the activation of PAR2 and the inhibition by the serine protease inhibitor nexin-1. The catalytically inactive serine protease CAP1/Prss8, when ectopically expressed in the mouse, retained the ability to induce skin disorders as well as its catalytically active counterpart (75%, n=81). Moreover, this phenotype was completely normalized in a PAR2-null background, indicating that the effects mediated by the catalytically inactive CAP1/Prss8 depend on PAR2 (95%, n=131). Finally, nexin-1 displayed analogous inhibitory capacity on both wild-type and inactive mutant CAP1/Prss8 in vitro and in vivo (64% n=151 vs. 89% n=109, respectively), indicating that the catalytic site of CAP1/Prss8 is dispensable for nexin-1 inhibition. Our results demonstrate a novel inhibitory interaction between CAP1/Prss8 and nexin-1, opening the search for specific CAP1/Prss8 antagonists that are independent of its catalytic activity.-Crisante, G., Battista, L., Iwaszkiewicz, J., Nesca, V., M??rillat, A.-M., Sergi, C., Zoete, V., Frateschi, S., Hummler, E. The CAP1/Prss8 catalytic triad is not involved in PAR2 activation and protease nexin-1 (PN-1) inhibition.</AbstractText>
                <CopyrightInformation>?? FASEB.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Crisante</LastName>
                    <ForeName>Giovanna</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Pharmacology and Toxicology and Swiss Institute of Bioinformatics, University of Lausanne, Lausanne, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Battista</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Pharmacology and Toxicology and Swiss Institute of Bioinformatics, University of Lausanne, Lausanne, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Iwaszkiewicz</LastName>
                    <ForeName>Justyna</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Pharmacology and Toxicology and Swiss Institute of Bioinformatics, University of Lausanne, Lausanne, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nesca</LastName>
                    <ForeName>Valeria</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Department of Pharmacology and Toxicology and Swiss Institute of Bioinformatics, University of Lausanne, Lausanne, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>M??rillat</LastName>
                    <ForeName>Anne-Marie</ForeName>
                    <Initials>AM</Initials>
                    <Affiliation>Department of Pharmacology and Toxicology and Swiss Institute of Bioinformatics, University of Lausanne, Lausanne, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sergi</LastName>
                    <ForeName>Chlo??</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Pharmacology and Toxicology and Swiss Institute of Bioinformatics, University of Lausanne, Lausanne, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zoete</LastName>
                    <ForeName>Vincent</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Department of Pharmacology and Toxicology and Swiss Institute of Bioinformatics, University of Lausanne, Lausanne, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Frateschi</LastName>
                    <ForeName>Simona</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Pharmacology and Toxicology and Swiss Institute of Bioinformatics, University of Lausanne, Lausanne, Switzerland simona.frateschi@unil.ch edith.hummler@unil.ch.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hummler</LastName>
                    <ForeName>Edith</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Department of Pharmacology and Toxicology and Swiss Institute of Bioinformatics, University of Lausanne, Lausanne, Switzerland simona.frateschi@unil.ch edith.hummler@unil.ch.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>FASEB J</MedlineTA>
            <NlmUniqueID>8804484</NlmUniqueID>
            <ISSNLinking>0892-6638</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">enzymatic activity</Keyword>
            <Keyword MajorTopicYN="N">prostasin</Keyword>
            <Keyword MajorTopicYN="N">serine protease</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">fj.14-253781</ArticleId>
            <ArticleId IdType="doi">10.1096/fj.14-253781</ArticleId>
            <ArticleId IdType="pubmed">25138159</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138158</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1530-6860</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</Title>
                <ISOAbbreviation>FASEB J.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The pathogenic mechanism of diabetes varies with the degree of overexpression and oligomerization of human amylin in the pancreatic islet ?? cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">fj.14-251744</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The aggregation of human amylin (hA) to form cytotoxic structures has been closely associated with the causation of type 2 diabetes. We sought to advance understanding of how altered expression and aggregation of hA might link ??-cell degeneration with diabetes onset and progression, by comparing phenotypes between homozygous and hemizygous hA-transgenic mice. The homozygous mice displayed elevated islet hA that correlated positively with measures of oligomer formation (r=0.91; P&lt;0.0001). They also developed hyperinsulinemia with transient insulin resistance during the prediabetes stage and then underwent rapid ??-cell loss, culminating in severe juvenile-onset diabetes. The prediabetes stage was prolonged in the hemizygous mice, wherein ??-cell dysfunction and extensive oligomer formation occurred in adulthood at a much later stage, when hA levels were lower (r=-0.60; P&lt;0.0001). This is the first report to show that hA-evoked diabetes is associated with age, insulin resistance, progressive islet dysfunction, and ??-cell apoptosis, which interact variably to cause the different diabetes syndromes. The various levels of hA elevation cause different extents of oligomer formation in the disease stages, thus eliciting early- or adult-onset diabetes syndromes, reminiscent of type 1 and 2 diabetes, respectively. Thus, the hA-evoked diabetes phenotypes differ substantively according to degree of amylin overproduction. These findings are relevant to the understanding of the pathogenesis and the development of experimental therapeutics for diabetes.-Zhang, S., Liu, H., Chuang, C. L., Li, X., Au, M., Zhang, L., Phillips, A R. J., Scott, D. W., Cooper, G. J. S. The pathogenic mechanism of diabetes varies with the degree of overexpression and oligomerization of human amylin in the pancreatic islet ?? cells.</AbstractText>
                <CopyrightInformation>?? FASEB.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Shaoping</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>The School of Biological Sciences and The Maurice Wilkins Centre for Molecular BioDiscovery, Faculty of Science, University of Auckland, Auckland, New Zealand Centre for Advanced Discovery and Experimental Therapeutics, Central Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester, UK; andThe School of Biological Sciences and The Maurice Wilkins Centre for Molecular BioDiscovery, Faculty of Science, University of Auckland, Auckland, New Zealand Centre for Advanced Discovery and Experimental Therapeutics, Central Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester, UK; and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Hong</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>The School of Biological Sciences and The Maurice Wilkins Centre for Molecular BioDiscovery, Faculty of Science, University of Auckland, Auckland, New Zealand Centre for Advanced Discovery and Experimental Therapeutics, Central Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester, UK; and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chuang</LastName>
                    <ForeName>Chia Lin</ForeName>
                    <Initials>CL</Initials>
                    <Affiliation>The School of Biological Sciences and The Maurice Wilkins Centre for Molecular BioDiscovery, Faculty of Science, University of Auckland, Auckland, New Zealand Centre for Advanced Discovery and Experimental Therapeutics, Central Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester, UK; and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Xiaoling</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>The School of Biological Sciences and The Maurice Wilkins Centre for Molecular BioDiscovery, Faculty of Science, University of Auckland, Auckland, New Zealand Centre for Advanced Discovery and Experimental Therapeutics, Central Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester, UK; and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Au</LastName>
                    <ForeName>Maggie</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>The School of Biological Sciences and The Maurice Wilkins Centre for Molecular BioDiscovery, Faculty of Science, University of Auckland, Auckland, New Zealand Centre for Advanced Discovery and Experimental Therapeutics, Central Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester, UK; and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Lin</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>The School of Biological Sciences and The Maurice Wilkins Centre for Molecular BioDiscovery, Faculty of Science, University of Auckland, Auckland, New Zealand Centre for Advanced Discovery and Experimental Therapeutics, Central Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester, UK; and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Phillips</LastName>
                    <ForeName>Anthony R J</ForeName>
                    <Initials>AR</Initials>
                    <Affiliation>The School of Biological Sciences and The Maurice Wilkins Centre for Molecular BioDiscovery, Faculty of Science, University of Auckland, Auckland, New Zealand Centre for Advanced Discovery and Experimental Therapeutics, Central Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester, UK; andThe School of Biological Sciences and The Maurice Wilkins Centre for Molecular BioDiscovery, Faculty of Science, University of Auckland, Auckland, New Zealand Centre for Advanced Discovery and Experimental Therapeutics, Central Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester, UK; and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Scott</LastName>
                    <ForeName>David W</ForeName>
                    <Initials>DW</Initials>
                    <Affiliation>The School of Biological Sciences and The Maurice Wilkins Centre for Molecular BioDiscovery, Faculty of Science, University of Auckland, Auckland, New Zealand Centre for Advanced Discovery and Experimental Therapeutics, Central Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester, UK; and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cooper</LastName>
                    <ForeName>Garth J S</ForeName>
                    <Initials>GJ</Initials>
                    <Affiliation>The School of Biological Sciences and The Maurice Wilkins Centre for Molecular BioDiscovery, Faculty of Science, University of Auckland, Auckland, New Zealand Centre for Advanced Discovery and Experimental Therapeutics, Central Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester, UK; andThe School of Biological Sciences and The Maurice Wilkins Centre for Molecular BioDiscovery, Faculty of Science, University of Auckland, Auckland, New Zealand Centre for Advanced Discovery and Experimental Therapeutics, Central Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester, UK; andThe School of Biological Sciences and The Maurice Wilkins Centre for Molecular BioDiscovery, Faculty of Science, University of Auckland, Auckland, New Zealand Centre for Advanced Discovery and Experimental Therapeutics, Central Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester, UK; and Centre for Endocrinology and Diabetes, Institute of Human Development, Faculty of Medical and Human Sciences, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, UK g.cooper@auckland.ac.nz.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>FASEB J</MedlineTA>
            <NlmUniqueID>8804484</NlmUniqueID>
            <ISSNLinking>0892-6638</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">apoptosis</Keyword>
            <Keyword MajorTopicYN="N">gene???dosage effect</Keyword>
            <Keyword MajorTopicYN="N">insulin resistance</Keyword>
            <Keyword MajorTopicYN="N">peptide aggregation</Keyword>
            <Keyword MajorTopicYN="N">transgenic mice</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">fj.14-251744</ArticleId>
            <ArticleId IdType="doi">10.1096/fj.14-251744</ArticleId>
            <ArticleId IdType="pubmed">25138158</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138129</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-2474</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>15</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC musculoskeletal disorders</Title>
                <ISOAbbreviation>BMC Musculoskelet Disord</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Identification of myeloid-derived suppressor cells in the synovial fluid of patients with rheumatoid arthritis: a pilot study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>281</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of innate immune cells with a granulocyte-like or monocyte-like phenotype and a unique ability to suppress T-cell responses. MDSCs have been shown to accumulate in cancer patients, but recent studies suggest that these cells are also present in humans and animals suffering from autoimmune diseases. We previously identified MDSCs in the synovial fluid (SF) of mice with experimental autoimmune arthritis. The goal of the present study was to identify MDSCs in the SF of patients with rheumatoid arthritis (RA).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">RA SF cells were studied by flow cytometry using antibodies to MDSC cell surface markers as well as by analysis of cell morphology. The suppressor activity of RA SF cells toward autologous peripheral blood T cells was determined ex vivo. We employed both antigen-nonspecific (anti-CD3/CD28 antibodies) and antigen-specific (allogeneic cells) induction systems to test the effects of RA SF cells on the proliferation of autologous T cells.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">SF from RA patients contained MDSC-like cells, the majority of which showed granulocyte (neutrophil)-like phenotype and morphology. RA SF cells significantly suppressed the proliferation of anti-CD3/CD28-stimulated autologous T cells upon co-culture. When compared side by side, RA SF cells had a more profound inhibitory effect on the alloantigen-induced than the anti-CD3/CD28-induced proliferation of autologous T cells.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">MDSCs are present among RA SF cells that are commonly regarded as inflammatory neutrophils. Our results suggest that the presence of neutrophil-like MDSCs in the SF is likely beneficial, as these cells have the ability to limit the expansion of joint-infiltrating T cells in RA.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kurk??</LastName>
                    <ForeName>J??lia</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Vida</LastName>
                    <ForeName>Andr??s</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Glant</LastName>
                    <ForeName>Tibor T</ForeName>
                    <Initials>TT</Initials>
                </Author>
                <Author>
                    <LastName>Scanzello</LastName>
                    <ForeName>Carla R</ForeName>
                    <Initials>CR</Initials>
                </Author>
                <Author>
                    <LastName>Katz</LastName>
                    <ForeName>Robert S</ForeName>
                    <Initials>RS</Initials>
                </Author>
                <Author>
                    <LastName>Nair</LastName>
                    <ForeName>Anjali</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Szekanecz</LastName>
                    <ForeName>Zolt??n</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author>
                    <LastName>Mikecz</LastName>
                    <ForeName>Katalin</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>BMC Musculoskelet Disord</MedlineTA>
            <NlmUniqueID>100968565</NlmUniqueID>
            <ISSNLinking>1471-2474</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1471-2474-15-281</ArticleId>
            <ArticleId IdType="doi">10.1186/1471-2474-15-281</ArticleId>
            <ArticleId IdType="pubmed">25138129</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138119</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">0253-6269</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Archives of pharmacal research</Title>
                <ISOAbbreviation>Arch. Pharm. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Isolation of a dihydrobenzofuran lignan, icariside E4, with an antinociceptive effect from Tabebuia roseo-alba (Ridley) Sandwith (Bignoniaceae) bark.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The antinociceptive activity of icariside E4, a dihydrobenzofuran-type lignan isolated from Tabebuia roseo-alba (Ridley) Sandwith (Bignoniaceae) bark, was evaluated in mice by using chemical and thermal models of nociception. Intraperitoneal (i.p.) administration of crude T. roseo-alba bark extract and its methanol fraction inhibited acetic acid-induced abdominal constriction in mice. Furthermore, i.p. administration of 0.1, 1, and 10??mg/kg of icariside E4 reduced the number of writhes evoked by acetic acid injection by 46.9, 82.3, and 66.6??%, respectively. Icariside E4 administration had no effect in the first phase of the formalin test, but it reduced nociceptive behavior in the second phase as indicated by a reduction in the licking time. Icariside E4 did not modify thermal nociception in the hot-plate test model, suggesting that it had a peripheral antinociceptive action. The antinociceptive effect of icariside E4 in the writhing test was reversed by pre-administration of glibenclamide, but not of naloxone, atropine, yohimbine, or haloperidol. Together, these results indicated that the antinociceptive activity of icariside E4 from T. roseo-alba in models of chemical pain occurred through ATP-sensitive K(+) channel-dependent mechanisms.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ferreira-J??nior</LastName>
                    <ForeName>Jesu C</ForeName>
                    <Initials>JC</Initials>
                    <Affiliation>Instituto de Qu??mica e Biotecnologia, Universidade Federal de Alagoas, Macei??-AL, 57072-970, Brazil.</Affiliation>
                </Author>
                <Author>
                    <LastName>Conserva</LastName>
                    <ForeName>Lucia M</ForeName>
                    <Initials>LM</Initials>
                </Author>
                <Author>
                    <LastName>Lyra Lemos</LastName>
                    <ForeName>Rosangela P</ForeName>
                    <Initials>RP</Initials>
                </Author>
                <Author>
                    <LastName>de Omena-Neta</LastName>
                    <ForeName>Genilda C</ForeName>
                    <Initials>GC</Initials>
                </Author>
                <Author>
                    <LastName>Cavalcante-Neto</LastName>
                    <ForeName>Araken</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Barreto</LastName>
                    <ForeName>Emiliano</ForeName>
                    <Initials>E</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Arch Pharm Res</MedlineTA>
            <NlmUniqueID>8000036</NlmUniqueID>
            <ISSNLinking>0253-6269</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12272-014-0468-4</ArticleId>
            <ArticleId IdType="pubmed">25138119</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138100</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-5438</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of human genetics : EJHG</Title>
                <ISOAbbreviation>Eur. J. Hum. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Identification of a novel ARL13B variant in a Joubert syndrome-affected patient with retinal impairment and obesity.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1038/ejhg.2014.156</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Joubert syndrome (JS) is a genetically heterogeneous autosomal recessive ciliopathy with 22 genes implicated to date, including a small, ciliary GTPase, ARL13B. ARL13B is required for cilia formation in vertebrates. JS patients display multiple symptoms characterized by ataxia due to the cerebellar vermis hypoplasia, and that can also include ocular abnormalities, renal cysts, liver fibrosis or polydactyly. These symptoms are shared with other ciliopathies, some of which display additional phenotypes, such as obesity. Here we identified a novel homozygous missense variant in ARL13B/JBTS8 in a JS patient who displayed retinal defects and obesity. We demonstrate the variant disrupts ARL13B function, as its expression did not rescue the mutant phenotype either in Arl13b(scorpion) zebrafish or in Arl13b(hennin) mouse embryonic fibroblasts, while the wild-type ARL13B did. Finally, we show that ARL13B is localized within the primary cilia of neonatal mouse hypothalamic neurons consistent with the known link between hypothalamic ciliary function and obesity. Thus our data identify a novel ARL13B variant that causes JS and retinopathy and suggest an extension of the phenotypic spectrum of ARL13B mutations to obesity.European Journal of Human Genetics advance online publication, 20 August 2014; doi:10.1038/ejhg.2014.156.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Thomas</LastName>
                    <ForeName>Sophie</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>1] INSERM U1163, H??pital Necker-Enfants Malades, Paris, France [2] Universit?? Paris Descartes, Sorbonne Paris Cit??, Institut Imagine, Paris, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cantagrel</LastName>
                    <ForeName>Vincent</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>1] INSERM U1163, H??pital Necker-Enfants Malades, Paris, France [2] Universit?? Paris Descartes, Sorbonne Paris Cit??, Institut Imagine, Paris, France [3] Laboratory of Neurogenetics, Howard Hughes Medical Institute, Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mariani</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Serre</LastName>
                    <ForeName>Val??rie</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>1] INSERM U1163, H??pital Necker-Enfants Malades, Paris, France [2] UMR7592CNRS, Jacques Monod Institute, Paris Diderot University, Paris, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Ji-Eun</ForeName>
                    <Initials>JE</Initials>
                    <Affiliation>Laboratory of Neurogenetics, Howard Hughes Medical Institute, Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Elkhartoufi</LastName>
                    <ForeName>Nadia</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>1] INSERM U1163, H??pital Necker-Enfants Malades, Paris, France [2] Universit?? Paris Descartes, Sorbonne Paris Cit??, Institut Imagine, Paris, France [3] D??partement de G??n??tique, H??pital Necker-Enfants Malades, AP-HP, Paris, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>de Lonlay</LastName>
                    <ForeName>Pascale</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>1] INSERM U1163, H??pital Necker-Enfants Malades, Paris, France [2] Universit?? Paris Descartes, Sorbonne Paris Cit??, Institut Imagine, Paris, France [3] D??partement de G??n??tique, H??pital Necker-Enfants Malades, AP-HP, Paris, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Desguerre</LastName>
                    <ForeName>Isabelle</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Service de neurom??tabolisme, H??pital Necker-Enfants Malades, AP-HP, Paris, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Munnich</LastName>
                    <ForeName>Arnold</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>1] INSERM U1163, H??pital Necker-Enfants Malades, Paris, France [2] Universit?? Paris Descartes, Sorbonne Paris Cit??, Institut Imagine, Paris, France [3] D??partement de G??n??tique, H??pital Necker-Enfants Malades, AP-HP, Paris, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Boddaert</LastName>
                    <ForeName>Nathalie</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Radiologie P??diatrique et INSERM U-797, H??pital Necker-Enfants Malades, AP-HP, Paris, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lyonnet</LastName>
                    <ForeName>Stanislas</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>1] INSERM U1163, H??pital Necker-Enfants Malades, Paris, France [2] Universit?? Paris Descartes, Sorbonne Paris Cit??, Institut Imagine, Paris, France [3] D??partement de G??n??tique, H??pital Necker-Enfants Malades, AP-HP, Paris, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Vekemans</LastName>
                    <ForeName>Michel</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>1] INSERM U1163, H??pital Necker-Enfants Malades, Paris, France [2] Universit?? Paris Descartes, Sorbonne Paris Cit??, Institut Imagine, Paris, France [3] D??partement de G??n??tique, H??pital Necker-Enfants Malades, AP-HP, Paris, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lisgo</LastName>
                    <ForeName>Steven N</ForeName>
                    <Initials>SN</Initials>
                    <Affiliation>The MRC-Wellcome Trust Human Developmental Biology Resource (HDBR), Institute of Genetic Medicine, International Centre for Life, Central Parkway, Newcastle Upon Tyne, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Caspary</LastName>
                    <ForeName>Tamara</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gleeson</LastName>
                    <ForeName>Joseph</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Laboratory of Neurogenetics, Howard Hughes Medical Institute, Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Atti??-Bitach</LastName>
                    <ForeName>Tania</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>1] INSERM U1163, H??pital Necker-Enfants Malades, Paris, France [2] Universit?? Paris Descartes, Sorbonne Paris Cit??, Institut Imagine, Paris, France [3] D??partement de G??n??tique, H??pital Necker-Enfants Malades, AP-HP, Paris, France.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Eur J Hum Genet</MedlineTA>
            <NlmUniqueID>9302235</NlmUniqueID>
            <ISSNLinking>1018-4813</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ejhg2014156</ArticleId>
            <ArticleId IdType="doi">10.1038/ejhg.2014.156</ArticleId>
            <ArticleId IdType="pubmed">25138100</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138076</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1421-9859</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Developmental neuroscience</Title>
                <ISOAbbreviation>Dev. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Proteomic Investigation of the Hippocampus in Prenatally Stressed Mice Implicates Changes in Membrane Trafficking, Cytoskeletal, and Metabolic Function.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Prenatal stress influences the development of the fetal brain and so contributes to the risk of the development of psychiatric disorders in later life. The hippocampus is particularly sensitive to prenatal stress, and robust abnormalities have been described in the hippocampus in schizophrenia and depression. The aim of this study was to determine whether prenatal stress is associated with distinct patterns of differential protein expression in the hippocampus using a validated mouse model. We therefore performed a comparative proteomic study assessing female hippocampal samples from 8 prenatally stressed mice and 8 control mice. Differential protein expression was assessed using 2-dimensional difference in gel electrophoresis and subsequent mass spectrometry. The observed changes in a selected group of differentially expressed proteins were confirmed by Western blotting. In comparison to controls, 47 protein spots (38 individual proteins) were found to be differentially expressed in the hippocampus of prenatally stressed mice. Functional grouping of these proteins revealed that prenatal stress influenced the expression of proteins involved in brain development, cytoskeletal composition, stress response, and energy metabolism. Western blotting was utilized to validate the changes in calretinin, hippocalcin, profilin-1 and the signal-transducing adaptor molecule STAM1. Septin-5 could not be validated via Western blotting due to methodological issues. Closer investigation of the validated proteins also pointed to an interesting role for membrane trafficking deficits mediated by prenatal stress. Our findings demonstrate that prenatal stress leads to altered hippocampal protein expression, implicating numerous molecular pathways that may provide new targets for psychotropic drug development. ?? 2014 S. Karger AG, Basel.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>F??cking</LastName>
                    <ForeName>Melanie</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Psychiatry, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Opstelten</LastName>
                    <ForeName>Rianne</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author>
                    <LastName>Prickaerts</LastName>
                    <ForeName>Jos</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Steinbusch</LastName>
                    <ForeName>Harry W M</ForeName>
                    <Initials>HW</Initials>
                </Author>
                <Author>
                    <LastName>Dunn</LastName>
                    <ForeName>Michael J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author>
                    <LastName>van den Hove</LastName>
                    <ForeName>Dani??l L A</ForeName>
                    <Initials>DL</Initials>
                </Author>
                <Author>
                    <LastName>Cotter</LastName>
                    <ForeName>David R</ForeName>
                    <Initials>DR</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Dev Neurosci</MedlineTA>
            <NlmUniqueID>7809375</NlmUniqueID>
            <ISSNLinking>0378-5866</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">000365327</ArticleId>
            <ArticleId IdType="doi">10.1159/000365327</ArticleId>
            <ArticleId IdType="pubmed">25138076</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138065</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1365-2249</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical and experimental immunology</Title>
                <ISOAbbreviation>Clin. Exp. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>CXCL13 as a new biomarker of Systemic Lupus Erythematodes (SLE) and Lupus Nephritis (LN) - from bench to bedside?</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1111/cei.12439</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Different studies over the last decade have linked the B-cell attracting chemokine CXC ligand 13 (CXCL13) to the autoimmune disease systemic lupus erythematosus (SLE). A pathogenetic role of this chemokine for disease manifestation in SLE was initially described in mouse models for SLE. Mechanisms of CXCL13 actions were also identified in SLE patients. Moreover various clinical studies have identified CXCL13 serum levels as a useful biomarker in patients with SLE of different ethnicities for disease activity. In addition CXCL13 seems to be a promising marker for the diagnosis of Lupus Nephritis, one of the most severe complications of SLE. However its exact place within the mechanisms that lead to SLE remains to be defined. Further research is needed to resolve more details of the pathomechanism and the signaling pathway of CXCL13 in SLE. Blocking CXCL13 or the signal pathways of CXCL13 is seen as a promising therapeutic approach for SLE and will be addressed in the near future.</AbstractText>
                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Schiffer</LastName>
                    <ForeName>Lena</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Medicine/Nephrology, Hannover Medical School, Carl Neuberg Str. 1, 30625 Hannover, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Worthmann</LastName>
                    <ForeName>Kirstin</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Haller</LastName>
                    <ForeName>Hermann</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Schiffer</LastName>
                    <ForeName>Mario</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Clin Exp Immunol</MedlineTA>
            <NlmUniqueID>0057202</NlmUniqueID>
            <ISSNLinking>0009-9104</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CXCL13</Keyword>
            <Keyword MajorTopicYN="N">Lupus Nephritis (LN)</Keyword>
            <Keyword MajorTopicYN="N">Systemic Lupus erythematodes (SLE)</Keyword>
            <Keyword MajorTopicYN="N">biomarker</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cei.12439</ArticleId>
            <ArticleId IdType="pubmed">25138065</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138052</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>10</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inhibition of lung tumor growth by targeting EGFR/VEGFR-Akt/NF-??B pathways with novel theanine derivatives.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The molecularly targeted agents, including anti-VEGF or anti-EGFR monoclonal antibody and some inhibitors of EGFR tyrosine kinase, are effective in the treatment of non-small-cell lung cancer (NSCLC) to a certain extent, but the benefit for a proportion of patients is still limited. Hence, it is necessary and urgent to develop more selective and effective molecular targeted agents against lung cancer. Here, we have synthesized novel theanine derivatives, methyl coumarin-3-carboxylyl L-theanine (TMC), ethyl coumarin-3-carboxylyl L-theanine (TEC), ethyl 6-fluorocoumarin- 3-carboxylyl L-theanine (TFC), and ethyl 6-nitrocoumarin-3-carboxylyl L-theanine (TNC), which are fluorescent small molecules, based on their parental compound theanine and studied their anticancer activities in vitro, ex vivo and in vivo models of human and mouse cancers. Our results show that the four theanine derivatives significantly inhibit the lung cancer cell migration and the growth of lung cancer and leukemia cell lines. TFC and TNC display enhanced effects with anticancer drugs cytarabine vincristine, andmethotrexate on inhibition of lung cancer cell growth and no toxicity to the normal human embryonic lung fibroblast and peripheral blood lymphocytes. TFC and TNC exhibit strong suppression of the highly metastatic Lewis lung cancer (LLC) and A549 tumor growth in tumor-bearing mice without toxicity to mice. TFC and TNC can effectively suppress the growth of lung cancer cells in vitro, ex vivo and in vivo by targeting EGFR/VEGFR-Akt/NF-??B pathways. Our study has suggested that TFC and TNC may have the therapeutic and/or adjuvant therapeutic applications in the treatment of lung cancers and other cancer.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Guoying</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Laboratory of Molecular Pharmacology, School of Pharmacy, Yantai University, Qing Quan Lu, Yantai, Shandong Province, China; State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, P R China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ye</LastName>
                    <ForeName>Xinshan</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, P R China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ji</LastName>
                    <ForeName>Dexin</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Laboratory of Molecular Pharmacology, School of Pharmacy, Yantai University, Qing Quan Lu, Yantai, Shandong Province, China; These authors contributed equally to this work.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Huarong</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Laboratory of Molecular Pharmacology, School of Pharmacy, Yantai University, Qing Quan Lu, Yantai, Shandong Province, China; These authors contributed equally to this work.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sun</LastName>
                    <ForeName>Fujia</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Laboratory of Molecular Pharmacology, School of Pharmacy, Yantai University, Qing Quan Lu, Yantai, Shandong Province, China; These authors contributed equally to this work.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shang</LastName>
                    <ForeName>Chunqing</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Laboratory of Molecular Pharmacology, School of Pharmacy, Yantai University, Qing Quan Lu, Yantai, Shandong Province, China; These authors contributed equally to this work.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Laboratory of Molecular Pharmacology, School of Pharmacy, Yantai University, Qing Quan Lu, Yantai, Shandong Province, China; Department of Pharmaceutical Sciences, North Dakota State University, Fargo, ND, USA; These authors contributed equally to this work.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Erxi</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Department of Pharmaceutical Sciences, North Dakota State University, Fargo, ND, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Fengfei</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Pharmaceutical Sciences, North Dakota State University, Fargo, ND, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Fei</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Laboratory of Molecular Pharmacology, School of Pharmacy, Yantai University, Qing Quan Lu, Yantai, Shandong Province, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tian</LastName>
                    <ForeName>Huihui</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Laboratory of Molecular Pharmacology, School of Pharmacy, Yantai University, Qing Quan Lu, Yantai, Shandong Province, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Xin</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Laboratory of Molecular Pharmacology, School of Pharmacy, Yantai University, Qing Quan Lu, Yantai, Shandong Province, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Linlin</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Laboratory of Molecular Pharmacology, School of Pharmacy, Yantai University, Qing Quan Lu, Yantai, Shandong Province, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Kun</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Laboratory of Molecular Pharmacology, School of Pharmacy, Yantai University, Qing Quan Lu, Yantai, Shandong Province, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Hanchen</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>The Center of Non-Traumatic Treatment and Diagnosis of Tumor, Binzhou Medical College affiliated The PLA 107 Hospital, Southern Zhichu Road, Yantai, Shandong Province, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Yishan</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>The Center of Non-Traumatic Treatment and Diagnosis of Tumor, Binzhou Medical College affiliated The PLA 107 Hospital, Southern Zhichu Road, Yantai, Shandong Province, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Wenhua</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>The Center of Non-Traumatic Treatment and Diagnosis of Tumor, Binzhou Medical College affiliated The PLA 107 Hospital, Southern Zhichu Road, Yantai, Shandong Province, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Guan</LastName>
                    <ForeName>Yukun</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Laboratory of Molecular Pharmacology, School of Pharmacy, Yantai University, Qing Quan Lu, Yantai, Shandong Province, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Qinwen</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>Department of Radiotherapy,307 Hospital of PLA,Academy of Military Medical Science,Beijing,P. R. China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhao</LastName>
                    <ForeName>Xiaohang</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>National Laboratory of Molecular Oncology, Cancer Institute &amp; Hospital, Chinese Academy of Medical Sciences, 17 Panjiayuan, Chaoyangqu, Beijing, P. R. China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wan</LastName>
                    <ForeName>Xiaochun</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Key Laboratory of Tea Biochemistry &amp; Biotechnology, Ministry of Agriculture, Anhui Agricultural University, Hefei, Anhui Province, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">2336</ArticleId>
            <ArticleId IdType="pubmed">25138052</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138050</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jun</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">PTPRD encodes the protein tyrosine phosphatase receptor type D and is frequently inactivated across many human cancers. Despite its frequent inactivation, it is unknown whether loss of PTPRD promotes tumorigenesis in vivo. PTPRD is located on chromosome 9p, as is CDKN2A, and the two loci are frequently deleted together. Here, we show that co-deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis. Interestingly,heterozygous loss of Ptprd was sufficient to promote tumorigenesis in our model, suggesting that Ptprd may be a haploinsufficient tumor suppressor. The loss of Ptprd resulted in changes to the tumor spectrum in mice and increased the frequency of lymphomas. In total, we reveal that Ptprd is a tumor suppressor that can promote tumorigenesis in concert with Cdkn2a loss.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ortiz</LastName>
                    <ForeName>Berenice</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Gerstner Sloan-Kettering Graduate School, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>White</LastName>
                    <ForeName>Julie R</ForeName>
                    <Initials>JR</Initials>
                    <Affiliation>The Tri-Institutional Laboratory of Comparative Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Wei H</ForeName>
                    <Initials>WH</Initials>
                    <Affiliation>Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chan</LastName>
                    <ForeName>Timothy A</ForeName>
                    <Initials>TA</Initials>
                    <Affiliation>Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Dept. of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA; Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">2106</ArticleId>
            <ArticleId IdType="pubmed">25138050</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25138022</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1521-0103</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of pharmacology and experimental therapeutics</Title>
                <ISOAbbreviation>J. Pharmacol. Exp. Ther.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>CO-ADMINISTRATING LUTEOLIN MINIMIZES THE SIDE EFFECTS OF THE AROMATASE INHIBITOR LETROZOLE.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">jpet.114.216754</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Aromatase inhibitors (AI) have been used as adjuvant therapeutic agents for breast cancer. Their adverse side effect on blood lipid is well documented. Some natural compounds have been shown to be potential AIs. In the present study, we compared the efficacy of the flavonoid luteolin to the clinically approved AI letrozole (Femara??) in a cell and a mouse model. In the in vitro experimental results for aromatase inhibition, the Ki values of luteolin and letrozole were estimated to be 2.44 ??M and 0.41 nM, respectively. Both letrozole and luteolin appeared to be competitive inhibitors. Subsequently, an animal model was used for the comparison. Aromatase-expressing MCF-7 cells were transplanted into ovariectomized athymic mice. Luteolin was given p.o. at 5, 20, and 50 mg/kg, while letrozole was administered by i.v. injection. Similar to letrozole, luteolin administration reduced plasma estrogen concentrations and suppressed the xenograft proliferation. The regulation of cell cycle and apoptotic proteins -- such as a decrease in the expression of Bcl-xL, Cyclin-A/D1/E, CDK-2/4, and increase in that of Bax -- was about the same in both treatments. The most significant disparity was on blood lipids. Contrasting to letrozole, luteolin increased fasting plasma HDL concentrations and produced a desirable blood lipid profile. These results suggested that the flavonoid could be a co-adjuvant therapeutic agent without impairing AI's action.</AbstractText>
                <CopyrightInformation>The American Society for Pharmacology and Experimental Therapeutics.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Fengjuan</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Peking University Health Science Center and Chinese University of Hong Kong;</Affiliation>
                </Author>
                <Author>
                    <LastName>Wong</LastName>
                    <ForeName>Tsz Y</ForeName>
                    <Initials>TY</Initials>
                    <Affiliation>Chinese University of Hong Kong;</Affiliation>
                </Author>
                <Author>
                    <LastName>Lin</LastName>
                    <ForeName>Shu-Mei</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>National Chiayi University;</Affiliation>
                </Author>
                <Author>
                    <LastName>Chow</LastName>
                    <ForeName>Simon</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Chinese University of Hong Kong;</Affiliation>
                </Author>
                <Author>
                    <LastName>Cheung</LastName>
                    <ForeName>Wing-Hoi</ForeName>
                    <Initials>WH</Initials>
                    <Affiliation>Chinese University of Hong Kong;</Affiliation>
                </Author>
                <Author>
                    <LastName>Chan</LastName>
                    <ForeName>Franky L</ForeName>
                    <Initials>FL</Initials>
                    <Affiliation>Chinese University of Hong Kong;</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Shiuan</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Beckman Research Institute of the City of Hope.</Affiliation>
                </Author>
                <Author>
                    <LastName>Leung</LastName>
                    <ForeName>Lai K</ForeName>
                    <Initials>LK</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-7781-3099</Identifier>
                    <Affiliation>Chinese University of Hong Kong; laikleung@cuhk.edu.hk.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Pharmacol Exp Ther</MedlineTA>
            <NlmUniqueID>0376362</NlmUniqueID>
            <ISSNLinking>0022-3565</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">aromatase inhibitors</Keyword>
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">drug interactions</Keyword>
            <Keyword MajorTopicYN="N">natural products</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">jpet.114.216754</ArticleId>
            <ArticleId IdType="doi">10.1124/jpet.114.216754</ArticleId>
            <ArticleId IdType="pubmed">25138022</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
